United States
Environmental Protection
Agency

FINAL
ECAO-CIN-424
September, 1988
Revised July, 1991

EPA

Research and Development

DRINKING WATER CRITERIA DOCUMENT FOR
HEXACHLOROBENZENE

Prepared for

OFFICE OF WATER

Prepared by

Environmental Criteria and Assessment Office
Office of Health and Environmental Assessment
U.S. Environmental Protection Agency
Cincinnati, OH 45268

DISCLAIMER

This document has been reviewed in accordance with the U.S. Environmental Protection Agency's peer and administrative review policies and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

PB92-173400	2. REPORT DATE July 1991	3. REPORT TYPE AND DATES COVERED

4. TITLE AND SUBTITLE
Final Drinking Water Criteria Document for HEXACHLOROBENZENE

5. FUNDING NUMBERS

6. AUTHOR(S)
Environmental Criteria and Assessment Office (ECAO)
Office of Health and Environmental Assessment (OHEA)

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
ECO/OHEA
U.S. EPA
26 West Martin Luther King Drive
Cincinnati, OH 45268

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
Office of Water
U.S. EPA
401 M St., S. W.
Washington, D. C. 20460

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES
Revises PB-86117777

12a. DISTRIBUTION/AVAILABILITY STATEMENT

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)

This document provides the health effects basis to be considered in establishing the MCLG. To achieve this objective, data on pharmacokinetics, human exposure, acute and chronic toxicity to animals and humans, epidemiology and mechanisms of toxicity are evaluated. Specific emphasis is placed on literature data providing dose-response information. Thus, while the literature search and evaluation performed in support of this document has been comprehensive, only the reports considered most pertinent in the derivation of the MCLG are cited in the document. The comprehensive literature data base in support of this document includes information published up to 1987; however, more recent data may have been added during the review process. Final revisions and editorial changes were made in 1991.

14. SUBJECT TERMS
-Volatile Organic Chemical
-Pentachlorophenyl Chloride
-Bunt-No-More

15. NUMBER OF PAGES
217

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements.*

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C	- Contract	PR	- Project
G	- Grant	TA	- Task
PE	- Program Element	WU	- Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report numbers(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. *(If known)*

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD	- See DoDD 5230.24, "Distribution Statements on Technical Documents."
DOE	- See authorities.
NASA	- See Handbook NHB 2200.2.
NTIS	- Leave blank.

Block 12b. Distribution Code.

DOD	- Leave blank.
DOE	- Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.
NASA	- Leave blank.
NTIS	- Leave blank.

Block 13. Abstract. Include a brief *(Maximum 200 words)* factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code *(NTIS only)*.

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Section 1412 (b)(3)(A) of the Safe Drinking Water Act, as amended in 1986, requires the Administrator of the Environmental Protection Agency to publish maximum contaminant level goals (MCLGs) and promulgate National Primary Drinking Water Regulations for each contaminant, which, in the judgment of the Administrator, may have an adverse effect on public health and which is known or anticipated to occur in public water systems. The MCLG is nonenforceable and is set at a level at which no known or anticipated adverse health effects in humans occur and which allows for an adequate margin of safety. Factors considered in setting the MCLG include health effects data and sources of exposure other than drinking water.

This document provides the health effects basis to be considered in establishing the MCLG. To achieve this objective, data on pharmacokinetics, human exposure, acute and chronic toxicity to animals and humans, epidemiology and mechanisms of toxicity are evaluated. Specific emphasis is placed on literature data providing dose-response information. Thus, while the literature search and evaluation performed in support of this document has been comprehensive, only the reports considered most pertinent in the derivation of the MCLG are cited in the document. The comprehensive literature data base in support of this document includes information published up to 1987; however, more recent data may have been added during the review process. Final revisions and editorial changes were made in 1991.

When adequate health effects data exist, Health Advisory values for less than lifetime exposures (1-day, 10-day and longer-term, ~10% of an individual's lifetime) are included in this document. These values are not used in setting the MCLG, but serve as informal guidance to municipalities and other organizations when emergency spills or contamination situations occur.

Tudor Davis, Director
Office of Science
and Technology

James Elder, Director
Office of Ground Water
and Drinking Water

DOCUMENT DEVELOPMENT

John Cicmanec, Document Manager
Environmental Criteria and Assessment Office, Cincinnati
U.S. Environmental Protection Agency

Special Note: This document was developed from the comprehensive information found in the Health Assessment Document for Chlorinated Benzenes (EPA 600/8-84-015F).

Scientific Reviewers and Contributors

Larry D. Anderson
Office of Drinking Water
U.S. Environmental Protection Agency
Washington, DC

W. Bruce Peirano
David J. Reisman
Michael L. Dourson
Franklin L. Mink
Environmental Criteria and Assessment Office, Cincinnati
U.S. Environmental Protection Agency

Tom Sutter (revised Chapter VII)
Becky Clark
University of Cincinnati, College of Medicine
Cincinnati, Ohio

Henry A. Peters
Department of Neurology
University of Wisconsin
Madison, Wisconsin

Douglas L. Arnold
Health and Welfare Canada
Ottawa, Ontario
Canada

Larry R. Valcovic
Reproductive Effects Assessment Group
U.S. Environmental Protection Agency
Washington, DC

William E. Pepelko
Carcinogen Assessment Group
U.S. Environmental Protection Agency
Washington, DC

Kevin Garrahan
Exposure Assessment Group
U.S. Environmental Protection Agency
Washington, DC

Document Preparation

Technical Support Services Staff, Environmental Criteria and Assessment Office, Cincinnati

TABLE OF CONTENTS

TABLE OF CONTENTS (cont.)

LIST OF TABLES

LIST OF TABLES (cont.)

LIST OF TABLES (cont.)

LIST OF ABBREVIATIONS

CCl_4	Carbon tetrachloride
CRAVE	Carcinogen Risk Assessment Verification Endeavor
DWEL	Drinking water equivalent level
GC/MS	Gas chromatography/mass spectrometry
GLC/MS	Gas liquid chromatography/mass spectrometry
HA	Health advisory
i.m.	Intramuscular
i.p.	Intraperitoneal
i.v.	Intravenous
LD_{50}	Dose lethal to 50% of recipients
LOAEL	Lowest-observed-adverse-effect level
MTD	Maximum tolerated dose
NOAEL	No-observed-adverse-effect level
NOEL	No-observed-effect level
PCT	Porphyria cutanea tarda
RBC	Red blood cell
RfD	Reference dose
TLC	Thin-layer chromatography
UV	Ultraviolet

I. SUMMARY

Hexachlorobenzene is imported but not produced commercially in the United States, and occurs as a by-product in the synthesis of nine other chlorinated hydrocarbons; 2-5 million pounds may be generated each year.

Hexachlorobenzene is a colorless crystalline (monoclinic prism) solid with a reported water solubility of 0.005 mg/ℓ at 25°C. In general, hexachlorobenzene has low water solubility, high octanol/water partition coefficient, low vapor pressure at 25°C, low flammability and is photochemically stable. Chemical analysis of hexachlorobenzene in water generally involves solvent extraction followed by a cleanup method being used to produce organic extracts suitable for GC/MS analysis.

The pharmacokinetics of hexachlorobenzene in a number of mammalian species have been studied in detail following oral administration and, to a lesser extent, following intravenous or intraperitoneal injection. No information was found regarding hexachlorobenzene metabolism following inhalation or topical application. Absorption of hexachlorobenzene from the intestinal tract appears to depend on the vehicle used during test material administration. Thus, when hexachlorobenzene is administered in olive oil, ~80% of the dose is absorbed; when it is administered in an aqueous solution, in 1% methyl cellulose or in a crystalline form, relatively little (<20%) is absorbed. Intestinal absorption of hexachlorobenzene occurs primarily through lymphatic channels, with only a minor portion being absorbed into the portal circulation.

Following absorption, hexachlorobenzene is distributed to tissues that have a high lipid content. The adipose tissue accumulates the greatest concentrations of hexachlorobenzene in all species studied, although bone marrow and skin, which contain large amounts of lipids, also accumulate hexachlorobenzene. The adrenal cortex accumulates hexachlorobenzene at concentrations approaching those of fat. Other body constituents (e.g., liver, kidneys, lungs, heart, spleen and blood) generally contain much lower amounts of hexachlorobenzene. Intravenous injection of hexachlorobenzene results in a tissue distribution similar to that seen following oral administration. Hexachlorobenzene is transported via the placenta and is distributed in fetal tissue as indicated by studies with rabbits, rats, mice, mink and ferrets.

Hexachlorobenzene is metabolized slowly into other chlorinated benzenes, chlorinated phenols and other minor metabolites and forms glucuronide and glutathione conjugates. Tissues were found to contain mainly unchanged hexachlorobenzene together with small amounts of metabolites. Similarly, only small amounts of hexachlorobenzene metabolites were detected in feces, whereas most of the metabolites were excreted in the urine together with small amounts of unchanged hexachlorobenzene. There are indications that females produce and excrete more hexachlorobenzene metabolites than do males.

The excretion of hexachlorobenzene from treated animals is slow and occurs mainly through the feces with relatively little being excreted in the urine. It is characterized by an initial rapid phase followed by one or more slow phases. This slow phase of excretion can be enhanced by the administration of mineral oil, paraffin or n-hexadecane. Both biliary and

intestinal excretion contribute to fecal excretion. A three-compartment mammillary model has been reported for the behavior of hexachlorobenzene in beagles and rhesus monkeys following a single i.v. injection. Radioactivity was not detected in exhaled air following i.p. injection of ^{14}C-hexachlorobenzene. Hexachlorobenzene has been detected in the milk of nursing mammals.

The acute oral toxicity of hexachlorobenzene has been found to be low with LD_{50} values ranging from 1700-10,000 mg/kg. Subchronic oral toxicity studies with a number of mammalian species indicated a significant increase in liver and kidney weights as well as other organ weights in hexachlorobenzene-treated animals. The livers from hexachlorobenzene-exposed animals have shown histologic changes such as irregularly shaped and moderately enlarged liver mitochondria and increases in the size of the centrilobular hepatocytes. Chronic toxicity studies revealed similar effects to those seen in the subchronic studies, plus hexachlorobenzene associated life-shortening and various hepatic and renal pathologies. These subchronic and chronic effects were usually dose-related. Other effects included multiple alopecia and scabbing, together with neurologic effects in rats, mice and dogs. A dose-related histopathologic change in the ovaries of monkeys has also been reported.

Increased porphyrin levels in the liver and in urine have been reported for all species studied except the dog. Hexachlorobenzene was found to cause the accumulation of β-H-steroids, which induce porphyrin biosynthesis, and to inhibit uroporphyrinogen decarboxylases. Indications are that females are more susceptible to hexachlorobenzene-induced porphyria than are

males, which may be related to the females estrogen levels and greater hexachlorobenzene metabolism. Hexachlorobenzene was reported to produce a mixed-type induction of cytochromes resembling that produced by a combination of phenobarbital (P-450) and 3,4-benzpyrene (P-448). In addition, the activities of several hepatic microsomal enzymes were found to be induced by hexachlorobenzene.

Hexachlorobenzene did not induce dominant lethal mutations in two studies but was reported to be mutagenic in a yeast, S. cerevisiae, assay at a concentration of 100 ppm. Hexachlorobenzene possessed no detectable levels of mutagenic activity in the Salmonella histidine reversion assay. Chronic feeding studies provide sufficient evidence for the carcinogenicity of hexachlorobenzene in animals (U.S. EPA weight-of-evidence classification of B2) since there was an increased incidence of malignant tumors of the liver in two species (haemangioendothelioma in hamsters and hepatocellular carcinoma in rats) as well as reports of hepatoma in mice, rats and hamsters. Hexachlorobenzene given to pregnant mice was found to produce cleft palates and renal agenesis in exposed pups. Certain chemicals were found to alter the toxicity of hexachlorobenzene in mammals, whereas hexachlorobenzene pretreatment was reported to increase CCl_4 toxicity and alter the immune responses of treated animals.

A few epidemiologic studies with occupationally-exposed workers have been reported, together with studies conducted in Turkey and in the United States (i.e., Louisiana) on the general population following accidental exposure to hexachlorobenzene. These studies qualitatively support the toxicity of hexachlorobenzene, but give little dose-response information. Biologic monitoring of plasma levels clearly shows more hexachlorobenzene in

the plasma of exposed compared with nonexposed individuals, although no biologically significant adverse health effects were seen during the observation periods. The exposure of humans to hexachlorobenzene in Turkey during 1955-1959 caused an epidemic of hexachlorobenzene-induced porphyria cutanea tarda (PCT), also known as porphyria turcica, which is manifested by disturbed porphyrin metabolism, cutaneous lesions and hyperpigmentation. The authors estimated that from 0.05-0.2 g/day were ingested. In exposed children under 1 year of age, pink sore was observed as well as 95% mortality in these infants.

Follow-up studies conducted with Turkish patients 20-25 years after the onset of porphyria showed that a few subjects still had active porphyria, whereas >50% exhibited hyperpigmentation scarring, as well as other dermatologic, neurologic and skeletal features of hexachlorobenzene toxicity. Hexachlorobenzene residues were also found in the blood, fat and breast milk of some patients.

A correlation was found between hexachlorobenzene levels in blood and the number of years worked in a chlorinated solvents plant. The concentration of urinary uroporphyrins and coproporphyrins ranged from 21-37 and 67-101 µg/ℓ, respectively, for the period between 1974 and 1977. An epidemiologic survey conducted with 86 residents in the vicinity of this chlorinated solvents plant showed elevated hexachlorobenzene residues in plasma. Higher levels of hexachlorobenzene residues were found in males than in females, but these were not associated with race or food consumption.

The quantitative risk assessment for hexachlorobenzene is based on animal data since human data are insufficient. Data are insufficient for the derivation of 1-day and 10-day HAs for a 10 kg child; therefore, the longer-term HA for a 10 kg child of 0.05 mg/ℓ is recommended as the 1-day and 10-day HAs for a 10 kg child. The longer-term HA for a 70 kg adult is 0.2 mg/ℓ. The lifetime DWEL derived from chronic toxicity data for a 70 kg adult is 0.03 mg/ℓ. The RfD is 0.0008 µg/kg bw/day and is based on the results of a 130-week study in rats and was verified in May 1988.

The 95% upper bound lifetime cancer risk associated with 1 µg/ℓ of hexachlorobenzene in drinking water is estimated to be 4.6×10^{-5}. Levels of 2.0×10^{-5}, 2.0×10^{-4} and 2.0×10^{-3} mg/ℓ of hexachlorobenzene in drinking water correspond to the 95% upper bound lifetime cancer risks of 10^{-6}, 10^{-5} and 10^{-4}, respectively. These values were verified by the CRAVE workgroup in March 1989. Hexachlorobenzene has been classified as a B2, probable human carcinogen.

II. PHYSICAL AND CHEMICAL PROPERTIES

Hexachlorobenzene is not manufactured as a commercial product in the United States, but an estimated 2-5 million pounds were produced each year during the synthesis of several chlorinated chemicals (Mumma and Lawless, 1975). Hexachlorobenzene is also an ingredient in a fungicide of which ~200,000 pounds are imported each year (IARC, 1979). Hexachlorobenzene is resistant to biodegradation, accumulates in the biologic environment and has been detected in ambient air, drinking and surface water, sediments, cropland and food (U.S. EPA, 1985).

Hexachlorobenzene is a colorless crystalline (monoclinic prisms) solid. Its water solubility was reported as 0.005 mg/ℓ at 25°C (Yalkowsky and Valvani, 1980). Hexachlorobenzene is sparingly soluble in cold alcohol and soluble in benzene, chloroform and ether (NLM, 1979). Impure commercial preparations may contain pentachlorobenzene (10-81,000 ppm), octachlorodibenzo-p-dioxin (0.05-212 ppm) and octachlorodibenzofuran (0.35-58.3 ppm) (Villeneuve et al., 1974). The chemical structure of hexachlorobenzene is shown in Figure II-1. Synonyms, trade names and identification numbers for hexachlorobenzene are listed in Table II-1.

Some physical properties of hexachlorobenzene are shown in Table II-2. In general., hexachlorobenzene has low water solubility, high octanol/water coefficient, low vapor pressure at 25°C and low flammability. Hexachlorobenzene has been demonstrated to be photochemically stable (Korte et al., 1978; Hustert et al., 1981).



FIGURE II-1

Chemical Structure of Hexachlorobenzene

TABLE II-1

Synonyms, Trade Names and
Identification Numbers of Hexachlorobenzene

Identification Numbers	Synonyms and Trade Names
CAS No. 118-74-1	Esaclorobenzene (Italian)
TSL No. DA2975000	Amatin
EPA Haz Waste No. U127	Anticarie
	Bunt-Cure
	Bunt-No-More
	Co-op Hexa
	Granox NM
	HCB
	HEXA C.B.
	Hexachlorobenzol (German)
	Hexachlorobenzene
	Julin's Carbon Chloride
	No Bunt
	No Bunt 40
	No Bunt 80
	No Bunt Liquid
	Pentachlorophenyl Chloride
	Perchlorobenzene
	Phenyl Perchloryl
	Sanocide
	Smut-Go
	Snieciotox

*Source: National Library of Medicine (NLM), Toxicology Data Bank (TDB)

TABLE II-2

Physical Properties of Hexachlorobenzene[a]

Molecular Weight	284.79
Melting Point	230°C
Boiling Point	322.9°C at 760 mm
Density at 23°C	1.57 g/mℓ
Henry's Law Constant[b] x 10^{-3}	0.12 atm. m^3 mol^{-1}
Log P°[b]	5.8
Water Solubility[c]	0.005 mg/ℓ at 25°C
Flash Point	468°F
Vapor Pressure (mm Hg)	1 at 144.4°C[d] 1.68 x 10^{-5} at 25°F[e] 1.089 x 10^{-5} at 20°C[f]
Specific Vapor Density (air = 1)	9.84[g]

[a]Data are from the National Library of Medicine (NLM), Toxicology Data Bank (TDB), except as noted.

[b]Mackay et al., 1979

[c]Yalkowsky and Valvani, 1980

[d]Weast, 1981

[e]Leoni and D'Arca, 1976

[f]Farmer et al., 1980

[g]Verschueren, 1977

P° = Partition coefficient at 25°C

Chemical Analysis

Chemical analysis of hexachlorobenzene in water generally involves solvent extraction followed by a cleanup method being used to produce organic extracts suitable for GC/MS analysis. The U.S. EPA (1982) (Method 612) has recommeded the use of Florisil column chromatography as a cleanup step before the quantification of the samples by GC with electron capture detector. This recommended method is applicable for the determination of hexachlorobenzene in drinking water and wastewater. The recovery of hexachlorobenzene by this method was found to be 95%.

A method for the determination of hexachlorobenzene in soil and chemical waste disposal site samples has been developed by DeLeon et al. (1980). The procedure involves methane extraction followed by temperature-programmed GC analysis using electron capture detection. Recoveries of samples spiked at the 10, 100 and 300 µg levels were 96.5% (±3.6), 93.1% (±8.1) and 78.0% (±2.6), respectively. The lower detection limit for this method is around 10 µg/g.

III. TOXICOKINETICS

Absorption

Absorption of hexachlorobenzene from the gut has been studied in detail; however, no information has been found in the available literature on hexachlorobenzene absorption through the lungs or skin. Absorption of hexachlorobenzene from the intestinal tract appears to depend on the solvent vehicle used during test material administration. Thus, when hexachlorobenzene is administered in olive oil, ~80% of the dose is adsorbed; when it is administered in an aqueous solution, in 1% methyl cellulose, or in a solid crystalline form, relatively little (<20%) is absorbed. Intestinal absorption of hexachlorobenzene occurs primarily through lymphatic channels (Iatropoulos et al., 1975), with only a minor portion being absorbed into the portal circulation.

Ingebrigtsen et al. (1981) investigated the absorption of [^{14}C]hexachlorobenzene (10 mg in peanut oil) administered to male, bile-duct-cannulated Wistar rats by gastric catheter. Four days after dosing, 24.8% of the administered ^{14}C had been recovered in the feces, indicating that at least 75% of the administered hexachlorobenzene was absorbed.

Albro and Thomas (1974) studied the absorption of hexachlorobenzene in a squalane/cotton seed oil vehicle by male rats following administration of a single dose by stomach intubation. The results indicated that at doses of 12 and 30 mg/kg, ~82 and 72%, respectively, were absorbed within 96 hours.

Koss and Koransky (1975) compared the absorption rates of [^{14}C]hexachlorobenzene in female Wistar rats following oral administration of olive

oil solutions or suspensions in 6% gum arabic in water (4, 20, 50.5, 60 and 180 mg/kg). Approximately 80% of the dose was absorbed from the olive oil solutions; however, only 6% was absorbed from the aqueous suspension.

Similarly, Zabik and Schemmel (1980) found that, when hexachlorobenzene (32 mg/kg/day) was administered in the diet, high-fat (45.3% w/w) diets resulted in greater accumulation of hexachlorobenzene in the tissues and less hexachlorobenzene excreted in the feces than did high-carbohydrate diets (67.7% w/w). The female rats received 32 mg hexachlorobenzene/kg body weight/day for 6, 12 or 18 days. Although this study did not include a control group receiving a balanced diet, the data suggest that high-fat diets increase the absorption of hexachlorobenzene.

Sundlof et al. (1982) administered seven consecutive daily oral doses of 10 or 100 mg crystalline hexachlorobenzene/kg body weight to male laboratory beagles. The results from the 100 mg/kg group indicated that hexachlorobenzene can continue to be absorbed from the intestines for up to 1 week following the cessation of dosing.

Bleavins et al. (1982) fed female European ferrets (Mustela putorius furo) a single dose of 57.6 µg hexachlorobenzene (^{14}C-labeled) in 7.5 g of standard mink diet (22% fat) and calculated that 98.5% of the hexachlorobenzene dose was absorbed by the ferrets. They made this calculation based on predicted hexachlorobenzene excretion as extrapolated from this study, and owing to a food passage time in the female ferret of just over 3 hours.

Distribution

Following intestinal absorption, hexachlorobenzene, which is lipophilic, distributes to tissues that are rich in lipid content. The adipose tissue accumulates the greatest concentrations of hexachlorobenzene in all species studied, although bone marrow and skin, which contain large amounts of lipids, also accumulate hexachlorobenzene. The adrenal cortex accumulates hexachlorobenzene at concentrations approaching those of fat. Other tissues (e.g., liver, kidneys, lungs, heart, spleen and blood) generally contain lower amounts of hexachlorobenzene. Intravenous injection of hexachlorobenzene results in a tissue distribution similar to that following oral administration. Hexachlorobenzene is transported via the placenta and is distributed in fetal tissue.

Mehendale et al. (1975) studied the disposition of ^{14}C-hexachlorobenzene by adult male rats following a single oral dose of 5 mg/kg. ^{14}C-Hexachlorobenzene was mixed with arachis oil and administered by stomach intubation. The animals were sacrificed 7 days later and the tissues and organs radioassayed. Forty-three percent of the total radioactivity administered was present in fat tissue 7 days after ^{14}C-hexachlorobenzene administration. In addition, muscle and skin tissues each contained ~9% of the radioactivity, whereas the other 12 tissues analyzed contained ~5% combined (Table III-1).

When ^{14}C-hexachlorobenzene was suspended in 1% methyl cellulose and a single oral dose containing 150 µg of hexachlorobenzene was administered to Sprague-Dawley rats, the absorption of ^{14}C-hexachlorobenzene by the walls of the stomach and duodenum 1 hour later was relatively low: ~1.0 and

TABLE III-1

Storage and Excretion of ^{14}C-HCB Administered Orally in Arachis Oil in Rats[a]

Organ or Tissue	Percent of Total Radioactivity Administered
Fat[b]	42.81 ± 6.14
Muscle[c]	9.41 ± 1.17
Skin[d]	8.64 ± 1.21
Liver	3.01 ± 0.23
Small intestine	2.43 ± 0.47
Bone[e]	1.04 ± 0.09
Kidneys	0.76 ± 0.11
Large intestine	0.43 ± 0.08
Stomach	0.36 ± 0.04
Blood	0.24 ± 0.04
Lungs	0.24 ± 0.04
Testes	0.21 ± 0.04
Heart	0.18 ± 0.03
Brain	0.17 ± 0.03
Spleen	0.04 ± 0.002
Total in tissues	70.09 ± 5.48
Excretion	
Feces	16.02 ± 2.31[f]
Urine	0.85 ± 0.13[f]
Gut contents	2.48 ± 0.45
Total recovery	89.44 ± 10.57

[a]Source: Mehendale et al., 1975

[b]Based on 9% body weight as fat

[c]Based on 50% body weight as muscle

[d]Based on 16% body weight as skin

[e]Based on 10% body weight as bone

[f]Cumulative total for 7 days

Adult male rats were given 5 mg/kg of hexachlorobenzene.

HCB = Hexachlorobenzene

0.6 ppm were found in the stomach and duodenum, respectively (Iatropoulos et al., 1975). Increased radioactivity was found in the jejunum and ileum as well as the lymph nodes and adipose tissues 3 hours after administration (Table III-2). Although the radioactivity also increased in the liver and kidneys, this increase was relatively low compared with that found in the lymph nodes and adipose tissue. Moreover, the radioactivity in the liver and kidneys decreased within a 2-day period, whereas the radioactivity in the lymph nodes and fat remained relatively constant. These results indicate that the portal venous transport of hexachlorobenzene to the liver appears to be a minor pathway, whereas the major part of the ingested hexachlorobenzene is absorbed by the lymphatic system in the duodenum and jejuno-ileum and deposited in the fat, bypassing the systemic circulation and the excretory organs.

Knauf and Hobson (1979) investigated the tissue distribution of hexachlorobenzene in six female rhesus monkeys following the gastric administration of daily doses of hexachlorobenzene [0 (one monkey), 8 (one monkey), 32 (one monkey), 64 (one monkey), or 128 (two monkeys) mg/kg/day] in 1% methyl cellulose for a period of 60 days. The highest concentrations of hexachlorobenzene were located in tissues with high lipid content. Tissue levels correlated more with body fat content than with dose, with the monkey that had the least adipose tissue producing the highest nonfat tissue and serum values (Table III-3).

The highest levels of hexachlorobenzene residues were found in fat tissue (215-930 ppm) and bone marrow (175-1700 ppm), and selectively higher levels were found in the adrenal cortex (30-325 ppm) than in the adrenal

TABLE III-2

Tissue Concentration (ppm) of ^{14}C-Hexachlorobenzene[a] and Its Metabolites in Sprague-Dawley Rats[b]

Tissue	Time (hours)									
	1		3		5		12		48	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Stomach	0.6	1.6	0.8	1.0	1.1	0.5	0.1	0.1	0.1	0.1
Duodenum	0.6	0.6	1.4	1.0	0.2	0.3	0.1	0.1	0.1	0.1
Jejuno-Ileum	0.1	0.2	0.6	0.8	1.0	0.3	0.3	0.3	0.2	0.1
Cecum	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.1
Colon	0.1	0.1	0.1	0.2	0.4	0.1	0.1	0.1	0.2	0.1
Liver	0.1	0.4	0.5	0.5	0.2	0.3	0.2	0.2	0.1	0.2
Mesenteric lymph node	0.1	0.6	0.4	1.3	2.0	1.0	1.5	1.0	1.9	2.1
Adipose tissue	0.1	0.2	1.7	1.2	2.3	1.5	1.3	1.1	2.6	2.7
Kidneys	0.1	0.2	0.4	0.3	0.5	0.2	0.2	0.1	0.2	0.1
Lungs	0.1	0.3	0.3	0.4	0.2	0.2	0.1	0.1	0.1	0.2

[a]150 µg hexachlorobenzene was administered by stomach tube suspended in 1% methyl cellulose.

[b]Source: Iatropoulos et al., 1975

TABLE III-3

Tissue Levels of HCB (ppm) in Adult Female Rhesus Monkeys[a,b]

Monkey No. Dose (mg/kg/day)	613[c] 128	618[d] 128	627[e] 64	817 32	1163 8	1826 0
Body fat	930	215	540	250	580	1.1
Bone marrow	460	175	1700	255	350	1.6
Adrenal cortex	150	30	325	90	50	0.1
Adrenal medulla	12	9	285	35	4	<0.1
Liver	20	50	365	40	30	<0.1
Kidney	18	19	258	11	3	<0.1
Brain	25	19	108	12	8	<0.1
Ovaries	6	23	133	3	1	<0.1
Muscle	4	21	24	7	2	<0.1
Serum	2.5	1.5	11.0	0.5	3.3	<0.1

[a]Source: Knauf and Hobson, 1979

[b]HCB was administered daily for 60 days in 1% methylcellulose (orally)

[c]Monkey was small and slight

[d]Monkey was obese

[e]Monkey had very little adipose tissue

HCB = Hexachlorobenzene

medulla (4-285 ppm). Residues in serum, muscle, ovaries, brain, kidneys and liver were relatively much lower (0.5-365 ppm).

Engst et al. (1976) reported the administration by gavage of 8 mg/kg of hexachlorobenzene in 1 mℓ of sunflower oil to male Wistar rats for a duration of 19 days. The animals were then sacrificed, and the liver, kidneys, adrenals, heart, spleen and intestinal fat were analyzed for hexachlorobenzene residues. The following results were reported: fat tissue, 82 µg/g; muscle, 17 µg/g; liver, 125 µg total; kidneys total 21 µg each; spleen total 9 µg; heart total 1.5 µg; and adrenals total 0.5 µg each. High levels of hexachlorobenzene residues in fat tissues also have been reported for female rats receiving 50.0 mg/kg (177 µmoles/kg) of hexachlorobenzene every second day for 10 weeks (Koss et al., 1980b).

Szymczynski and Waliszewski (1981) analyzed human semen and testicular and fat tissues, and identified several chlorinated pesticides that included hexachlorobenzene. The compound was not detected in testicular tissue, but was present in semen and fat tissues at concentrations of 0.001 and 0.128 µg/g, respectively. Similarly, hexachlorobenzene was one of several chlorinated compounds found in semen collected in 1979 from 132 college students (Dougherty et al., 1981).

Sundlof et al. (1982) studied the distribution of ^{14}C-hexachlorobenzene or unlabeled hexachlorobenzene in male beagles following a single intravenous dose of 1 mg/kg in olive oil. Two dogs each were sacrificed after 2, 4, 8, 16, 32 and 48 hours and after 12 weeks; hexachlorobenzene concentrations were determined in 16 tissues and organs as well as in the

blood (Table III-4). Two hours after dosing, the highest concentration was found in the lungs (36.14 ppm). This was considered to be a property of the injection vehicle rather than a property of hexachlorobenzene per se. That is, it was believed that the olive oil vehicle formed microemboli in the blood which became trapped in the capillaries of the lung. Residue levels in the lungs then dropped (4.4 ppm), and a concurrent increase in hexachlorobenzene was detected in fat tissues (10.32 ppm in subcutaneous, perirenal and mesenteric fat) 4 hours postinjection. Residues in all tissues, organs and blood declined during the 48 hours postinjection except for fat tissue, which remained constant. Twelve weeks after dosing, tissue concentrations were very low in all tissues, including fat (>0.01-0.46 ppm), indicating significant excretion of the compound by that time.

Yang et al. (1978) studied the distribution of hexachlorobenzene in male Sprague-Dawley rats and female rhesus monkeys following intravenous injection of ^{14}C-hexachlorobenzene in 1,2-propanediol:plasma (1:8). Rats received 0.1 mg of ^{14}C-hexachlorobenzene and then were replaced in metabolic cages for 48 hours before sacrifice. About 0.2 and 1.0% of the administered dose was excreted in the urine and feces, respectively. No radioactivity was exhaled from the animals. Over 20 tissues from the rats were analyzed and all were found to contain radioactivity. The highest levels were in fat (~3 µg/g of tissue). The adrenal glands also contained a relatively high level of radioactivity, whereas the other tissues contained much lower levels, generally in the range of 1/12 to 1/300 of those in fat tissue.

TABLE III-4

HCB Concentrations in Tissues of Male Beagles
Receiving Single Intravenous Doses of 1 mg/kg bw in Olive Oil*

Tissue	HCB Concentration (ppm) Time Interval After Dosing		
	2 hours	48 hours	12 weeks
Lungs	36.14	0.08	<0.01
Adrenals	2.82	0.38	0.06
Subcutaneous fat	1.14	3.38	0.37
Perirenal fat	1.00	3.24	0.46
Mesenteric fat	0.56	2.40	0.41
Spleen	0.54	0.01	<0.01
Liver	0.51	0.04	0.02
Thyroid	0.37	NR	0.02
Heart	0.28	0.04	0.01
Kidneys	0.18	0.02	0.01
Stomach	0.18	0.36	0.01
Pancreas	0.17	0.06	0.07
Brain	0.15	0.02	0.02
Duodenum	0.12	0.02	0.02
Colon	0.12	0.01	<0.01
Small intestine	0.07	0.02	0.01
Blood	0.07	0.03	0.01

*Source: Sundlof et al., 1982

NR = Not reported

HCB = Hexachlorobenzene

The tissue distribution of ^{14}C-hexachlorobenzene in rhesus monkeys was determined in individual animals 100 days, 6 months and 1 year after intravenous injection of ^{14}C-hexachlorobenzene at 0.38, 0.32 and 0.22 mg/kg, respectively. The results again indicated that the highest levels were present in fat (6069 ng/g on day 100 and 828 ng/g on day 365) and bone marrow (1638 ng/g on day 100 and 373 ng/g on day 365) among the 30 tissues analyzed in all three monkeys. The adrenal glands contained ~1/6 to 1/8 of the levels present in fat, whereas the other tissues contained radioactivity levels ranging between 1/10 to <1/800 of those in fat.

The transplacental transfer of hexachlorobenzene from pregnant mice, rats and rabbits has also been reported. Brandt et al. (1980) conducted a qualitative study on the distribution of ^{14}C-hexachlorobenzene and several of its sulfur-containing metabolites in pregnant mice. The mice were injected i.v. and sacrificed at intervals ranging between 20 minutes and 32 days after injection. The animals were frozen, sectioned and submitted to autoradiography. The autoradiograms showed a strong uptake of hexachlorobenzene in the adipose tissues. Hexachlorobenzene was found to persist in the adipose tissues for more than 1 month after the administration. Radioactive hexachlorobenzene was also found to penetrate the placenta, resulting in the blood and liver concentrations in the fetuses that appeared to equal those of the dams.

Villeneuve and Hierlihy (1975) studied the placental transfer of hexachlorobenzene in Wistar rats and reported that hexachlorobenzene crosses the placenta and accumulates in the fetus in a dose-dependent manner. The females were dosed orally daily (5, 10, 20, 40 and 80 mg/kg) from gestation

day 6-16 and then sacrificed on day 22. Only liver, brain and whole fetal residue levels were determined in this study. Fetal liver residues (1.8-35.8 µg/g) were much lower than those of the dams (9.3-86.0 µg/g). The fetal brain and whole fetal levels were 1.1-17.5 µg/g and 1.5-18.9 µg/g, respectively.

Villeneuve et al. (1974) also reported that the transplacental transport of hexachlorobenzene in New Zealand rabbits was dose-dependent. Rabbits were mated and then dosed orally with hexachlorobenzene from days 1-27 with subtoxic doses of 0, 0.1, 1.0 or 10 mg/kg. On day 28 the dams were killed for fetal and maternal tissue analysis of hexachlorobenzene. In dams, the hexachlorobenzene residue concentrations were highest in fat, followed by the liver, heart, kidneys, brain, lung, spleen and plasma. Hexachlorobenzene residues were higher in the fetal liver than in the maternal liver.

Courtney et al. (1976) reported on the distribution of hexachlorobenzene (assayed 90.4% hexachlorobenzene and 9.6% pentachlorobenzene) administered via oral intubation on days 7-11 of gestation at a dose of 50 mg/kg/day in a corn oil acetone mix to five pregnant and two non-pregnant CD-1 mice. They found there were no remarkable differences in the hexachlorobenzene tissue levels between the pregnant and non-pregnant animals sampled at day 12 of pregnancy. The levels of pentachlorobenzene in sampled tissues were low as compared with the very high hexachlorobenzene levels detected in the thymus, skin, fat and urinary bladder. No detectable levels of hexachlorobenzene or pentachlorobenzene were found in the control mice.

Courtney et al. (1979) studied the tissue distribution of hexachlorobenzene in the maternal and fetal tissues of CD rats and CD-1 mice and reported that placentas and fetuses of both species demonstrated a dose-dependent relationship for hexachlorobenzene residues, with levels in the fetuses being higher than those in their corresponding placentas. The dams were treated via oral intubation with single or multiple oral doses (10, 50 or 100 mg/kg in corn oil) at different periods during gestation. The hexachlorobenzene concentrations in mice and rat fetuses at mid-gestation were very similar. In mice, multiple low doses of hexachlorobenzene resulted in higher concentrations of hexachlorobenzene in maternal and fetal tissues than single doses of equivalent total doses. In another study, Courtney and Andrews (1979) reported that in mice the fetus could be exposed to hexachlorobenzene from maternal body burdens, established before fetal implantation, and was not limited to maternal exposure during the postimplantation gestation.

Bleavins et al. (1982) studied the tissue distribution and transfer of a single dose of hexachlorobenzene given to female European ferrets (Mustela putorius furo). They gave a single 57.6 µg hexachlorobenzene (^{14}C-labeled) dose in 7.5 g of standard mink diet (22.2% fat) to each of three bred and five non-bred ferrets. The dosed ferrets and offspring were observed for 5 weeks after the kits were born, at which time they were killed and tissue ^{14}C-hexachlorobenzene levels were determined (Table III-5). One ferret kit per litter was also collected at birth and at weeks 1, 2, 3 and 4 for whole body residue determinations (Table III-6). These results indicate that nursing mothers can significantly reduce their body burdens of hexachlorobenzene, when compared with unbred female counterparts, by transferring a large amount of the hexachlorobenzene to their offspring.

TABLE III-5

Mean (±SE) Hexachlorobenzene Radioactivity (dpm/g) of Selected European Ferret Tissues[a,b]

Tissues	Group I (n=3)	Group II (n=5)	Kits[c] (n=3)
Blood	49 ± 34.6[d]	166 ± 26.8	--
Subcutaneous fat	4472 ± 780.5[e]	19,525 ± 1503.9	11,678 ± 712.4[f]
Visceral fat	4429 ± 867.6[e]	19,704 ± 1666.0	--
Muscle	53 ± 14.4[d]	384 ± 64.0	561 ± 204.8
Heart	34 ± 9.2[d]	310 ± 56.8	--
Kidney	105 ± 31.1[e]	611 ± 80.4	209 ± 37.2
Spleen	13 ± 7.5[e]	180 ± 24.8	--
Liver	248 ± 68.9[e]	1,445 ± 145.2	1,420 ± 185.6[g]
Lung	1 ± 0.3[e]	241 ± 18.4	--
Brain	61 ± 30.0[e]	395 ± 48.5	130 ± 29.4

[a]Source: Bleavins et al., 1982

[b]at 62 days postdosing from adult bred (group I) and unbred (group II) female ferrets exposed to a single 57.6 µg dose of ^{14}C-labeled hexachlorobenzene and from offspring born to the bred females.

[c]Kit tissues, from 5-week-old offspring, were contrasted only with maternal (group I) tissues.

[d]Significantly different ($p<0.05$) from group II tissue of the same type.

[e]Significantly different ($p<0.01$) from group II tissue of the same type.

[f]Significantly different from maternal tissue (group I) at $p<0.01$.

[g]Significantly different from maternal tissue (group I) at $p<0.05$.

HCB = Hexachlorobenzene

TABLE III-6

Mean (±SE) HCB Radioactivity (dpm x 10^a) of European Ferret Kits[a,b]

Measure	Number	Weeks Postpartum					
		0	1	2	3	4	5
Per gram of kit	3	3.0 ± 0.19	2.7 ± 0.57	4.3 ± 0.67	3.9 ± 0.73	3.5 ± 0.50	2.7 ± 0.14
Per whole kit	3	25.1 ± 1.43	76.7 ± 14.35	311.4 ± 63.39	492.5 ± 92.22	672.8 ± 117.63	805.7 ± 54.25
Increase over previous week		--	51.6	234.7	181.1	180.3	132.8
Milk (per ml)	3	--	--	6.1 ± 0.66	2.9 ± 0.45	1.8 ± 0.17	0.8 ± 0.20

[a]Source: Bleavins et al., 1982

[b]Born to female ferrets exposed to a single dose of ^{14}C-labeled hexachlorobenzene and the milk produced by those dams

HCB = Hexachlorobenzene

The mothers' milk contaminated with hexachlorobenzene seems to be a large contributor to the kits' body burdens with a reported milk to placental exposure ratio of 31:1. The distribution of hexachlorobenzene in ferrets follows similar trends, as observed in the other mammals, where the highest hexachlorobenzene levels were found in the lipid rich tissues.

The transfer of hexachlorobenzene to nursing infant rhesus monkeys from lactating mothers receiving via oral intubation 64 mg/kg/day hexachlorobenzene suspended in 1% methyl cellulose, for 60 days was reported by Bailey et al. (1980). Milk concentrations were on the average 17-fold higher than maternal serum levels, whereas infant serum levels were about 2- to 5-fold higher than serum levels of their mothers. Similarly, the infants had higher tissue residues than their mothers and hexachlorobenzene was concentrated in the infant fat, bone marrow, adrenals and lymph nodes.

Hexachlorobenzene residues also have been reported in human fat in the United Kingdom (Abbott et al., 1981, Japan (Curley et al., 1973), and Australia (Brady and Siyali, 1972) and in human milk collected in Sweden (Westoo and Noren, 1978; Hofvander et al., 1981), Canada (Mes and Davies, 1979), Norway (Bakken and Seip, 1976; Skaare, 1981), and Hawaii (Takahashi et al., 1981).

Metabolism

The metabolism of hexachlorobenzene has been studied in male and female rats following oral administration, rhesus monkeys and beagles following i.v. injection, and in rabbits following i.p. injection (Renner, 1981). Hexachlorobenzene is metabolized slowly into other lower chlorinated benzenes, chlorinated phenols and other minor metabolites and forms

glucuronide and glutathione conjugates. Tissues were found to contain mainly unchanged hexachlorobenzene together with small amounts of metabolites. Similarly, only small amounts of hexachlorobenzene metabolites were detected in feces, whereas most of the metabolites were excreted in the urine together with small amounts of unchanged hexachlorobenzene.

Mehendale et al. (1975) studied the metabolism of hexachlorobenzene in male Sprague-Dawley rats 7 days after oral intubation administration of a single 5 mg/kg dose in arachis oil. The fat, liver, intestines, kidneys, lungs and brain were found to contain hexachlorobenzene primarily, along with trace amounts of other chlorinated benzenes. Analysis of these chlorinated benzenes suggested the presence of pentachlorophenol, 2,4,5-trichlorophenol, pentachlorobenzene and the tetrachlorobenzenes. Extraction and analysis of fecal radioactivity, which accounted for 16% of the dose, did not reveal the presence of metabolites. Although urine contained only 0.85% of the administered radioactivity, it provided the only evidence of hexachlorobenzene metabolite excretion. Several unidentified metabolites were evident following thin-layer chromatography (TLC) separation of urine, in addition to 2,4,5-trichlorophenol, pentachlorophenol and one spot was reported to contain a mixture of chlorinated benzenes.

In vitro metabolism studies with homogenates of the liver, lungs, kidneys and small intestines produced trace amounts of chlorobenzene metabolites when incubated with [^{14}C]-hexachlorobenzene in the presence or absence of added cofactors. Liver microsomal preparations produced amounts of one or more chlorophenols when fortified with NADPH; in the presence of UDPGA, pentachlorophenol was reported to form the glucuronide conjugate.

Fortification of kidney homogenates with glutathione resulted in the appearance of unextractable radioactivity in the aqueous phases, indicating that glutathione conjugates of polar hexachlorobenzene metabolites might also be formed (Mehendale et al., 1975).

The metabolism of hexachlorobenzene in male and female Sprague-Dawley rats each receiving nine oral doses of 85.6 mg/kg hexachlorobenzene (99.7% pure) in arachis oil over a period of 1 month was reported by Richter et al. (1981). The animals were sacrificed 3, 24 and 52 days after the last dose, and various tissues were analyzed for hexachlorobenzene and its metabolites by CDE/GLC and GLC/MS. In addition to hexachlorobenzene, the following metabolites were also detected: pentachlorobenzene (PCB), pentachlorophenol (PCP), pentachlorothiophenol (PCTP) and 2,3,4,6- and 2,3,5,6-tetrachlorophenol (TCP). The results reported for the liver and kidneys for day 3 indicated that the livers of the females contained significantly more PCTP, a derivative of a glutathione conjugate, than those of the males (Table III-7). However, it is not known whether this increase is due to a higher rate of PCTP production or to a lower rate of elimination.

Rizzardini and Smith (1982) investigated the sex differences in hexachlorobenzene metabolism in young F344/N rats who had been intubated every other day for 103 days with 14 mg/kg hexachlorobenzene (analytical grade) dissolved in arachis oil. Three hexachlorobenzene metabolites were analyzed for: pentachlorobenzene, pentachlorothiophenol and 2,3,5,6-tetrachlorobenzene-1,4-diol, and all three were found to be produced in larger concentrations in the female rats during the first 10 weeks of hexachlorobenzene treatment. The greater quantities of hexachlorobenzene metabolites being formed in female rats was believed due to their body estrogen levels.

TABLE III-7

Concentrations of HCB and its Metabolites (mg/kg) in the Liver and Kidneys of Male and Female Rats[a,b]

Tissue/Sex	HCB	PCB	PCP	PCTP	TCP
Liver					
Males	192	0.05	3.16	0.23	0.02
Females	147[c]	0.03[c]	2.12[c]	0.36[c]	0.04[c]
Kidneys					
Males	127	0.05	5.79	0.24	0.09
Females	111	0.01	3.69	0.10	0.08

[a]Source: Richter et al., 1981

[b]Determined 3 days after the last of nine oral doses of 85.6 mg/kg HCB given within 1 month in arachis oil

[c]Statistically significant from males ($p<0.05$)

HCB = Hexachlorobenzene; PCB = pentachlorobenzene; PCP = pentachlorophenol; PCTP = pentachlorothiophenol; TCP = 2,3,5,6-tetrachlorophenol

Engst et al. (1976) detected several urinary metabolites in male Wistar rats receiving by gavage 8 mg/kg of hexachlorobenzene daily dissolved in sunflower oil for 19 days. The results of this study were presented qualitatively, and the authors reported that the major metabolic route for hexachlorobenzene was to pentachlorophenol. In addition, the feces contained mainly unchanged hexachlorobenzene together with traces of pentachlorobenzene.

Koss et al. (1976) investigated the metabolism of hexachlorobenzene in female Wistar rats given 2-3 i.p. doses of [^{14}C]hexachlorobenzene (260 or 390 mg/kg total dose). At the end of 4 weeks, 7% of the administered radioactivity was excreted in the urine, with >90% of this amount contained in the major metabolites (pentachlorophenol, tetrachlorohydroquinone, and pentachlorothiophenol). An isomer of tetrachlorothiophenol was detected as a minor urinary metabolite. Twenty-seven percent of the administered radioactivity was excreted in the feces, of which 70% was identified as unchanged hexachlorobenzene. Only pentachlorophenol and pentachlorothiophenol were identified as fecal metabolites of hexachlorobenzene. In the tissues of the animals, only pentachlorophenol was detected in measurable quantities, accounting for 10% of the radioactivity in blood and <0.1% in body fat. Total radioactivity contained in the metabolites detected in the animal bodies and excreted at the end of the 4 weeks accounted for 16% of the administered radioactivity.

In follow-up studies, Koss et al. (1978a) compared the formation of hexachlorobenzene metabolites in rats, mice, guinea pigs, Japanese quail, laying hens and rainbow trout. The only metabolites detected were penta-

chlorophenol, tetrachlorohydroquinone and pentachlorothiophenol; however, the species tested differed greatly in their ability to metabolize hexachlorobenzene (Table III-8).

Gas-liquid chromatography of urine, bile and fecal extracts from male beagle dogs receiving a single i.v. injection of ^{14}C-hexachlorobenzene at 1 mg/kg revealed that 96% of the fecal radioactivity occurred as the parent compound. Hexachlorobenzene accounted for 4% of the biliary radioactivity, but no parent compound was detected in urine (Sundlof et al., 1982).

Kohli et al. (1976) studied the metabolism of several chlorinated benzenes, including hexachlorobenzene, in rabbits following i.p. injection. The urine was collected for 10 days after injection and analyzed for metabolites following extraction and gas-liquid chromatography, but no hexachlorobenzene metabolites were found in the urine.

Excretion

The excretion of hexachlorobenzene from treated animals is slow and occurs mainly through the feces, with relatively little being excreted in the urine. It is characterized by an initial rapid phase followed by a very slow phase. This slow phase of excretion can be enhanced by the administration of mineral oil, paraffin and n-hexadecane. Both biliary and intestinal excretion contribute to fecal excretion. A three-compartment mammillary model has been reported for the behavior of hexachlorobenzene in beagles and rhesus monkeys following i.v. injection of a single dose. Radioactivity was not detected in exhaled air following i.p. injection of ^{14}C-hexachlorobenzene.

TABLE III-8

Hexachlorobenzene and Its Major Metabolites
in the Excreta of Different Animal Species[a]

Species[b]	Total Dose[c] (mMol/kg)	Total Amount of Substances			
		HCB	PCP	TCH	PCTP
Rat	0.92	6.1[d]	2.0	0.4	1.8
Mouse	0.92	2.6	0.3	0.1	ND
Guinea pig	0.92	1.8	0.9	0.2	0.5
Japanese quail	2.76	7.5	trace	trace	3.2
Laying hen	0.92	0.6	0.1	0.07	0.04
Rainbow trout	2.76	1.8	0.4	ND	ND

[a]Source: Koss et al., 1978a

[b]2-3 animals were used per each species investigated

[c]Hexachlorobenzene was dissolved in oil and administered intraperitoneally

[d]Figures are given in µMol/kg bw/day

ND = Not detected. The lower detection limit of the metabolites was determined to be 0.03 nMol/mℓ urine or g feces.

HCB = Hexachlorobenzene; PCP = pentachlorophenol; TCH = tetrachlorohydroquinone; PCTP = pentachlorothiophenol

Studies conducted by Mehendale et al. (1975) with rats receiving a single oral dose indicated that only 16.0 and 0.85% were excreted in the feces and urine, respectively, 7 days after treatment (see Table III-1). Ingebrigtsen et al. (1981) reported that 4 days after intragastric administration of ^{14}C-hexachlorobenzene, a total of 24.8 and 2.1% of the administered radioactivity were recovered in the feces and urine, respectively. In addition, an average of 3.6% of the dose was recovered in the bile of bile-duct-cannulated rats within 48 hours after dosing. Of the radioactivity excreted in the bile, only 2% was unchanged hexachlorobenzene, 1.8% was pentachlorobenzene, 24% was pentachlorophenol and ~72% was unidentified metabolites.

Rozman et al. (1977) studied the excretion of hexachlorobenzene in female rhesus monkeys receiving 110 µg ^{14}C-hexachlorobenzene/day/monkey via diet for 15 months. The excretion and storage patterns showed a very slow approach to a saturation level, indicating a high tendency for hexachlorobenzene accumulation in rhesus monkeys. A total of 5.8 and 3.6% of the administered dose was excreted in the urine of male and female monkeys, respectively, after 15 months, of which 50% was pentachlorophenol, 25% pentachlorobenzene and the remaining 25% consisting of unidentified metabolites with varying amounts of hexachlorobenzene. A total of 47.9 and 27.5% of the dose was present in the feces of male and female monkeys, respectively, of which 99% was hexachlorobenzene.

Koszo et al. (1978) administered hexachlorobenzene (0.2% in the diet) to young male and female Wistar rats for as long as 200 days and measured the accumulation of hexachlorobenzene in the liver and fatty tissue and the

excretion of hexachlorobenzene and pentachlorophenol in the urine and feces. The concentration of hexachlorobenzene in the liver and fat increased steadily throughout the treatment period. Pentachlorophenol appeared in both the urine and feces in increasing amounts throughout the treatment period, with the excretion of other apolar and polar products being markedly enhanced after 5-6 weeks.

Rizzardini and Smith (1982) investigated the sex differences in hexachlorobenzene metabolism and excretion of hexachlorobenzene metabolites in young F344/N rats. These rats were intubated with 14 mg/kg analytical grade hexachlorobenzene dissolved in arachis oil every other day for 103 days and were analyzed for the three main hexachlorobenzene metabolites, pentachlorophenol, pentachlorothiophenol and 2,3,5,6-tetrachlorobenzene-1,4-diol, in urine and feces. Results indicated that the combined urinary excretion of metabolites was greater in the female rats, especially during the first 10 weeks, with pentachlorothiophenol being particularly high in the females. No wide variations between the sexes were seen in the analyzed feces hexachlorobenzene metabolites after 103 days of treatment. Combined urine and feces excretion of metabolites at the end of the study were found not to be significantly different between males (2291$\pm$116 nmole/ 24 hours/kg) and females (2425$\pm$182 nmole/24 hours/kg). It was stated, though, that the total excretion of pentachlorothiophenol was always significantly higher in the female rats.

Koss and Koransky (1975) studied the metabolism of hexachlorobenzene in rats when the compound was orally administered in an aqueous suspension or in olive oil. The animals received different amounts of ^{14}C-hexachloro-

benzene in a single dose, and the feces and urine were collected at varying time intervals and radioassayed. When administered in water, hexachlorobenzene was not readily absorbed; 76-97% of the dose was excreted in the feces, and <0.1-0.4% was excreted in the urine 1 day after administration. When administered in oil, only 45-46% of the dose was excreted in the feces and 2.1-3.8% was excreted in the urine after 14 days of treatment. Rats receiving 4 mg/kg of ^{14}C-hexachlorobenzene administered i.p. excreted a total of 5 and 34% of the dose in the urine and feces, respectively, within 14 days. About 4 and 80% of the excreted radioactivity in the urine and feces, respectively, was unchanged hexachlorobenzene. Animals injected i.p. with 50.5 mg/kg [^{14}C]hexachlorobenzene released no radioactivity in exhaled air (Koss and Koransky, 1975).

Rozman et al. (1981) reported that administration of mineral oil or n-hexadecane to female Sprague-Dawley rats or male or female rhesus monkeys who were pretreated with ^{14}C-hexachlorobenzene enhanced the fecal elimination of ^{14}C-hexachlorobenzene. All animals were administered ^{14}C-hexachlorobenzene (100 mg/kg) in 1% methyl cellulose as a single oral dose intubation except for one monkey that received three consecutive daily doses and two monkeys that received ^{14}C-hexachlorobenzene (0.11 mg/kg) in sugar pellets daily for 750 consecutive days. Aliphatic hydrocarbons were administered to the treated animals 11-40 days after hexachlorobenzene treatment. When mineral oil was added to the diet of the rhesus monkeys, fecal excretion of hexachlorobenzene was enhanced 6- to 9-fold. Similarly, dietary administration of hexadecane resulted in the same increase in fecal excretion of hexachlorobenzene in both the rhesus monkeys and rats. Residue analyses indicated an enhanced depletion of hexachlorobenzene from blood and

of stored hexachlorobenzene from adipose tissue. Enhanced fecal excretion of hexachlorobenzene as a result of dietary administration of aliphatic hydrocarbons was primarily due to increased hexachlorobenzene elimination in the large intestine.

Richter and Schafer (1981) studied the intestinal excretion of hexachlorobenzene in male Sprague-Dawley rats using the pendular perfusion method. The animals were injected i.p. with hexachlorobenzene at 100 mg/kg and, 1 and 4 weeks after treatment, various parts of the intestines were perfused with paraffin or squalane for 5 hours. The largest amount of hexachlorobenzene excreted was into the jejunum followed by the ileum and colon. The ratios of total hexachlorobenzene excreted during paraffin treatment were: jejunum/ileum = 1.26 and jejunum/colon = 2.43. The authors concluded that these results indicate the importance of intestinal excretion in the elimination of hexachlorobenzene, and that paraffin treatment can be one of the measures by which a long-term stimulation of hexachlorobenzene excretion can be achieved.

Beagle dogs receiving a single i.v. dose of 1 mg/kg excreted 44 and <6% of the dose in the feces and urine, respectively, during a 12-week period (Sundlof et al., 1982). Both biliary and intestinal excretion contributed to fecal excretion; however, the data indicated that biliary excretion was the major contributor to fecal excretion. A computer-assisted pharmacokinetic analysis of blood, urine and fecal radioactivity levels during a 12-week period suggested a three-compartment model for the behavior of hexachlorobenzene in beagles. The biologic half-life values were calculated for the three dogs used and ranged from 6 weeks to 3 years.

Yang et al. (1978) reported that the elimination rate of hexachlorobenzene from male Sprague-Dawley rats and rhesus monkeys injected i.v. with hexachlorobenzene was slow because hexachlorobenzene is stored in the fat tissue. The major route of excretion for the radiolabel in treated monkeys was via the feces. About 17.1, 8.8 and 28.2% of the dose was excreted in the feces after 100 days, 6 months and 1 year, respectively, after treatment of individual monkeys, with ~90% of the radioactivity determined to be unchanged ^{14}C-hexachlorobenzene. The cumulative urinary excretion of hexachlorobenzene metabolites was determined to be 1.6% of the administered dose after 1 year. An open system, three-compartment mammillary model was found to fit the data for plasma, fecal and metabolized hexachlorobenzene in the rhesus monkey.

Koss et al. (1983) administered 100 mg/kg hexachlorobenzene in olive oil every other day, via stomach tube, to female Wistar rats for a period of 6 weeks and then observed the rats for an additional 18 months. At cessation of hexachlorobenzene treatment they tried to assess the biologic half-life of hexachlorobenzene and determined a value of 8 days for the start of the elimination phase, a value of 10 weeks when assessed 3 months later, and finally a value of 1.5 years after 12 months. The authors then concluded that it is not possible to establish a valid biologic half-life for the total elimination phase of hexachlorobenzene in rats.

Bleavins et al. (1982) studied the excretion and transfer of hexachlorobenzene given to female European ferrets (Mustela putorius furo). Three bred and five non-bred female ferrets were each given a single dose of 57.6 µg ^{14}C-hexachlorobenzene in 7.5 g of standard mink diet (22.2% fat).

The investigators indicated that there were no significant differences in the excretion of hexachlorobenzene metabolites, between bred and non-bred groups, in urine for the entire 8-week study period or in feces during the beginning of the study. The observed fecal excretion during the middle weeks to the end of the study showed a leveling of the cumulative fecal excretion in the bred females and a continued increase in fecal excretion in the non-bred female ferrets, although it was stated that this difference was not statistically significant. Excretion of hexachlorobenzene or metabolites in the milk was found to be an important route of excretion for lactating females, ~20.3% of the initial dose was eliminated by the fifth week of lactation, and found to be a very important route of exposure to nursing offspring. The importance of placental transfer and milk excretion is further presented by observing the time required for 50% of the initial hexachlorobenzene dose to be excreted. The bred females required 32 days to excrete 50% while 41 days was required for the unbred females.

Summary

The pharmacokinetics of hexachlorobenzene in a number of mammalian species have been studied in detail following oral administration and, to a lesser extent, following i.v. or i.p. injection. No information was present in the available literature on hexachlorobenzene metabolism following inhalation or topical application. Absorption of hexachlorobenzene from the intestinal tract appears to depend on the solvent vehicle used during test material administration. Thus, when hexachlorobenzene is administered in olive oil, ~80% of the dose is absorbed; when it is administered in an aqueous solution, in 1% methyl cellulose or in a crystalline form, relatively little (<20%) is absorbed. Intestinal absorption of hexachloro-

benzene occurs primarily through lymphatic channels, with only a minor portion being absorbed into the portal circulation.

Following absorption, hexachlorobenzene distributes to tissues that have a high lipid content. The adipose tissue accumulates the greatest concentrations of hexachlorobenzene in all species studied, although bone marrow and skin, which contain large amounts of lipids, also accumulate hexachlorobenzene. The adrenal cortex accumulates hexachlorobenzene at concentrations approaching those of fat. Other tissues (e.g., liver, kidneys, lungs, heart, spleen and blood) generally contain much lower amounts of hexachlorobenzene. Intravenous injection of hexachlorobenzene results in a tissue distribution similar to that seen following oral administration. Hexachlorobenzene is transported via the placenta and is distributed in fetal tissue in rabbits, rats, mice, minks and ferrets.

Hexachlorobenzene is metabolized slowly into other chlorinated benzenes, chlorinated phenols and other minor metabolites and forms glucuronide and glutathione conjugates. Tissues were found to contain mainly unchanged hexachlorobenzene together with small amounts of metabolites. Similarly, only small amounts of hexachlorobenzene metabolites were detected in feces, whereas most of the metabolites were excreted in the urine together with small amounts of unchanged hexachlorobenzene. There are indications that females produce and excrete more hexachlorobenzene metabolites than do males.

The excretion of hexachlorobenzene from treated animals is slow and occurs mainly through the feces with relatively little being excreted in the urine. It is characterized by an initial rapid phase followed by one or

more slow phases. This slow phase of excretion can be enhanced by the administration of mineral oil, paraffin or n-hexadecane. Both biliary and intestinal excretion contribute to fecal excretion. A three-compartment mammillary model has been reported for the behavior of hexachlorobenzene in beagles and rhesus monkeys following i.v. injection of a single dose. Radioactivity was not detected in exhaled air following i.p. injection of ^{14}C-hexachlorobenzene. Hexachlorobenzene has been detected in the milk of nursing mammals.

IV. HUMAN EXPOSURE

This chapter will be submitted by the Science and Technology Branch, Criteria and Standards Division, Office of Drinking Water.

V. HEALTH EFFECTS IN ANIMALS

Acute Toxicity

Information on the acute toxicity of hexachlorobenzene was limited to oral LD_{50} values determined with a few mammalian species. The following LD_{50} values were reported in the available literature: rats, 3500-10,000 mg/kg; rabbits, 2600 mg/kg; cats, 1700 mg/kg; and mice, 4000 mg/kg (IARC, 1979; NAS, 1977; Sax, 1979).

Graef et al. (1979) reported that hexachlorobenzene blocked the activity of rat hepatic 3-hydroxysteroid dehydrogenase leading to the accumulation of 5ß-H-steroids, which are known inducers of porphyrin biosynthesis. Hexachlorobenzene-induced porphyria has also been reported to occur as a result of a deficiency in the uroporphyrinogen decarboxylation process that is catalyzed by porphyrinogen carboxylase. This enzyme is the only one in the heme pathway that exhibits a decrease in activity. The inhibition of porphyrinogen carboxylase in liver homogenates from female Wistar rats with severe porphyria induced by hexachlorobenzene was studied by Rios de Molina et al. (1980). Hexachlorobenzene had no effect on enzyme activity at 10^{-3} M, whereas pentachlorophenol caused a 90% inhibition at the same concentration. However, pentachlorophenol did not inhibit the enzyme at a concentration of 10^{-5} M. It was concluded that a concentration $>10^{-5}$ M of pentachlorophenol, possibly together with other hexachlorobenzene metabolites, was needed to cause enzyme inhibition.

Hexachlorobenzene has also been reported to induce the activity of hepatic microsomal enzymes in male or female rats following subchronic administration (Carlson, 1978; Carlson and Tardiff, 1976; Chadwick et al.,

1977). Hexachlorobenzene produced a so-called "mixed-type" induction of cytochrome P-450 content in female rats resembling that produced by a combination of phenobarbital (cytochrome P-450) and 3,4-benzopyrene (cytochrome P-448) (Goldstein et al., 1982; Debets et al., 1980a). In female rats, hexachlorobenzene increased the activities of δ-aminolevulinic acid synthetase and aminopyrine demethylase (Ariyoshi et al., 1974), ethoxyresorufin-O-deethylase, aminopyrine demethylase, aryl hydrocarbon hydroxylase, p-nitrophenol glucuronyl transferase, and NADPH-cytochrome c reductase (Goldstein et al., 1982; Debets et al., 1980a). Similarly, in male rats, hexachlorobenzene increased the activities of hepatic ethyl morphine N- and p-nitroanisol O-demethylases, aniline hydroxylase, and UDP glucuronyl transferase (Mehendale et al., 1975), acetanilide hydroxylase, acetanilide esterase, procaine esterase, and arylesterase activities (Carlson et al., 1979; Carlson, 1980).

Subchronic Toxicity

Several oral subchronic studies of hexachlorobenzene have been reported, but no studies were located on the effects of hexachlorobenzene following inhalation. In several animal species, hexachlorobenzene was found to cause alopecia and scabbing, decreased body weight, increased liver and kidney weights and increased porphyrin levels in the urine and in several organs. Histopathologic changes were noted in the liver and kidneys of rats, gastric lymphoid tissue of dogs, and ovaries of monkeys. When placed on untreated diets, rats were able to recover from most of the toxic effects of hexachlorobenzene treatment. Hexachlorobenzene was also reported to cause certain neurologic effects (ataxia, paralysis, etc.) on rats, mice, hamsters and female beagles, and to induce an increase in hepatic microsomal enzyme activity. Toxicity data for hexachlorobenzene can be found in Table V-1.

TABLE V-1

Summary of Toxicity Studies on Hexachlorobenzene

Species	Route	Dose	Duration	Effects	Reference
Rat (females)	oral	100 mg/kg every other day	up to 43 days	Suggested covalent binding of hexachlorobenzene metabolites to cytosolic proteins	Koss et al., 1980a
Rat	oral (diet)	0.5 mg/kg/day	15 weeks exposed and held to 48 weeks	Transient increases in liver porphyrin levels in females after termination of exposure	Kuiper-Goodman et al., 1977
		2.0 mg/kg/day	15 weeks exposed and held to 48 weeks	Increases in liver porphyrin levels in females after termination of exposure, increased size of centrilobular hepatocytes	
		8.0 mg/kg/day	15 weeks exposed and held to 48 weeks	Increased liver weights, increased liver, kidney and spleen porphyrin levels in females (porphyria), centrilobular liver lesions especially in females at 48 weeks	
		32.0 mg/kg/day	15 weeks exposed and held to 48 weeks	Increased mortality in females, intension tremors in males and females and ataxia in a few females, increased liver, kidney and spleen weights, increased liver; kidney and spleen porphyrin levels in females (porphyria), centrilobular liver lesions and splenomegaly	
Rat (females)	oral (gavage)	50 mg/kg every other day	15 weeks	Increased liver, kidney, spleen and adrenal weights, porphyria (increased liver porphyrin levels and increased excretion of porphyrins and precursors), tremors, hair loss and skin lesions	Koss et al., 1978b
Rats (females)	oral (gavage)	0.5 mg/kg twice weekly	29 weeks	Increase in relative liver weight	Böger et al., 1979
		2.0 mg/kg twice weekly	29 weeks	Increase in relative liver weight, moderately enlarged hepatocytes	
		8.0 mg/kg twice weekly	29 weeks	Porphyria, markedly enlarged hepatocytes, increase in relative liver weight	
		32.0 mg/kg twice weekly	29 weeks	Porphyria, markedly enlarged hepatocytes, increase in liver weights	
Rat (females)	oral (diet)	100 mg/kg diet	98 days	Porphyria (increased liver lobe porphyrins), decreased activity of uroporphyrinogen decarboxylase	Smith et al., 1980

TABLE V-1 (cont.)

Species	Route	Dose	Duration	Effects	Reference
Rat	oral (diet and nursing)	50 mg/kg diet	gestation until 5 weeks of age	Depressed resistance to L. monocytogenes and T. spiralis, enhanced thymus-dependent antibody response	Vos et al., 1979b
		150 mg/kg diet	gestation until 5 weeks of age	Increased serum IgM and IgG, depressed resistance to L. monocytogenes and T. spiralis, enhanced thymus-dependent antibody response, increased liver and adrenal weights	
Rat	oral (diet and nursing)	4, 20 or 100 mg/kg diet	gestation until 5 weeks of age	Increased IgM and IgG responses to tetanous toxiod, delayed-type hypersensitivity reactions to ovalbumin, noted accumulation of alveolar macrophages; no change in T. spiralis resistance	Vos et al., 1983a,b
Rat	oral (diet)	500, 1000 or 2000 mg/kg diet	3 weeks	Dose-related increases in relative spleen, lymph nodes, liver, adrenals, thyroid, testes and kidney weights, dose-related increase in serum IgM levels, no change in serum IgG levels, dose-related pathologic changes in liver, lymph nodes and spleen	Vos et al., 1979a
Rat	oral (diet)	2000 mg/kg diet	10 weeks	Porphyria found microscopically at 5 weeks and grossly at 10 weeks using fluorescence	Gralla et al., 1977
Rat (male)	oral (diet)	2000 mg/kg diet	100 days	Elevated hepatic enzymes by 1 week and increased urinary porphyrin and ALA levels (porphyria) as early as 40 days	Lissner et al., 1975
Rat (female)	oral (diet)	3000 mg/kg diet	11 weeks	Decreased uroporphyrinogen decarboxylase activity and porphyria after 4 weeks	Elder et al., 1976
Rat (female)	oral (gavage)	50, 100 or 200 mg/kg	120 days	Dose- and time-dependent increase in liver and urine porphyrins (porphyria)	Carlson, 1977
Rat	oral (gavage)	14 mg/kg every other day	103 days	Porphyria in treated females, susceptibility of females to porphyria may be related to estrogen levels	Rizzardini and Smith, 1982
Rat (females)	oral (gavage)	100 mg/kg every other day	6 weeks exposed and held for additional 18 months	Porphyria (liver uroporphyrin levels peaked 7 months postexposure and levels had not returned to normal by 18 months), decreased liver protoporphyrin and coproporphyrin levels, inhibition of uroporphyrinogen decarboxylase activity until 18 months postexposure	Koss et al., 1983
Rat (females)	oral (diet)	6-8 mg/kg/day	75-90 weeks	Decline in body weights, porphyria, enlarged livers and liver tumors	Smith and Cabral, 1980

TABLE V-1 (cont.)

Species	Route	Dose	Duration	Effects	Reference
Rat	oral (diet)	75 mg/kg diet (4-5 mg/kg/day) 150 mg/kg diet (8-9.5 mg/kg/day)	up to 2 years	Porphyria, time-related appearance of severe hepatic and renal pathologies, after 1 year increases in hepatomas, hepatocarcinomas, bile duct adenomas, renal adenomas and renal carcinomas	Lambrecht et al., 1983a,b
Rat	oral (diet)	75 or 150 mg/kg diet	up to 2 years	Decreased nerve conduction velocities 8 and 31% in 75 and 150 ppm groups, respectively; muscles showed signs of denervation, fibrillations and pseudomyotonia	Sufit et al., 1986
Rat	oral (diet)	800 mg/kg diet	20 weeks	Reduced nerve conduction velocities, no muscle abnormalities as observed in 2-year study	Sufit et al., 1986
Rat	oral (diet)	0.32, 1.6, 8.0 or 40 mg/kg diet	~130 days	Hematologic changes at all dose levels in males, increases in liver and heart weights in males at 8.0 and 40 ppm diets, no treatment-related effects observed in bred females	Arnold et al., 1985
	oral (diet and nursing)	0.32 or 1.6 mg/kg diet	gestation through lifetime (130 weeks)	Glycogen depletion in 1.6 mg/kg males; no effects reported at 0.32 mg/kg	
		8.0 mg/kg diet	gestation through lifetime (130 weeks)	Increase in liver pathologies	
		40 mg/kg diet	gestation through lifetime (130 weeks)	Increased mortality as pups, increase in liver and kidney pathologies, increase in adrenal pheochromocytomas in females and parathyroid tumors in males	
Rat	oral (diet)	10 or 20 mg/kg diet	F_0 to F_4 generations	No effects reported	Grant et al., 1977
		40 mg/kg diet	F_0 to F_4 generations	Increases in liver weights and aniline hydroxylase activity	
		80 mg/kg diet	F_0 to F_4 generations	Decreased body weights, F_3 and F_4 generations had decreased lactation index and postnatal viability and increased stillbirths	
		160 mg/kg diet	F_0 to F_4 generations	Increased mortality and decreased lactation index starting in F_1 generation	
		320 and 640 mg/kg diet	F_0 to F_4 generations	20 and 50% mortality in F_0 320 and 640 mg/kg groups, respectively, greatly reduced fertility index and litter size and increase in stillbirths, viability index zero in F_1	

TABLE V-1 (cont.)

Species	Route	Dose	Duration	Effects	Reference
Rat	oral (diet)	60, 80, 100, 120 or 140 mg/kg diet	F_0 to F_{1a} and F_{1b} generations	Increased mortality in all groups at 21 days, 21-day LD_{50} values for pups were 100 and 140 mg/kg for F_{1a} and F_{1b} generations, respectively	Kitchin et al., 1982
Rat	oral (diet)*	0 or 80 mg/kg diet	gestation and nursing or cross nursed with controls	Nursing exposure produced greater effects than did gestational exposure, effects noted were: smaller brains, hearts, kidneys and spleens, increased liver weights	Mendoza et al., 1978
Rat	oral (diet)	80 mg/kg diet	2 weeks prior to mating to 35-36 days after weaning	Increased porphyrin levels and decreased liver esterase activity in dams, no changes in gestation indices or neonatal survival	Mendoza et al., 1979
Rat	oral (gavage)	10, 20, 40, 60, 80 or 120 mg/kg	days 6-21 of gestation	Maternal toxicity (weight loss, tremors and convulsions) and reduced fetal weights at 120 and 80 mg/kg maternal doses, dose-related increase in incidence of unilateral and bilateral 14th rib, sternal defects were also noted in one experiment	Khera, 1974
Mouse	oral (diet)	2.5, 25 or 250 mg/kg diet	21 days	Dose-related increase in liver and decrease in prostate and seminal vesicle weights, dose-related alterations in testosterone metabolism, altered hepatic enzyme levels	Elissalde and Clark, 1979
Mouse (male)	oral (diet)	10 mg/kg diet (8.4 (mg/mouse/24 weeks) or 50 mg/kg diet (35.3 mg/mouse/ 24 weeks)	24 weeks	Dose-related reduction in weight gain, no tumor pathology observed	Shirai et al., 1978
Mouse (male)	oral (diet)	167 mg/kg diet	3-6 weeks	Impairment in host resistance as measured by increased sensitivity to S. typhosa and P. berghei, and decrease in IgA levels	Loose et al., 1978a,b
Mouse	oral (diet)	6, 12, 24 and 36* mg/kg/day	101-120 weeks *(15 weeks exposed held until 120 weeks)	Reduced growth rate at all dose levels, shortened lifespan associated with tremors and convulsions in 24 and 36 mg/kg/day groups, dose-dependent increase in liver-cell tumors in the 12, 24 and 36 mg/kg/day dose groups	Cabral et al., 1979
Mouse	oral (gavage)	100 mg/kg/day to pregnant mice	days 7-16 of gestation	Increased maternal livers and decreased fetal body weights, increased incidence of abnormal fetuses per litter observed	Courtney et al., 1976
Hamster	oral (diet)	200 or 400 mg/kg diet	90 days	Precirrhotic and cirrhotic hepatic lesions, bile-duct hyperplasias and hepatomas	Lambrecht et al., 1982a

TABLE V-1 (cont.)

Species	Route	Dose	Duration	Effects	Reference
Hamster	oral (diet)	4, 8 or 16 mg/kg/day	lifespan	Shortened lifespan in 16 mg/kg/day group, increase in hepatomas at all dose levels, increase in liver haemangioendothelioma in males and females and an increase in thyroid alveolar adenomas in males in 16 mg/kg/day group	Cabral et al., 1977
Cats (breeding females)	oral (diet)	3 or 8.7 mg/day/cat	142 days	Weight loss and increased disease susceptibility in bred females, dose-related decrease in litter size and survival of offspring, hepatomegaly in offspring	Hansen et al., 1979
Minks	oral (diet)	1 or 5 mg/kg diet	during gestation until 17 weeks of age	Dose-related increase in offspring mortality, induction of hepatic MFO enzymes in exposed offspring	Rush et al., 1983
Dog (female)	oral (capsule)	50 or 150 mg/kg/day	21 days	Liver and hepatocyte enlargement, dose-induced electroencephalogram dysrhythmias	Sundlof et al., 1981
Dog	oral (capsule)	1, 10, 100 or 1000 mg/day/dog	1 year	Increase in mortality, neutrophilia, and anorexia in the 100 and 1000 mg dose groups, dose-related nodular hyperplasia of gastric lymphoid tissue in all treated animals	Gralla et al., 1977
Monkey (female)	oral (gavage)	8, 32, 64 or 128 mg/kg/day	60 days	Dose-related pathology in liver, kidney, ovaries and thymus	Iatropoulus et al., 1976
Monkey	oral (nursing)	7.51-186 ppm milk	60 days	2 of 3 infants died as a result of exposures	Bailey et al., 1980

Iatropoulos et al. (1976) reported that five adult female rhesus monkeys given daily gavage treatments of hexachlorobenzene suspended in 1% carboxymethylcellulose at 8, 32, 64 or 128 mg/kg/day for 60 days, showed extensive morphologic changes in the ovaries. These changes were dose-related.

Subchronic studies conducted by Koss et al. (1980a) with groups of four female rats treated orally (probably by gavage) with 100 mg/kg of hexachlorobenzene in olive oil every other day, suggested that hexachlorobenzene metabolites covalently bind to cytosolic proteins although no binding to uroporphyrinogen decarboxylase was specifically demonstrated.

Elissalde and Clark (1979) reported a significant increase in the in vitro metabolism of ^{3}H-testosterone by liver microsomes from male mice fed diets containing 250 mg hexachlorobenzene/kg for 21 days. In addition, decreases in the concentration of testosterone in the serum and in the weights of seminal vesicles and ventral prostates were reported. Hexachlorobenzene was also reported to cause certain neurologic lesions in male and female rats, hamsters and mice fed diets containing various levels of hexachlorobenzene for 13 weeks. These included hyperemia, edema, arborization and hemorrhages in the brain and meninges. The lesions extended to the cerebrum, cerebellum, medulla, spinal cord and their meninges. The severity of these lesions was higher in males and was dose dependent in both sexes (Headley et al., 1981). Physiologic changes (electroencephalogram dysrhythmias) in the central nervous system were reported in 10 female beagles receiving gelatin capsules containing doses of 50 or 150 mg/kg of hexachlorobenzene for 21 days (Sundlof et al., 1981).

Kuiper-Goodman et al. (1977) conducted a 15-week subchronic feeding study wherein groups of 70 male and 70 female COBS rats were fed diets providing 0, 0.5, 2, 8 or 32 mg/kg bw/day of hexachlorobenzene originally dissolved in corn oil (5%) and mixed with the feed. Female rats were more susceptible to hexachlorobenzene than males, as indicated by all the parameters studied, and a NOEL of 0.5 mg/kg/ day was suggested by the authors. This NOEL may be better interpreted as a NOAEL since a transient increase in liver porphyrin levels was observed in females 4 weeks after removal from hexachlorobenzene. The 2 mg/kg/day dose may be interpreted as a LOAEL since this level caused increases in liver porphyrin levels in females even 33 weeks after removal from hexachlorobenzene, and increases in the relative observed severity of centrilobular liver lesions as compared with control rats. About 40% mortality occurred in females, but none in males at the highest dose. Clinical signs included intention tremor, excessive irritability, multiple alopecia, scabbing and ataxia, with hind leg paralysis at the highest dose. There was a significant increase in liver and kidney weights at the higher doses. An increase in liver weight was also found in groups of 36 female Wistar rats treated by gavage twice weekly with hexachlorobenzene dissolved in olive oil at 32 mg/kg for 29 weeks (Boger et al., 1979)[a]. Similarly, Koss et al. (1978b) reported a 1.5- to 2-fold increase in the weights of the liver, spleen, kidneys and adrenal glands from female Wistar rats treated orally (esophageal tube) with 50 mg/kg of hexachlorobenzene dissolved in corn oil every other day for 15 weeks. When hexachlorobenzene-treated rats were placed on untreated diets, they no longer showed signs of hexachlorobenzene toxicity, such as dermal lesions, and body and organ weights returned to normal (Kuiper-Goodman et al., 1977; Koss et al., 1978b). Enlarged livers were reported in subchronic studies with female

beagles (Sundlof et al., 1981) and male mice (Shirai et al., 1978) administered hexachlorobenzene in diet.

A dose-dependent enlargement of hepatocytes was observed in groups of 36 female Wistar rats receiving gavage treatments of olive oil containing hexachlorobenzene (99.8% pure) 0.5, 2.0, 8.0 and 32 mg/kg twice weekly for 29 weeks (Boger et al., 1979). This effect was associated with the proliferation of the smooth endoplasmic reticulum in the centrilobular area, and an increase in glycogen deposits; however, animals receiving 0.5 mg/kg did not develop enlarged hepatocytes. In addition, atypical membrane complexes in treated animals were noted and liver-cell mitochondria were moderately enlarged and had irregular shapes. Kuiper-Goodman et al. (1976) also reported significantly enlarged hepatocytes in male and female COBS rats receiving hexachlorobenzene in diets, containing 5% corn oil, at the 8.0 and 32.0 mg/kg bw dose levels for 15 weeks. They observed that this hepatocyte enlargement consisted to a large degree of proliferation of the smooth endoplasmic reticulum. In males this proliferation was often associated with large whorls of compacted membranes surrounding lipid droplets. The nuclei of enlarged hepatocytes were also enlarged while the mitochondria were very small and sparse. They stated that this proliferation of smooth endoplasmic reticulum was related to the increased drug metabolizing enzyme activity of the liver and was considered an adaptive rather than toxic response to the hexachlorobenzene, since the enzyme activity and liver morphology returned to normal after exposures were discontinued. An increase in the size of centrilobular hepatocytes was also reported in male and female rats receiving 2 mg/kg/day for 15 weeks, together with histopathologic changes in the spleen (Kuiper-Goodman et al., 1977).

Nodular hyperplasia of gastric lymphoid tissue was reported in groups of 6 male and 6 female beagles receiving daily gelatine capsules containing 1, 10, 100 and 1000 mg hexachlorobenzene/dog/day for 12 months (Gralla et al., 1977). Extensive dose-related histopathologic changes were also observed in ovaries from groups of two rhesus monkeys given daily methyl cellulose/ distilled water solutions containing doses of 8, 16, 32, 64 or 128 mg hexachlorobenzene/kg of body weight by gavage for 60 days (Knauf and Hobson, 1979; Iatropoulas et al., 1976). Shirai et al. (1978) conducted a 24-week study with male mice fed diets containing 10 or 50 ppm of hexachlorobenzene, followed by a recovery period of 14 weeks. Histologic examination revealed no pathologic changes in the liver or any other organ.

Lambrecht et al. (1982a) fed male and female Syrian golden hamsters hexachlorobenzene at doses of 0, 200 and 400 ppm in their diet for 90 days. The hamsters were killed on day 91 and at 6-week intervals through day 361. No differences were seen in growth and food consumption between control and exposed animals. The liver was reported as the most severely affected organ exhibiting a variety of precirrhotic and cirrhotic lesions, bile-duct hyperplasias and hepatomas. The incidence of neoplasms found in this study will be further discussed in the Carcinogenicity Section.

Hexachlorobenzene has been found to cause increased porphyrin levels in the liver of male and female rats receiving the compound incorporated into the diet at doses of 8 and 32 mg/kg/day for 15 weeks (Kuiper-Goodman et al., 1977). Koss et al. (1978b) reported that female rats treated orally with 50 mg hexachlorobenzene/kg every other day for 15 weeks still showed increased levels of porphyrin in the liver, 38 weeks after the last treatment. In

addition, porphyrin, δ-aminolevulinic acid, and porphobilinogen levels in the urine gradually increased during the 15-week treatment period, but subsequently decreased to normal levels. Smith et al. (1980) reported that the lobes of livers from female Agus rats fed diets containing 0.01% hexachlorobenzene developed porphyria at different rates. During the initial course of treatment, porphyria in the caudate lobe developed at a significantly slower rate than the median, left or right sections of the liver, but eventually, all lobes became equally porphyric. In contrast, porphyria was not observed when viewed for hepatic fluorescence of porphyrins in male and female beagle dogs treated daily with 0, 1, 10, 100 or 1000 mg/dog/day for 1 year (Gralla et al., 1977). Gralla et al. (1977) observed that female CD rats fed 0.2% hexachlorobenzene were porphyric using this fluorescence method.

Rizzardini and Smith (1982) clearly confirmed that female rats are more susceptible to hexachlorobenzene-induced porphyria than are male rats, and that this difference in susceptibility is probably associated with the faster metabolism of hexachlorobenzene in females. They intubated male and female F344/N rats every other day for 103 days with 14 mg/kg (50 μmole/kg) hexachlorobenzene dissolved in arachis oil and monitored the rats for hexachlorobenzene metabolites and porphyrin levels. The results indicated that after 75 days of hexachlorobenzene treatment the excretion of urinary porphyrins increased rapidly in the females and after 103 days the females had urine and liver porphyrin levels 40- and 310-fold higher, respectively, than did the males. During this treatment period the females were found to excrete greater quantities of hexachlorobenzene metabolites, especially pentachlorothiophenol, than the males. Estrogen levels seem to play an

important part in the increased susceptibility of females to hexachlorobenzene-induced porphyria. When both male and female rats were pretreated intraperitoneally with four doses of 20 μmole/kg of diethylstilboestrol dipropionate (an estrogenic drug), both sexes had stimulated excretion of hexachlorobenzene metabolites.

Hexachlorobenzene pretreatment has been reported to cause altered immune responses. Vos et al. (1979b) studied the effect of hexachlorobenzene on the immune system after combined pre- and postnatal exposure. Wistar rats were fed diets containing 0, 50 or 150 mg/kg hexachlorobenzene during pregnancy and lactation. The pups were weaned after 3 weeks and continued on the test diets until 5 weeks of age, when their immune system was functionally assessed. At the higher dietary level, hexachlorobenzene caused a significant increase in serum IgM and IgG concentrations.

Hexachlorobenzene treatment also caused a decreased resistance to infection with Listeria monocytogenes (Vos et al., 1979b). The LD_{50} values were reported to be 14×10^5, 7.1×10^5 and 5.0×10^5 bacteria in pregnant Wistar rats receiving diets containing 0, 50 and 150 mg/kg, respectively. Similarly, decreased resistance of Trichinella spiralis infection, as indicated by an increase in the number of larvae found in muscle tissue, was noted. Hexachlorobenzene also enhanced the thymus-dependent antibody response to T. spiralis antigen and to tetanus toxoid. No effects were observed on allograft rejection, mitogenic response of thymus and spleen cells, thymus-independent IgM response to Escherichia coli lipopolysaccharide, passive cutaneous anaphylaxis, or on the clearance of carbon particles and L. monocytogenes. The authors concluded that hexachlorobenzene suppressed cellular immunity and enhanced humoral immunity in both test groups.

In a second combined pre- and postnatal hexachlorobenzene dietary study Wistar rats were similarly exposed to diets containing 0, 4, 20 or 100 mg/kg hexachlorobenzene during gestation, nursing and until 5 weeks of age (Vos et al., 1983a,b). The primary and secondary IgM and IgG responses to tetanous toxoid (humoral immunity parameters) were observed to be significantly increased in all test groups compared with controls. Delayed-type hypersensitivity reactions to ovalbumin (cell-mediated immunity parameter) were significantly enhanced in the 4 and 100 mg/kg groups and the 20 mg/kg group was observed as markedly increased (non-significantly) compared with controls. No hexachlorobenzene induced effects were observed on the resistance to Trichinella spiralis, on the antibody response to ovalbumin, and on the in vitro natural cytotoxic activity of spleen cells against YAC lymphoma cells. Even at the 4 mg/kg diet level accumulation of macrophages were noted in the lung alveoli of exposed rats. At the 4 mg/kg diet level liver weights, morphology and microsomal enzymes were not altered, except for an increase in the activity of 7-ethoxyresorufin-o-deethylase. These results led the authors to conclude that the developing immune system is particularly vulnerable to hexachlorobenzene exposure.

In contrast, hexachlorobenzene pretreatment of weanling rats did not alter their cell-mediated immunity, but did stimulate their humoral immune response and enhanced the in vitro responsiveness of spleen cells to different mitogens, which was mainly a result of an increase in the number of splenic lymphocytes. The rats received diets containing 1000 µg hexachlorobenzene/g for 3 weeks after weaning, before assessing their immune system (Vos et al., 1979a).

Loose et al. (1978a,b) found that hexachlorobenzene pretreatment also resulted in impaired host resistance. Male BALB/c mice received diets containing 167 µg hexachlorobenzene/g for 3 or 6 weeks before assessing their immune functions. The concentration of IgA was significantly decreased,whereas those of IgG and IgM did not exhibit consistent significant altera- tions as compared with the controls. Hexachlorobenzene-treated mice were more sensitive to gram-negative endotoxin (Salmonella typhosa), showed a decreased resistance to a malaria challenge (Plasmodium berghei), and exhibited signficantly depressed antibody synthesis.

Chronic Toxicity

Cabral et al. (1977) studied the tumorigenicity of hexachlorobenzene in 6-week-old Syrian golden hamsters given 0, 50 (4 mg/kg/day), 100 (8 mg/kg/day) and 200 (16 mg/kg/day) ppm hexachlorobenzene in their diets for their remaining lifespan. Shortened lifespan was observed in the male and female 200 ppm dose groups after 70 weeks of exposure along with marked weight reduction in the males. Neoplasms were increased by the hexachlorobenzene exposures and are reported in the Carcinogenicity Section. No other pathologies were reported in this study.

Cabral et al. (1979) studied the tumorigenicity of 6- to 7-week-old male and female outbred Swiss mice given 0, 50 (6 mg/kg/day) 100 (12 mg/kg/day) and 200 (24 mg/kg/day) ppm hexachlorobenzene for 101-120 weeks and 300 ppm (36 mg/kg/day) hexachlorobenzene for 15 weeks and held until 120 weeks of age. Results indicated that shortened lifespan occurred in the 200 and 300 ppm dose groups starting after the 30th week of the test and that this

reduced survival was associated with tremors and convulsions. Reduction in the rate of growth was observed in female mice in the 50, 200 and 300 ppm dose groups and more pronounced growth rate reduction was observed in male mice in the 100, 200 and 300 ppm dose groups. An increase in neoplasms were found as a result of hexachlorobenzene exposures and are discussed in the Carcinogenicity Section. No other pathologies were reported in this study.

Smith and Cabral (1980) fed young female Agus or MRC Wistar rats 100 ppm (6-8 mg/kg/day) hexachlorobenzene in a diet containing 2% arachis oil for 90 weeks. Hexachlorobenzene exposure resulted in a steady decline in body weights over the study period and in the exposed rats possessing less hair than the controls. Tremors or other nervous symptoms were not seen during this study. Onset of porphyria was observed in the hexachlorobenzene treated rats after ~3 months, as indicated by urines fluorescing red under UV light, and liver porphyria was confirmed at autopsy by a red fluorescence of the liver. The livers were enlarged 2-fold in the hexachlorobenzene-exposed females and were associated with multiple liver cell tumors. This neoplastic incidence will be discussed in the Carcinogenicity Section.

Male and female Sprague-Dawley rats were fed hexachlorobenzene diets for 2 years containing 0, 75 or 150 ppm hexachlorobenzene (Lambrecht et al., 1983a,b). Four rats per group were killed at weeks 0, 1, 2, 3, 4, 8, 16, 32, 48 and 64 of the study and liver and kidney evaluations were made. Times of appearance of lesions were as follows: 4 weeks -- hepatic hyperemia, edema, parenchymal and hydropic degeneration, renal hyperemia, congestion, swelling and parenchymal degenerations; 32 weeks -- renal tubular nephritis with hyaline casts, severe parenchymal degeneration, epithelial

necrosis accompanied by proximal convoluted tubular regeneration, and pre-neoplastic foci; and 36 weeks -- hepatic preneoplastic foci; and 64 weeks -- hepatic neoplasms and renal neoplasms. The incidence of neoplasms will be further discussed in the Carcinogenicity Section.

In a short communication by Sufit et al. (1986), hexacholorobenzene-induced nerve function detriments were reported in rats. Rats fed hexachlorobenzene for 2 years at 150 and 75 ppm diet were observed with prolonged conduction times from the sciatic nerve to the foot of 31 and 8%, respectively. Needle electromyograph of the muscle showed signs of denervation, fibrillation, and chronic repetitive discharges (pseudo-myotonia). Hepatocarcinomas and other disorders were also seen but not described. In a second study male Sprague-Dawley rats were fed 800 ppm hexachlorobenzene in diet for 20 weeks prior to testing. They reported a significantly ($p=0.02$) reduced nerve conduction velocity in the hexachloro-benzene fed rats when compared to controls. Needle electromyograph of the gastrocnemius showed no fibrillations or other abnormalties. The authors stated that hexachlorobenzene had a definite detrimental effect on nerve function and suggested an axomal effect.

A two-generation hexachlorobenzene (analytical grade) feeding study was conducted using Sprague-Dawley rats fed diets containing 0 (64 males, 64 females), 0.32 (40 males, 40 females), 1.6 (40 males, 40 females), 8.0 (40 males, 40 females), or 40.0 (66 males, 66 females) ppm hexachlorobenzene (Arnold et al., 1985). The parental rats (F_0) received their respective test diets for 90 days before mating and until 21 days after parturition (at weaning), at which time they were killed and evaluated for hexachloro-

benzene-induced effects. The number of offspring (F_1 generation) from these matings were reduced to 50 males and 50 females per dose group at 28 days of age and fed their respective parents' diets. Thus, the F_1 animals were exposed to hexachlorobenzene and metabolites in utero, from maternal nursing and from their diets for the remainder of their lifetime (130 weeks).

The results from this two-generation study indicated no consistent treatment-related effects upon growth or food consumption in either generation and no change in fertility, gestation or lactation indices. A decreased viability index was noted in the 40.0 ppm group relative to controls. No treatment-related effects were found in the F_0 females. The F_0 males were found to have significantly increased liver, heart and brain absolute weights in the 8.0 ppm group and significantly increased liver and heart absolute weights in the 40.0 ppm group. The F_0 males were observed to have various significant changes in hematologic parameters at all dose levels. Neoplasms were seen in the F_1 generation and are discussed in the Carcinogenicity Section. In the F_1 generation the following changes were seen:

1) Centrilobular basophilic chromogenesis showed a significant dose-related trend in both males and females. Additionally, at doses of 8.0 and 40.0 ppm the increases were significant in comparison with controls for both males and females.

2) Increases in peribiliary lymphocytosis were significant in the 0.32, 1.6 and 40.0 ppm male groups, while increases in peribiliary fibrosis were statistically significant in the 0.32 and 40.0 ppm male groups.

3) Increases in severe chronic nephrosis were observed which were dose-related, but significant relative to controls only for the 40.0 ppm male dose group.

In a second study conducted by Arnold et al. (1985), 50 male Sprague-Dawley rats per group were fed hexachlorobenzene (0 or 40 ppm) and various levels of vitamin A diet (0.1, 1 or 10 times normal control levels). The test groups were as follows: control diet; control diet plus 40 ppm hexachlorobenzene; 1/10 vitamin A diet; 1/10 vitamin A diet plus 40 ppm hexachlorobenzene, 10 times control vitamin A diet; and 10 times vitamin A diet plus 40 ppm hexachlorobenzene. Five rats per group were killed and evaluated both at 25 and 49 weeks and the remaining animals were killed and evaluated after 119 weeks.

Results revealed that the animals on the 1/10 vitamin A diet had significantly reduced body weights and survivability when compared with control diet animals. The animals on 1/10 vitamin A plus 40 ppm hexachlorobenzene diet had significantly decreased body weights and did not survive as long as rats receiving the control diet plus 40 ppm hexachlorobenzene. Hematologic evaluations revealed no consistent treatment-related effects. Neoplasms were observed in the test animals and are discussed in the Carcinogenicity Section. No significant differences were found in the incidence of any pathological lesions between the test groups.

Mutagenicity

In a dominant lethal mutation study (Simon et al., 1979), male rats (strain not given) received by oral gavage 0, 70 or 221 mg hexachlorobenzene/kg body weight dissolved in corn oil for 5 consecutive days. A dose-dependent reduction in male reproductive performance was observed, but hexachlorobenzene did not induce dominant lethal mutations. Khera (1974) also reported a lack of dominant lethal mutations in Wistar rats following

oral administration of 0, 20, 40 or 60 mg hexachlorobenzene/kg in 0.25% aqueous gum traqacanth for 10 consecutive days. In 14 sequential mating trials, no significant differences in the incidence of pregnancies, corpora lutea, live implants and deciduomas between the treated and control groups were observed. Mutagenic activity has been observed in a yeast, Saccharomyces cerevisiae, assay (Guerzoni et al., 1976). The mutagenicity of hexachlorobenzene was investigated in three strains of S. cerevisiae using reversion from histidine and methionine auxotrophy, and hexachlorobenzene was reported to be mutagenic at a minimum concentration of 100 ppm.

Lawlor et al. (1979) measured the activity of hexachlorobenzene in the Ames assay, strains TA98, TA100, TA1535, TA1537 and TA1538, at five unspecified dose levels both with and without metabolic acitivation by Aroclor 1254 induced rat liver microsomes. Hexachlorobenzene possessed no detectable levels of mutagenic activity in any of the Salmonella strains used either with or without microsomal activation. These results were reported in an abstract with few experimental details. In addition, this result is not unexpected because the Salmonella test system is generally insensitive to chlorinated compounds (Rinkus and Legator, 1980).

Carcinogenicity

Studies on the carcinogenic potential of hexachlorobenzene have been carried out on hamsters, mice and rats.

Hamster Studies.

Cabral et al. (1977) -- In one study on Syrian golden hamsters (Cabral et al., 1977) hexachlorobenzene was administered in the diet at 50, 100 or 200 ppm. These concentrations correspond to dosages of 4, 8 and 16 mg/kg/

day based on body weight and food intake averages. The hexachlorobenzene was prepared by dissolution in corn oil which was then mixed with the feed. The feed was analyzed periodically to insure that the intended level of hexachlorobenzene was maintained (Mollner, 1983). The hexachlorobenzene preparation used in this study was 99.5% pure. Impurities reported to be present in some hexachlorobenzene preparations include chlorinated dibenzofuran and chlorinated dibenzo-p-dioxin, both members of classes of compounds that are carcinogens (Villeneuve et al., 1974). The dosages selected for this study were chosen in order to be comparable with those believed to be consumed by victims of accidental hexachlorobenzene ingestion in Turkey.

In this study on hamsters it was difficult to determine from the published report whether an MTD was reached or exceeded because the information on mortality and weight changes was not detailed enough for an unambiguous evaluation. Although mortality was monitored, the investigators only stated that 71% of the treated animals were alive at 50 weeks and that at the highest dose, 16 mg/kg bw/day, there was a reduced lifespan among treated animals after 70 weeks. The study was run for the lifetime of the animals, but the actual duration in weeks was not given. Since the investigators also reported "marked weight reduction" in the highest dose group one could conclude that the MTD may have been reached. However, in the absence of weight data definite conclusions cannot be made.

The tumor incidence among the hamsters is given in Table V-2. The incidence of hepatomas in males and females was statistically significant ($p<0.05$) in all treated groups. The incidence of liver haemangioendothelioma in males and females was statistically significant ($p<0.05$) in the

TABLE V-2

Tumor Incidence in Hamsters Given HCB in the Diet*

Group	Effective No.	TBA No.	%	No. of Tumors		More Than One Tumor		Thyroid		Hepatoma		Haemangioendotheliomas					
												Liver		Spleen		Other	
				No.	per Hamster	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Control	39 F	5	12.8	5	0.13	0	0	0	0	0	0	0	0	1	2.5	4	10.2
	40 M	3	7.5	3	0.08	0	0	0	0	0	0	0	0	0	0	3	7.5
50 ppm	30 F	16	53.3	21	0.70	4	13.3	2	6.6	14	46.6	0	0	0	0	5	16.6
(4 mg/kg)	30 M	18	60.0	27	0.90	8	26.6	0	0	14	46.6	1	3.3	1	3.3	11	36.6
100 ppm	30 F	18	60.0	32	1.06	11	36.6	1	3.3	17	56.6	2	6.6	3	10.0	9	30.0
(8 mg/kg)	30 M	27	90.0	45	1.50	14	46.6	1	3.3	26	86.6	6	20.0	3	10.0	9	30.0
200 ppm	60 F	52	86.6	73	1.21	15	25.0	3	5.0	51	85.0	7	11.6	4	6.6	8	13.3
(16 mg/kg)	57 M	56	98.2	87	1.52	27	47.3	8	14.0	49	85.9	20	35.0	4	7.0	6	10.5

*Source: Cabral et al., 1977

TBA - Tumor-bearing animals

HCB - Hexachlorobenzene

high-dose groups and in males in the middle-dose groups. There was a significant dose-related trend for both tumor types. Three instances of metastases were found among the animals with liver haemangioendothelioma. No hepatoma metastases were found. One of the hepatomas in a female animal was found at necropsy at 18 weeks; the investigators did not indicate which dosage level this animal received.

Hamsters in the control groups showed no thyroid tumors but thyroid alveolar adenomas were significantly increased in the high dose males and there was a significant dose-related trend. Thyroid tumors occurred in all treated groups of females but were not statistically significant.

Chemical induction of thyroid tumors has not been identified with chemically related compounds except for toxaphene, which is a mixture of chlorinated camphene derivatives. Other chemicals associated with induction of thyroid tumors are thioureas, thiouracils, 3-amino-4-ethoxyacetanilide, amitrok, o-anisidine, 2,4-diaminanisole sulfate, ethionamide, 4,4'-methylene bis(n,n'-dimethyl) n,n'-dimethylbenzenamine, 1,5-naphthylenediamine, 4,4'-oxydianaline, pronetalol•HCl, 4,4'-thiodianaline, iodoform, dibromomethane and dichloroethane (Kraybill, 1983; Weisburger, 1983). Hexachlorobenzene is in a different chemical class from these agents.

Induction of thyroid tumors in the animal studies is of particular interest because a very high incidence of enlarged thyroids was found among victims of accidental exposure to hexachlorobenzene in Turkey (Peters et al., 1983). The incidence among females, over 25 years after the incident, is 61.4% whereas the background incidence in that geographic area for

females is about 5% (Peters et al., 1983). The data and pathology reports have not been made available yet, but it is clear that the cohort exposed to hexachlorobenzene has an unexpectedly high incidence of enlarged thyroid. It cannot be stated at present what percentage if any of the enlarged thyroids was the result of tumorigenesis.

This hamster study provides strong positive evidence of tumorigenicity and evidence of carcinogenicity of hexachlorobenzene, as indicated by the significant increase in hepatomas, significant increase of thyroid adenomas in males and the occurrence of metastasizing liver haemangioendotheliomas in treated but not in control animals. Although not reported in detail in this one page publication, the authors noted an increase in adrenal neoplasms as well. The data presented show that the tumor incidence is positively dose-dependent in most instances and that this is true not only of the number of animals with tumors of all sites but also for the number of tumors per animal. The authors also indicated that latency period was reduced, but actual supporting data was not presented. Although strong evidence for carcinogenicity was provided in the hamster study, a cautionary note should be added regarding the results of this study and possibly other hexachlorobenzene studies as well. The hexachlorobenzene used was reported to be 99.5% pure. However, chlorinated dibenzofuran and chlorinated dibenzo-p-dioxin, both very potent carcinogens, have been reported in the past to be present in some samples of hexachlorobenzene. Very small amounts of such contaminants could influence results.

Lambrecht et al. (1982a) Hamster Study -- Another study on hamsters, carried out in a different laboratory, adds further suggestive evidence for

the tumorigenicity of hexachlorobenzene in hamsters (Lambrecht et al., 1982a). This study, reported only in abstract form, was also carried out in the Syrian golden hamster. In this study the animals were exposed for only 90 days to the hexachlorobenzene. On day 91, half of the initial exposed 50 animals were sacrificed. The remaining animals were sacrificed periodically until the end of the 1-year study. The exposure levels used were 200 or 400 ppm hexachlorobenzene in the diet. Assuming that the hamsters from the Cabral et al. (1977) study were comparable in weight and dietary consumption, these ppm figures would be approximately equal to and twice those of the high dose used in the lifetime studies of Cabral et al. (1977). Lambrecht et al. (1982a) reported the incidence of hepatoma at the 200 ppm level to be 7.7% in males and 6.7% in females; at the 400 ppm level the incidence was 5% in females and 14.3% in males. These figures are based on the numbers of animals at risk at the time of the earliest observed tumor. The time to first tumor was relatively late in the study, 276 days for males and 255 days for females of the lower dose and 153 days for males and 299 days for females at the higher dose. Since the test animals were systematically sacrificed from 3 months onward, the time to tumor figures should be reasonably close to actual time to tumor. Table V-3 shows the results reported by Lambrecht et al. (1982a).

The tumorigenicity and carcinogenicity of hexachlorobenzene has been demonstrated by one lifetime study in hamsters. Additional suggestive evidence for tumorigenicity is found in a 90-day study in another laboratory. In both cases hepatomas resulted. The longer period of exposure also produced thyroid adenomas and metastatic liver haemangioendotheliomas.

TABLE V-3

Effect of HCB on Hamsters: Liver Tumors and Other Liver Lesions[a]

Sex	HCB (ppm)	PC+C[b] Incidence	BDH[c] Incidence	Day First Observed	Hepatomas Incidence	Day First Observed
M	0	3/50	0		0	
	200	48/49	0		1/13	276
	400	50/50	1/25	101	1/20	153
F	0	10/43	0		0	
	200	48/49	1/6	340	1/15	255
	400	45/45	2/20	174	1/7	299

[a]Source: Lambrecht et al., 1982a

[b]Precirrhotic + cirrhotic

[c]Biliary duct hyperplasia

HCB = Hexachlorobenzene

Mouse Studies.

Cabral et al. (1979) -- Cabral et al. (1979) reported that outbred Swiss mice were fed hexachlorobenzene (99.5% purity) in their diets for up to 120 weeks. The hexachlorobenzene content of the diet was monitored periodically during the study and the diet was found to be free of aflatoxins. The exposure levels used were 50, 100 and 200 ppm corresponding to dosages of 6, 12 or 24 mg/kg/day based on body weight and food intake averages. One other test group was given 300 ppm (36 mg/kg/day) for only 15 weeks and retained on an hexachlorobenzene-free diet for the remainder of the study.

Growth rates were monitored but not given in detail in the published report. The investigators stated that among female mice there was a reduced growth rate for all doses except in the 12 mg/kg/day dose group and among males for all doses except in the 6 mg/kg/day dosage group.

Survival times were reported in detail. Survival was essentially unaffected in the two lower dosage level groups at 50 weeks, while at that time it was down by 60% of the original number in the females and 52% of the original number in the males in the highest dosage group. By 70 weeks on test the survival was decreased in the two lower dose groups as well, and in the highest dose group it was down to 14% in females and 10% in males. At 90 weeks there were only four surviving males out of the 50 and no surviving females in the highest dosage group as compared with 96 and 100% survival in the female and male controls.

The yield of tumors in this study is given in Tables V-4 and V-5. In Table V-4, the effective number of animals is the number of animals alive at

TABLE V-4

Liver Tumor Incidence in Mice Fed HCB[a]

Group	Effective[b] No. Animals	Mice with LCT		Node Size (mm)		Multiplicity		Age at Death (weeks)	
		No.	%	<8	≥8	Single	Multiple	Range	Average
HCB 100	F 12	3	25	2	1	1	2	87-104	98
	M 12	3	25	1	2	2	1	83-98	89
HCB 200	F 26	14	54	5	9	3	11	47-85	67
	M 29	7	24	4	3	2	5	46-101	73
HCB 300 (15 weeks exposure)	F 10	1	10	--	1	1	--	101	101
	M 3	1	33	--	1	--	1	97	97

[a]Source: Cabral et al., 1979

[b]Survivors at time first LCT was observed in each group

LCT = Liver cell tumors

HCB = Hexachlorobenzene

TABLE V-5

Tumor Data on Mice Fed HCB[a]

Group	Initial No. Animals	Effective[b] No. Animals	Animals with Tumors: TBA[c] No.	TBA[c] %	Lymphomas No.	Lymphomas %	Lymphomas Average Age at Death (weeks)	Lung No.	Lung %	Lung Average Age at Death (weeks)	Liver-cell No.	Liver-cell %	Gonads No.	Gonads %	Other No.	Other %
Control	F 50	49	39	80	21	43	89.6	14	29	89.0	0	0	3	6	9[d]	18
	M 50	47	22	47	12	26	80.8	13	28	83.8	0	0	0	0	4[e]	9
HCB 50	F 30	30	21	70	16	53	69.8	4	13	84.5	0	0	2	7	2[f]	7
	M 30	30	15	50	13	43	73.7	4	13	87.0	0	0	0	0	0	0
HCB 100	F 30	30	13	43	5	17	94.4	6	20	83.5	3	10	1	3	3[g]	10
	M 30	29	10	34	7	24	70.4	0	0	--	3	10	0	0	1[h]	3
HCB 200	F 50	41	19	46	5	12	58.2	2	5	66.5	14	34	1	2	1[i]	2
	M 50	44	12	27	4	9	53.2	4	9	82.5	7	16	1	2	0	0
HCB 300 (15 weeks)	F 30	26	20	77	8	31	97.7	4	15	91.2	1	4	3	12	8[j]	31
	M 30	16	5	31	3	19	68.6	2	13	83.5	1	6	0	0	0	0

[a]Source: Cabral et al., 1979

[b]Number of survivors at moment of appearance of first tumor at any site in each group

[c]In relation to the effective number

[d]Skin fibrosarcoma, uterine haemangioendothelioma, one skin haemangioendothelioma, two adrenal adenoma, two mammary adenoma

[e]Urinary bladder transition cell carcinoma, one liver haemangioendothelioma, one skin haemangioendothelioma, one skin fibrosarcoma

[f]One uterine haemangioendothelioma, one skin fibrosarcoma

[g]Two skin fibrosarcoma, one skin haemangioendothelioma

[h]One skin squamous-cell carcinoma

[i]One intestinal leiomyosarcoma

[j]One skin fibrosarcoma, two liver haemangioendothelioma, one cecum carcinoma, one stomach papilloma, one skin haemangioendothelioma, one uterine adenoma, one mammary adenoma

HCB = Hexachlorobenzene

the earliest time a liver cell tumor was observed in each group while in Table V-5 the effective number of animals is that number of animals alive at the earliest appearing tumor for any site in the body within that group. There was a statistically significant elevation in the incidence of liver cell tumors at the high dose in females and a marginal increase in high-dose males, with a positive dose-related trend in both cases. There was also a dose-dependent decrease in latent period and a dose-dependent increase in the size and multiplicity of liver cell tumors (see Table V-4). The liver cell tumors were subsequently defined as hepatomas (Cabral, 1983).

In this study there was a high incidence of both lymphoma and lung tumors in control mice. A dose-related decrease in the incidence of lymphomas appears in the treated groups. The investigators attributed this to the decreased survival time of hexachlorobenzene-treated animals. This seems reasonable but does not explain the reduction in lung tumors in the 50 ppm (6 mg/kg/day) group when they are compared to controls, since there was not an appreciable reduction of lifespan in this low dose group.

This study by Cabral et al. (1979) demonstrates the tumorigenicity of hexachlorobenzene in Swiss mice by the significant increase in liver cell tumors in both sexes and by the demonstration of dose-dependency in the response with respect to tumor incidence, tumor size, multiplicity and latent period duration. Tumorigenicity was detected as low as 12 mg/kg bw/day (100 ppm) for lifetime exposure but not at 6 mg/kg bw/day (50 ppm).

Lambrecht et al. (1982b) -- Swiss mice exposed to hexachlorobenzene for only 90 days at levels of 100 and 200 ppm in the diet showed degenera-

tive changes of liver and kidneys when examined at various intervals after they were removed from the hexachlorobenzene-containing diet (Lambrecht et al., 1982b). Although liver tumors were not reported, treated animals showed lymphosarcomas in both dosage groups in both sexes at levels significantly above those of controls. Exposure to hexachlorobenzene in this instance produced leukemogenic changes. The animals were not permitted to live beyond selected intermediate sacrifice dates, so it was not possible to determine whether survivors would have developed liver or other tumors. The method of preparation of the hexachlorobenzene-containing diet may have been different in the Cabral et al. (1979) and Lambrecht et al. (1982b) studies, but detailed information was not presented in the Lambrecht et al. (1982b) abstract.

Mice may be somewhat less sensitive than hamsters to hexachlorobenzene as evidenced by the difference in incidence of hepatoma formation at various doses. These animal species may differ in the distribution of the hexachlorobenzene into various tissue compartments (Lambrecht et al., 1981), and differ in rates of metabolism and absorption. Administration of the same levels of hexachlorobenzene in the feed can be expected to give different effective dosages.

Shirai et al. (1978) -- Shirai et al. (1978) administered hexachlorobenzene to male ICR mice (35 animals/group) at levels of 10 or 50 ppm in the diet for periods of 24 weeks. Polychlorinated terphenyl was given alone to another group at 250 ppm, and in combination with 50 ppm hexachlorobenzene to a third group. Animals were examined histologically at 40 weeks.

Final body weights were slightly lower in the hexachlorobenzene-treated groups while liver weights were higher. Examination of the livers showed that the hexachlorobenzene-treated groups had hypertrophy of the centrilobular area at both doses. No liver tumors were found in either group. The total intake of hexachlorobenzene was calculated to be 8.4 and 35.3 mg/mouse over 24 weeks in the 10 ppm and 50 ppm groups, respectively.

Polychlorinated terphenyl alone, at 250 ppm (total dose 207.4 mg/mouse) gave 3/28 (10.7%) nodular hyperplasia. When this same level of polychlorinated terphenyl was given along with hexachlorobenzene at 50 ppm (total dose 36.9 mg/ mouse) there were 23/26 (88.5%) nodular hyperplasia and 8/26 (30.8%) hepatocellular carcinoma. This response indicates that hexachlorobenzene can enhance the carcinogenic potency of polychlorinated terphenyl.

The duration of administration, 24 weeks, in this mouse study and the doses used were below those used in the Cabral et al. (1979) study on Swiss mice and also below the levels used in the 13-week study by Lambrecht et al. (1982b) on Swiss mice. Therefore, it is not surprising that hepatomas were not found when hexachlorobenzene was given alone. The occurrence of liver lesions, however, does indicate the liver is a target organ.

These three studies in mice demonstrate the tumorigenicity of hexachlorobenzene with respect to the induction of hepatomas, the leukemogenic effect of subchronic exposure and the ability of hexachlorobenzene to enhance the carcinogenic effect of another compound.

Rat Studies.

Smith and Cabral (1980) -- The carcinogenic potential of hexachlorobenzene was tested in several different laboratories in rats. In one study (Smith and Cabral, 1980) small numbers of female Agus rats, and even smaller numbers of female Wistar rats, were used. There were 12 control and 14 treated Agus rats and 4 control and 6 treated Wistar rats. The hexachlorobenzene was analytical grade (99.5% purity) dissolved in arachis oil and mixed with the feed to give 100 ppm in the diet. This dietary level supplied an average daily dose of 6-8 mg/kg/day to the rats.

In this study the Agus rats showed signs of porphyria after 3 months exposure to hexachlorobenzene, but other toxic manifestations were not found. The investigators stated that "there was a steady decline in body weight to eventually 80% of control animals" (Table V-6). Examination of the weight data presented in the publication indicates that this interpretation is based upon comparison of "final" average weight in control (286±19 g) and treated (225±16 g) animals (see Table V-6), representing a 21% difference in weight. This method of comparison can be misleading since the final weights represent accumulated differences in growth rates and varying composition of the groups because of animal deaths. An effect produced, even transiently, at an early age, may persist in the figures, even though all subsequent growth may be normal. Growth rates, rather than absolute difference in weights provide a more suitable picture of the animal response. Growth rates for the time intervals reported were calculated based on the data given in the publication and are shown in Table V-7. The equation used was:

$$R = \frac{\text{weight at end of interval - weight at start of interval}}{\text{weight at start of interval}} \times 100$$

TABLE V-6

Body Weights of Female Agus Rats Fed Hexachlorobenzene for 90 Weeks[a]

Weeks of Diet	Body Weight (g)		% Difference
	Control	HCB	
0	46 ± 6 (8)	45 ± 24 (9)	2
10	191 ± 5	180 ± 17	6
30	236 ± 13	212 ± 13[b]	10
50	257 ± 17	221 ± 19[c]	14
90	286 ± 19 (8)	225 ± 16 (7)[c]	21

[a]Source: Smith and Cabral, 1980

[b]Significantly different from controls as assessed by Student's t-test $p<0.01$

[c]$p<0.001$

Female Agus rats were fed HCB (100 ppm) in MRC 418 diet for 90 weeks and then killed. Weights are means (no. of animals in parentheses) ± S.D.

HCB = Hexachlorobenzene

TABLE V-7

Growth Rates for Female Agus Rats on a Diet Containing 100 ppm HCB*

Interval (on diet)	Average Growth Rate %/week	
	Control	Treated
0-10 weeks	31.5	30.0
10-30 weeks	1.2	0.89
30-50 weeks	0.45	0.22
50-90 weeks	0.28	0.05

*Source: Calculated from Smith and Cabral, 1980

HCB = Hexachlorobenzene

According to this calculation both groups of animals grew during each time interval.

The survival of the treated Agus rats was good; one test animal was sacrificed at 52 weeks and a second one died of pneumonia at 70 weeks. Both of these animals had liver cell tumors found by histologic examination. Another five treated animals were sacrificed at 75 weeks and the remaining seven treated animals lived until the end of the experiment at 90 weeks. Among controls, one was killed at 63 weeks and three more at 75 weeks. The remaining eight were killed at 90 weeks.

No control animals had liver pathology. In contrast, 14/14 (100%) of the treated Agus rats had liver tumors; the earliest of these was detected at 52 weeks. The livers of the treated animals were grossly enlarged and some of the tumors were 1.5-2 cm in diameter. Although one liver cell tumor was described as pedunculated, histopathology detail was not given, except to note the absence of metastases in all cases. Four of the six (67%) Wistar rats also had liver cell tumors and none of the four controls showed such pathology at 75 weeks.

In this rat study hexachlorobenzene was a potent inducer of liver tumors, causing a 100% incidence with the earliest tumor observed at 52 weeks. It is important to determine whether the magnitude of the effect is all attributable to the hexachlorobenzene or whether contaminants, unusual characteristics of the test animals, or procedural factors were operative in this study. In this context the following points are noted.

First, historical control data on tumor incidence for Agus rats were not available, but, according to Cabral (1983), the Agus rat is a strain particularly sensitive to porphyria and hepatic tumors. In regard to the question of contaminants, peanut oil is generally believed to be free of aflatoxins [they are destroyed in processing (NAS, 1977)] and the feed was analyzed for both aflatoxins and dibenzofurans and found to be free of both (Cabral, 1983). Absorption is another factor to consider. The absorption of the hexachlorobenzene in these animals might be enhanced by dissolution in the arachis oil.

Lambrecht et al. (1983a,b, 1984) -- Another study on rats was carried out by Lambrecht et al. (1983a,b, 1984). In this study 94 Sprague-Dawley rats of each sex for each dosage and control groups were used. Four animals of each group were sacrificed at each of 10 intervals: 0, 1, 2, 3, 4, 8, 16, 32, 48 and 64 weeks. The remaining 54 animals of each group were allowed to continue until they died, or to the end of the 2 years. The number of animals at risk was considered to be those that survived at least 12 months, since this was the earliest time to tumor. This number would be, at minimum, 54 plus some animals from the last sacrifice time.

The hexachlorobenzene was highly purified and the prepared diet monitored for hexachlorobenzene levels periodically. The preparation was also analyzed for aflatoxins and found to be negative. The test diet was prepared by mixing the hexachlorobenzene with dextrose and Wayne laboratory feed (1.5 g hexachlorobenzene + 98.5 g dextrose + 9.9 kg lab chow to give 150 ppm hexachlorobenzene). Half the amount of hexachlorobenzene was used in the mix for the 75 ppm hexachlorobenzene level. This oil-free vehicle is

different from the vehicle used by both Smith and Cabral (1980) and Arnold et al. (1985). The hexachlorobenzene was well absorbed as demonstrated by progressive accumulation in fat which was measured in this study.

Based on an average food consumption of 22.6 g/rat/day for males and 16.5 g/rat/day for females, and on an average adult weight for females of 265 g and for males of 400 g, the low dose was calculated to be 4-5 mg/kg/day and the high dose, 8-9.5 mg/kg/day. In order to compare the results obtained in this study with those obtained in Sprague-Dawley rats by Arnold et al. (1985), more detailed calculation of doses at different time periods on test are given in Table V-8.

The administration of hexachlorobenzene in the diet at these doses in the Lambrecht et al. (1983a) chronic feeding study in rats resulted in liver pathology just before the appearance of hepatoma or hepatocellular carcinoma. Pathology observed at the early sacrifice time included parenchymal degeneration, preneoplastic foci and adenoma. At 48 and 64 weeks of the test females had gross liver tumors which measured between 1 and 2 mm^2. Porphyria was also detected.

Rats that lived 12 months or longer showed a significant increase in hepatoma incidence in both sexes. A statistically significant increase in the incidence of hepatocellular carcinoma was found at both doses in the females, and in males a slight non-significant increase was found. None of the liver cell tumors metastasized. Table V-9 summarizes the findings.

TABLE V-8

Dosage Levels in the Chronic Feeding Study of Hexachlorobenzene in Sprague-Dawley Rats[a]
(mg/kg/day)

Time on Diet[b] (weeks)	Males		Females	
	75 ppm	150 ppm	75 ppm	150 ppm
0	19.5	37.0	16.1	32.2
26	3.2	7.1	3.7	8.7
52[c]	3.3	6.4	3.8	8.0
79	3.4	6.7	3.5	8.4
99	6.2	10.0	4.3	10.6

[a]Source: Calculations and data provided by Lambrecht, 1984

[b]The animals were 3 weeks old when placed on test

[c]At 52 weeks on test the males consumed an average of 24.7 g of the diet/day and weighed an average of 553.7 g. The females consumed an average of 16.0 g diet/day and weighed an average of 311.7 g.

TABLE V-9

Liver and Kidney Tumors in Sprague-Dawley Rats Given Hexachlorobenzene in the Diet for up to 2 years[a,b]

Exposure Level	Hepatoma		Hepatocellular Carcinoma		Renal Cell Adenoma		Renal Cell Carcinoma	
	M	F	M	F	M	F	M	F
0	0/54	0/52	0/54	0/52	7/54	1/52	0/54	1/52
percentage	0	0	0	0	13	2	0	2
75 ppm	10/52	26/56	3/52	36/56	41/52	7/56	0/52	2/56
percentage	19	46	6	64	79	13	0	4
150 ppm	11/56	35/55	4/56	48/55	42/56	15/54	0/56	2/54
percentage	20	64	7	87	75	28	0	4

[a]Source: Lambrecht et al., 1983a,b; Lambrecht, 1983

[b]The diet was prepared without solubilization of the hexachlorobenzene, but by mixing it as a pulverized solid.

Renal cell adenoma was found to be significantly elevated in both sexes but with greater frequency in males. In this study the control male group had a high incidence of renal cell adenoma which was not explained; nevertheless, the increase in the hexachlorobenzene-treated animals was statistically significant. The incidence of renal cell carcinoma in treated animals was not significantly increased over control animals in either males or females.

In an updated report from this laboratory (Peters et al., 1983) histopathology details were supplied. These data show that in addition to the liver and kidney lesions there was an increase in adrenal pheochromocytoma in female rats that was statistically significant at both 75 and 150 ppm. Females also had elevated incidences of adrenal cortical adenoma and hemangioma in the treated groups. Among males the background incidence of adrenal pheochromocytomas is high (76.5%), making it difficult to determine whether the 90.6% incidence found in the 150 ppm group has any biologic significance. Other adrenal neoplastic and non-neoplastic lesions were detailed: hyperemia and/or congestion, cortical hyperplasia, preneoplastic foci, cysts, lipoma and adenocarcinoma; none of these were elevated in the treated animals. The adrenal tumor incidences are given in Table V-10.

One point to consider in the interpretation of the results, particularly in terms of their application to risk assessment, is the form in which the hexachlorobenzene was administered in the diet. The absorption from a particulate form introduces an additional possible exposure route, namely, from the food preparation by inhalation. This consideration does not invalidate the study, but raises the question of the actual exposure levels

TABLE V-10

Adrenal Tumors in Sprague-Dawley Rats Given Hexachlorobenzene in the Diet for up to 2 Years[a,b]

	MALES					
Days on diet	400-599			600+		
Exposure ppm hexachlorobenzene	0	75	150	0	75	150
Number of tissues examined	17	23	28	34	25	23
Cortical adenoma (%)	3	2	6	6	3	4
Pheochromocytoma (%)	3 (17.6)	6 (26.1)	9 (32.1)	26 (76.5)	17 (68)	21 (91.3)
Hemangioma (%)	0	0	0	0	0	0
	FEMALES					
Days on diet	400-599			600+		
Exposure ppm hexachlorobenzene	0	75	150	0	75	150
Number of tissues examined	12	5	13	35	47	32
Cortical adenoma (%)	0	3	2	2 (5.7)	11 (23.4)	6 (18.8)
Pheochromocytoma (%)	0	0	2	5 (14.3)	31 (66)	29 (90.6)
Hemangioma (%)	0	0	2	3 (8.5)	8 (17)	5 (15.6)

[a]Source: Peters et al., 1983

[b]The diet was prepared without solubilization of the hexachlorobenzene, but by mixing it as a pulverized solid.

if an additional route of exposure was occurring in the same experiment simultaneously with oral ingestion. The effect of mixing the hexachlorobenzene in the diet in an oil free form may also affect absorption and thereby the effective dose.

Arnold et al. (1985) -- In this study hexachlorobenzene (99% pure) was administered to parental male and female Sprague-Dawley rats for 3 months. These animals were mated at that time and the females continued to receive hexachlorobenzene-containing diets during pregnancy and throughout lactation. At weaning, 50 pups of each sex were separated and fed for the remainder of their lifetime on hexachlorobenzene-containing diets. Controls were fed diets free of hexachlorobenzene. The range of doses used in this study is considerably lower than those used by either Smith and Cabral (1980) or Lambrecht et al. (1983a,b). Table V-11 shows the doses used in the Arnold et al. (1985) study at particular points in time since the doses were not adjusted throughout the study. These doses represent a greater exposure to the test animals from the point of view of exposure duration, since the F_1 animals were exposed in utero and during nursing in addition to their exposure from feeding on an hexachlorobenzene-containing diet. Total doses cannot be calculated since the actual dose received during nursing is not known.

Arnold et al. (1985) found no differences in treated F_1 animals when compared to controls with respect to growth rates, food consumption or hematology. The only observed difference was a decreased viability index for pups in the 40.0 ppm dose group.

TABLE V-11

Exposure Levels in the Chronic Feeding, 2-Generation Study of Hexachlorobenzene in Sprague-Dawley Rats[a] (mg/kg/day)

Time on Diet[b] (weeks)	Exposure Level			
	0.32 ppm	1.6 ppm	8.0 ppm	40.0 ppm
		MALES		
1	0.04	0.18	0.93	4.85
30[c]	0.01	0.06	0.29	1.5
70	0.01	0.05	0.25	1.3
		FEMALES		
1	0.04	0.17	0.84	4.64
30[c]	0.02	0.08	0.40	1.9
70	0.01	0.06	0.32	1.6

[a]Source: Calculations and data provided by Arnold, 1984

[b]The animals were placed on feed at 6 weeks of age.

[c]The mean body weight of male controls was 663 g and for the highest dose group males 653 g. The mean weekly food consumption for male controls at that time was 178 g and for the highest dose group 169 g. Females of the same age weighed 351 g for controls and 353 g for the highest dose treated group and the mean weekly food consumption was 113 and 118 g, respectively.

histopathology showed that F_1 females had a significant elevation in neoplastic liver nodules and in adrenal pheochromocytoma in the high dose females compared to controls (Table V-12). There was also a significant positive dose-related trend in the incidence of these tumors in F_1 females.

Among F_1 males, in the highest dose group parathyroid tumors were significantly increased: 25% (12/48) in the treated groups and 4.2% (2/48) among controls. Females also showed a few parathyroid tumors in the two highest dose groups but none in controls or in the two lowest dose groups. The differences were not significantly different from controls. Table V-12 gives the tumor incidences. Although kidney tumors were not reported to be elevated, there was an increased chronic nephrosis in the F_1 treated animals.

Arnold et al. (1985) -- In another study by Arnold et al. (1985) which was related to the 2-generation study, the effect of vitamin A, because of its supposed antitumorigenic properties, was tested in conjunction with hexachlorobenzene. This was a 1-generation study and the level of hexachlorobenzene was the same as the highest dose of the 2-generation study, 40 ppm. There were six separate groups of 50 animals each and the experiment ran for 119 weeks. At 29 weeks and at 49 weeks five animals from each group were sacrificed and evaluated histologically. The six groups are shown in Table V-13. The vitamin A did not apparently alter the effects of hexachlorobenzene. The number of animals with parathyroid tumors and adrenal pheochromocytomas was somewhat elevated in all the cases in which hexachlorobenzene was administered compared with the total cases with the three levels of vitamin A and no hexachlorobenzene. The significance of

TABLE V-12

Tumors in Organs that Showed Statistical Differences from Control in F_1 Sprague-Dawley Rats Treated with Hexachlorobenzene[a] (Incidence (%))

Dose at 30 weeks (mg/kg bw/day)	Parathyroid Adenoma		Adrenal Pheochromocytoma		Hepatocellular Carcinoma		Neoplastic Liver Nodules	
	Males	Females	Males	Females	Males	Females	Males	Females
Controls	2/48 (4.2)	0/49 (0)	10/48 (20.8)	2/49 (4.1)	0/48 (0)	0/49 (0)	2/48 (4.2)	0/49 (0)
0.01-0.02	4/48 (8.3)	0/49 (0)	12/48 (25.0)	4/49 (8.0)	2/48 (4.2)	0/49 (0)	0/48 (0)	0/49 (0)
0.06-0.08	2/48 (4.2)	0/50 (0)	7/48 (14.6)	4/50 (8.0)	1/48 (2.1)	0/49 (0)[b] 1/49 (2.0)[b]	0/48 (0)	2/50 (4.0)
0.29-0.40	1/49 (2.0)	1/49 (2.0)	13/49 (26.5)	4/49 (10.2)	3/49 (6.1)	0/50 (0)	2/49 (4.1)[b] 3/49 (6.1)[b]	2/49 (4.1)[b] 3/49 (6.1)[b]
1.5-1.9	12/49 (24.5)	2/49 (4.1)	17/49 (34.7)	17/49 (34.7)	0/49 (0)	0/49 (0)[b] 1/49 (2.0)[b]	1/49 (2.0)	10/49 (20.4)[b] 9/49 (18.4)[b]
Other statistical tests								
IARC trend test	$p \leq 0.01$	$p \leq 0.05$	$p \leq 0.01$	$p \leq 0.01$				$p \leq 0.01$
Armitage time-related trend test	$p \leq 0.01$	$p \leq 0.05$	$p \leq 0.05$	$p \leq 0.01$				$p \leq 0.01$
Fisher exact treated vs. control	$p \leq 0.05$			$p \leq 0.01$				$p \leq 0.01$

[a]Source: Arnold et al., 1985; Arnold, 1984

[b]Different results of two different pathologists reading the same slides

TABLE V-13

Parathyroid and Adrenal Pheochromocytomas in Sprague-Dawley Rats Maintained on Synthetic Diets of Varying Vitamin A Content and With or Without Hexachlorobenzene*

Group	No. with Parathyroid Tumors	No. with Adrenal Pheochromocytoma
Controls on diet with normal vitamin A content	3	3
Control diet + 40 ppm HCB	4	6
Diet with 0.1 times normal vitamin A	0	2
Diet with 0.1 times normal vitamin A + 40 ppm HCB	0	2
Diet with 10X vitamin A	1	4
Diet with 10X vitamin A + 40 ppm HCB	3	7
Total without HCB	4	9
Total with HCB 40 ppm	7	15

*Source: Arnold et al., 1985

HCB = Hexachlorobenzene

these tumor incidences cannot be determined by simple comparison because it was also found in the study that vitamin A had an effect on the background level of some common tumors and these data have not yet been completely analyzed.

Discussion of Rat Studies. It seems appropriate to compare the findings of Smith and Cabral (1980) in Agus and Wistar rats, Lambrecht et al. (1983a,b) and Arnold et al. (1985) in Sprague-Dawley rats. None of the three studies agree precisely on all four of the tumor target organs: Smith and Cabral reported liver tumors, Lambrecht reported liver, adrenal and kidney tumors and had some liver carcinomas not found by Smith and Cabral. Arnold found adrenal and parathyroid tumors and neoplastic liver nodules but no increase in kidney tumors. We find that, although differences do occur, the results are not contradictory for the following reasons:

1. The dosages used in the Arnold et al. (1985) study were below those used by either Smith and Cabral (1980) or Lambrecht et al. (1983a,b). The range of doses used by Smith and Cabral was given as 6-8 mg/kg/day and those used by Lambrecht were 3-9 mg/kg bw/day. Those of Arnold were, at most, between 1.5 and 2.0 mg/kg bw/day.

2. There were notable differences in the animals used: in the case of Smith and Cabral the liver tumor susceptible strain of Agus rat was used, although tumors were also found with Wistar rats. We do not have full data on historical tumor incidences in these animals to allow for more detailed evaluation.

3. The conditions of the Smith and Cabral study and those of Lambrecht were both different from the 2-generation study of Arnold. Differences in sensitivity due to prenatal exposure may occur because of rapid cell division and/or differences in xenobiotic metabolism compared with older animals. The dose received transplacentally and from nursing is also uncertain.

4. The method of preparation of the hexachlorobenzene in the diet was different in that both Smith and Cabral and Arnold used arachis oil and corn oil as hexachlorobenzene solvents while Lambrecht did not use an oil vehicle. Absorption characteristics are known to depend upon the vehicles used.

5. The Sprague-Dawley animals used by Arnold may have more fat than those used by Lambrecht as they were somewhat larger. Distribution into different tissue compartments, especially into fat where it is likely the hexachlorobenzene is at least temporarily stored, is likely to alter the effective concentration in target tissues. In this regard the hexachlorobenzene is known to concentrate in adrenal tissue; the degree of such concentration may well vary with strain or diet of the host animals.

In summary, orally administered hexachlorobenzene has induced hepatocellular carcinoma in male Sprague-Dawley (S-D) rats as well as hepatomas in female Agus and Wistar rats and in S-D rats of both sexes. At the lowest dose used in any of the studies (40 ppm in the diet or 1.5 mg/kg/day), neoplastic nodules were induced in S-D rats, whereas hepatocellular carcinomas occurred in the same strain at a higher dose (4-5 mg/kg/day). Adrenal pheo-

chromocytoma was significantly elevated in two separate studies in female S-D rats. In the same strain one investigator reported parathyroid tumors and a different investigator reported kidney tumors; neither of these findings has been repeated by other authors. Table V-14 summarizes this information.

Other Studies. In addition to the studies described on hamsters, mice and rats there are a few studies that cover specific kinds of tests other than lifetime exposure and examination of all potential target tissues for tumorigenic or carcinogenic response.

One such study was that of Theiss et al. (1977) in which the experiment was designed to detect only pulmonary tumors following i.p. injection of organic chemicals found as contaminants of drinking water. In this assay hexachlorobenzene was one of the chemicals tested. Strain A mice were given three dosage levels of hexachlorobenzene with the top level as the MTD. A total of 24 injections over a period of 8 weeks were given to 20 mice/group. The total doses received were 190, 480 and 960 mg/kg. The lungs were the only organ examined and hexachlorobenzene did not increase tumor incidence in that organ. The study ran for 32 weeks. Although this assay has proved useful in detecting some pulmonary carcinogens, it is not designed to detect other tumors.

In another study on beagle dogs (Gralla et al., 1977) in which hexachlorobenzene was given in daily gelatin capsules to 30 animals of each sex/dosage group the duration of the study was only 1 year. Although this is not a long enough period of time for a carcinogenicity study in dogs, it

TABLE V-14

Qualitative Comparison of Tumor Development in Rats Following Hexachlorobenzene Administration in Different Studies

Strain/Sex	Dosage (lowest dose that produced tumor)	Liver	Kidney	Adrenal	Parathyroid	Reference
Agus/Female	100 ppm (6-8 mg/kg bw/day)	liver-cell tumor (F)	NA	NA	NA	Smith and Cabral, 1980
Wistar/Female	prepared by dissolving in oil and mixing oil with food	liver-cell tumor (F)	NA	NA	NA	Smith and Cabral, 1980
Sprague-Dawley/ Male and female	75 ppm (3-4 mg/kg bw/day) prepared in feed sans oil vehicle	hepatocellular carcinoma (M&F) hepatoma (M&F)	renal cell adenoma (M&F)	pheochromo-cytoma (F) cortical adenoma (F)	NA	Lambrecht et al., 1983a,b
Sprague-Dawley/ Male and female F_1 animals of 2-generation study	40 ppm (0.3-1.5 mg/kg bw/day) prepared in oil and mixing oil with food at weaning -- animals exposed <u>in utero</u> and during nursing	neoplastic liver nodules (F)	not found	pheochromo-cytoma (F)	adenoma (M)	Arnold et al., 1985

NA = It is not known whether or not these tissues were examined.

is of interest to note that the doses of 100, 10, 1 and 0.1 mg/kg bw/day produced a number of toxic manifestations in the liver including bile duct hyperplasia, hepatomegaly and liver necrosis. This study is more appropriately considered under chronic toxicity.

Finally, Pereira et al. (1982) designed a study to determine whether hexachlorobenzene increased γ-glutamyltranspeptidase-positive foci in rats. These foci are believed to be preneoplastic in the liver. The assay was designed to test initiation/promotion in this case by employing diethyl-N-nitrosamine (DENA) as the initiating agent and hexachlorobenzene as the promoter. Unfortunately, there are some errors in reporting of the results in the published paper and some important controls were not included (Pereira, 1983). We have not yet received a corrected manuscript.

Carcinogenicity Summary. In a lifetime study of hexachlorobenzene administration to hamsters, hepatomas were induced in both males and females. The response at a dose of 4-5 mg/kg/day dissolved in corn oil and mixed in the feed was 47% for both sexes and controls had no hepatomas. In addition to hepatomas, hamsters responded to hexachlorobenzene treatment with malignant liver haemangioendotheliomas and thyroid adenomas. The incidence of haemangioendothelioma was 20% in males (versus 0 in controls) at 8 mg/kg/day and 12% in females (versus 0 in controls) at 16 mg/kg/day. The thyroid adenoma occurred at 14% incidence in males treated with 16 mg/kg hexachlorobenzene (versus 0 in controls).

Liver cell tumors, described as hepatomas, were also produced in both sexes in Swiss mice. At 24 mg/kg/day the incidence was 34% for females and

16% for males and the response showed a dose-dependency not only in the number of tumor-bearing animals but also in the latent period, multiplicity and size of tumors. In ICR mice, hexachlorobenzene administered concurrently with polychlorinated terphenyl induced hepatocellular carcinomas.

In rats target organs for hexachlorobenzene-induced tumors included liver, kidney, adrenal gland and parathyroid gland in various studies. Liver tumors were found in three studies that included three different strains of rat: Agus (a liver tumor sensitive strain), Wistar and Sprague-Dawley rats. These tumors were induced with doses between 1.5 and 8 mg/kg/day. The incidence was as high as 100% in Agus rats but lower for the other strains. Renal cell tumors were found in one study on Sprague-Dawley rats. In two studies on Sprague-Dawley rats, significant increases in adrenal pheochromocytoma in females were found. In one of these studies the incidence of parathyroid tumors in males was significantly increased as well.

Table V-15 summarizes the tumor data for hamsters, mice and rats for hexachlorobenzene experiments.

The data on hexachlorobenzene provide sufficient evidence of the carcinogenicity and tumorigenicity of hexachlorobenzene since there were increased incidences of malignant tumors of the liver in two species (haemangioendothelioma in hamsters and hepatocellular carcinoma in rats) as well as reports of hepatoma in mice, rats and hamsters.

The appearance of thyroid tumors in hamsters and adrenal pheochromocytomas and parathyroid tumors in rats as a result of hexachlorobenzene exposure

TABLE V-15

Significantly Increased Incidence of Tumors in Animals Given Hexachlorobenzene in Diet

Animal (strain)	Organ	Tumor	% Treated/% Control		Lowest Dose to Produce Tumor (mg/kg bw/day)	Reference
			Males	females		
Hamsters	liver	hepatoma	47/0	47/0	4	Cabral et al., 1977
Hamsters	liver	haemangioendothelioma	20/0	12/0	8 in males 16 in females	Cabral et al., 1977
Mice	liver	hepatoma	16/0	34/0	24	Cabral et al., 1979
Rats (S.D.)	liver	neoplastic nodules	NS	20/0	1.5	Arnold et al., 1985
Rats (S.D.)	liver	hepatoma	19/0	46/0	4-5	Lambrecht et al., 1983a
Rats (S.D.)	liver	hepatocellular carcinoma	NS	64/0	4-5	Lambrecht et al., 1983a
Rats (Wistar)	liver	hepatoma		67/0	6-8	Smith and Cabral, 1980.
Rats (Agus)	liver	hepatoma		100/0	6-8	Smith and Cabral, 1980
Rats (S.D.)	adrenal	pheochromocytoma	NS	35/4	1.5	Arnold, 1984; Arnold et al., 1985
Rats (S.D.)	adrenal	pheochromocytoma	NS	91/14	4-5	Peters et al., 1983
Rats (S.D.)	kidney	renal cell adenoma	79/13	13/2	4-5	Lambrecht et al., 1983b
Rats (S.D.)	parathyroid	adenoma	25/4	NS	1.5	Arnold et al., 1985
Hamsters	thyroid	adenoma	14/0		16	Cabral et al., 1977

NS = Not stated

is particularly interesting because of the clinical association of adrenal pheochromocytomas with parathyroid and thyroid tumors in humans (Fraumeni, 1974; Hill, 1974), and because follow-up of individuals in Turkey, who were accidentally exposed to hexachlorobenzene over 25 years ago, shows a marked elevation in thyroid tumors. Only a few of these subjects have had their thyroid tumors examined histologically and the pathology reports are not yet available.

If the IARC criteria for the classification of carcinogens were used, this animal evidence would be considered "sufficient." In the absence of human evidence of carcinogenicity, hexachlorobenzene would be classed in IARC category 2B, meaning that it has been demonstrated to be carcinogenic in animals and is probably carcinogenic in humans.

Reproductive and Teratogenic Effects

Hexachlorobenzene has been shown to cross the placenta into fetal tissues and to be present in the milk of nursing dams (see Chapter III). The NOEL in a 4-generation reproduction study with rats was reported to be 20 ppm of hexachlorobenzene in the diet. Pups from treated dams (receiving diets containing 80 ppm hexachlorobenzene) recovered from elevated liver weights when nursed by foster dams. Hepatomegaly and reduced survival was reported in kittens from cats receiving 263 ppm of hexachlorobenzene in their diets. Infant rhesus monkeys developed clinical signs of toxicity, but histologic examination showed only mild effects. Fetal mice from dams treated with 100 mg/kg/day during days 7-16 of gestation exhibited teratogenic abnormalities.

Results from a 4-generation reproduction study with Sprague-Dawley rats was reported by Grant et al. (1977). Weanling rats, in groups of 20 females and 10 males, were fed diets containing 0, 10, 20, 40, 80, 160, 320 or 640 µg hexachlorobenzene/g and at 100 days of age the F_0 generation was mated to produce the F_{1a} generation. The F_{1a} pups were weaned at 21 days, and the F_0 rats were rested for 14 days and again mated to produce the second litter, F_{1b} animals. The F_{1b} animals were then used to produce the next generation, and this sequence was followed to the F_{4b} generation. The two highest doses (320 and 640 µg/g) were toxic to the mothers and resulted in 20 and 50% mortality, respectively, before the first whelping and 25% in each high dose group before the second whelping. In addition, the fertility index in these rats was greatly reduced in these two dose groups and the average litter size was decreased in the F_{1b}, F_{2a} and F_{2b} generations. The pups exhibited no gross abnormalities, but there was an increased number of stillbirths and all pups born alive died within 5 days in the 320 and 640 µg/g diet groups.

At the 160 µg/g level, 55% of the pups survived to day 5 but survival to day 21 was greatly reduced. The number of live births and survival was normal for the first two generations at the 80 µg/g dietary level, but by the third generation there were stillbirths and a low degree of postnatal viability. In addition, birth and weanling body weights were consistently less than those of the control group. At 40 µg/g diet only the liver weights of the 21-day-old pups were significantly increased, while the kidney, heart and brain weights were not affected. Tissue concentrations of hexachlorobenzene were dose-related, with body fat having the highest concentration. The NOEL was reported to be 20 ppm in the diet.

The effect of hexachlorobenzene on rat reproduction was also reported by Kitchin et al. (1982). Female Sprague-Dawley rats (10 animals/treatment group) were fed diets containing 0, 60, 80, 100, 120 and 140 µg hexachlorobenzene/g of diet. The females were mated with untreated males after 96 days and then bred a second time 12 days after weaning of the F_{1a} litter. Fertility and fecundity of treated females were not affected by treatment; however, a dose-related 21-day increase in mortality was observed in both litters and the LD_{50} values were determined to be 100 and 140 µg/g (maternal dietary concentration) for the F_{1a} and F_{1b} generation, respectively.

Mendoza et al. (1978) studied the effects of hexachlorobenzene on preweanling Wistar rats after a reciprocal transfer between 5 treated and 5 control dams. A significant increase in the liver weight over that of the control was observed in pups nursed by dams fed diets containing 80 µg hexachlorobenzene/g for 2 weeks before mating until birth, but this effect did not persist after the treated pups were transferred to a control foster dam. Similarly, the pups nursed by treated dams had smaller brains, hearts, kidneys and spleens than the controls, and these organs were larger in treated pups nursed by control dams. The authors concluded that hexachlorobenzene transmission via the milk had greater effects on the pups than transmission via the placenta.

Mendoza et al. (1979) placed female Wistar rats on diets containing 80 µg hexachlorobenzene/g beginning 2 weeks before mating until 35-36 days after weaning. Results indicated that there were no marked differences in the external appearance, body weight, liver weight, gestation, or neonatal

survival between the hexachlorobenzene treated and control females. In addition, there were no differences in the number of litters, average number of pups/litter, average number of pups at birth and gestation index.

Hansen et al. (1979) studied the effects of hexachlorobenzene on reproduction in cats fed contaminated pork cakes for 142 days. These cakes contained 90±51 µg hexachlorobenzene/g, equivalent to an intake of 3 mg/day/cat, and were obtained from gilts fed diets containing 100 µg hexachlorobenzene/g for 6-8 weeks before slaughter. The positive and untreated control groups received pork cakes from gilts fed diets that did not contain hexachlorobenzene, with the positive control group receiving hexachlorobenzene-spiked cakes (263±120 µg/g equivalent to 8.7 mg/day/cat). These females were mated with untreated males and the resulting kittens did not receive hexachlorobenzene-containing cakes. Effects on survival were noted in kittens born to only those cats receiving hexachlorobenzene-spiked cakes and was apparently due to the kittens being too weak to survive the stress of weaning. There was a tendency for reduced average litter sizes and increased mortality of nursing positive control kittens, and statistically significant hepatomegaly and reduction in positive control kitten survival at weaning. Treated positive control females exhibited a net weight loss and increased susceptibility to disease but no changes in relative organ weights, hematologic parameters, or fecal coproporphyrin excretion.

Rush et al. (1983) fed adult male and female standard dark minks (Mustela vision) diets containing 0, 1 or 5 ppm hexachlorobenzene and then mated the males to the females in each of the respective study groups. The progeny were fed their parents respective diets after weaning from their

mothers. The effects of exposures to hexachlorobenzene in utero and from nursing milk resulted in increased mortality in the hexachlorobenzene-treated weanlings with mortality in the 0, 1 and 5 ppm groups being 8.2, 44.1 and 77.4%, respectively. The surviving kits from all three groups had no observed alterations in whole body, kidney or liver weights and no observed damage to the kidneys or livers at 17 weeks of age. Induction of hepatic mixed-function oxidases was observed in the surviving hexachlorobenzene-exposed kits without any observable frank hepatotoxicity.

Bailey et al. (1980) studied the transfer of hexachlorobenzene to three nursing infant rhesus monkeys from three lactating mothers receiving by gavage 64 mg/kg/day of hexachlorobenzene suspended in methyl cellulose for 60 days. The hexachlorobenzene concentrated in the mothers' milk ranged from 7.51-186 ppm during the dosing schedule. One infant, by day 22, had developed symptoms of hypoactivity and lethargy that progressed to ataxia and death 1 week later. Necropsy revealed severely congested lungs. A second infant died on day 38 and necropsy revealed a subdural hematoma and bilateral hemorrhagic pneumonia. This indicated that the risk of exposure to nursing infants was greater than the risk to their mothers. Blood (0.42-49.44 ppm) and tissue levels in the infants were higher than in their mothers (0.41-16.16 ppm blood), and the infants developed clinical symptoms of toxicity while the mothers were asymptomatic.

Studies on the placental transfer of hexachlorobenzene in Wistar rats and New Zealand rabbits did not reveal any apparent adverse effects on fetal development. The female rats were dosed daily with 5, 10, 20, 40 or 80 mg/kg from day 6-16 of gestation, whereas the rabbits were treated with 0,

0.1, 1.0 or 10 mg/kg from day 1-27 of gestation. The compound was dissolved in corn oil and administered by means of a stomach tube (Villeneuve et al., 1974; Villeneuve and Hierlihy, 1975).

Khera (1974) conducted a teratogenicity study with groups of 7-16 female Wistar rats given single oral doses of 0, 10, 20, 40, 60, 80 or 120 mg hexachlorobenzene/kg suspended in corn oil or 0.25% aqueous gum tragacanth during gestation days 6-21. Maternal toxicity and reduction in fetal weights resulted from the two higher doses. Maternal toxicity was characterized by loss in body weight, hyperesthesia, tremors and convulsions. A significant increase in the incidence of unilateral and bilateral 14th rib was observed and was related to the duration of treatment (days 10-13, 6-16 or 6-21 of gestation) and the dose. Sternal defects were observed in only 1 of 4 experiments, which lead the authors to conclude that it was doubtful that hexachlorobenzene caused the observed sternal defects. There were no hexachlorobenzene-related effects on external morphology. Visceral abnormalities were not observed, and microscopic examinations did not reveal any treatment-related change in the histology of the fetuses. Values for live and dead fetuses, resorption sites, and fetal weight were within the control limits.

Courtney et al. (1976) studied the effects of ingestion of 100 mg/kg/day hexachlorobenzene on days 7-16 of gestation in 10 pregnant CD-1 mice. This study was undertaken to evaluate the possibility that hexachlorobenzene could be responsible for fetal malformations seen in pregnant animals exposed to hexachlorobenzene-contaminated pentachloronitrobenzene. The results showed that the hexachlorobenzene-treated mice had significantly

increased maternal liver-to-body weight ratios and decreased fetal body weights. Also, a significant increase in the incidence of abnormal fetuses per litter were observed as compared with control mice. The abnormalities that were observed in these affected fetuses were cleft palates, one straight leg, small kidneys, one renal agenesis, and enlarged renal pelvis. They concluded from this study that the teratogenic activity of contaminated pentachloronitrobenzene was probably due to hexachlorobenzene.

Summary

The acute oral toxicity of hexachlorobenzene has been found to be low, with LD_{50} values ranging from 1700-10,000 mg/kg. Subchronic oral toxicity studies with a number of mammalian species indicated a significant increase in liver and kidney weights in hexachlorobenzene-treated animals. Some studies have shown increases in other organs as well. The livers from hexachlorobenzene-exposed animals have shown histologic changes such as irregular shaped and moderately enlarged liver mitochondria and increases in the size of the centrilobular hepatocytes. Chronic oral toxicity studies revealed similar effects to those seen in the subchronic studies plus hexachlorobenzene-associated life-shortening and various hepatic and renal pathologies. These subchronic and chronic effects were usually dose-related. Other effects included multiple alopecia and scabbing, together with neurologic effects in rats, mice and dogs. A dose-related histopathologic change in the ovaries of monkeys has also been reported.

Increased porphyrin levels in the liver and in urine have been reported for all species studied except the dog, which does not exhibit increased porphyrin levels. Hexachlorobenzene was found to cause the accumulation of

β-H-steroids, which induce porphyrin biosynthesis, and to inhibit uroporphyrinogen decarboxylases. The inhibition of uroporphyrinogen decarboxylases appears to be due to pentachlorophenol, a hexachlorobenzene metabolite. Indications are that females are more susceptible to hexachlorobenzene-induced porphyria than are males, which may be related to the female estrogen levels and greater hexachlorobenzene metabolism. Hexachlorobenzene was reported to produce a mixed-type induction of cytochromes resembling that produced by a combination of phenobarbital (P-450) and 3,4-benzpyrene (P-448). In addition, the activities of several hepatic microsomal enzymes were found to be induced by hexachlorobenzene.

Hexachlorobenzene did not induce dominant lethal mutations in two studies but was reported to be mutagenic in a yeast, S. cerevisiae, assay at a concentration of 100 ppm. Hexachlorobenzene possessed no detectable levels of mutagenic activity in the Salmonella histidine reversion assay. The chronic toxicity studies provide sufficient evidence of the carcinogenicity of hexachlorobenzene in animals since there was an increased incidence of malignant tumors of the liver in two species, haemangioendothelioma in hamsters and hepatocellular carcinoma in rats as well as confirmed reports of hepatoma in both of these species. Hexachlorobenzene was found to cause teratogenic effects in fetal mice whose mothers were ingesting 100 mg/kg/day of hexachlorobenzene during days 7-16 of gestation.

VI. HEALTH EFFECTS IN HUMANS

The effects of hexachlorobenzene on humans as a result of accidental or occupational exposure have been reviewed by Courtney (1979) and Currier et al. (1980). A few reports of data collected on occupationally exposed workers have been reported with studies conducted in Turkey and in the United States (i.e., Louisiana) on the general population following accidental exposure to hexachlorobenzene. The exposure of humans to toxicologically significant levels of hexachlorobenzene in Turkey from 1955-1959 by ingestion of contaminated grain, as reported by Cam (1959, 1960), Cam and Nigogosyan (1963) and Peters et al. (1966), caused an epidemic of hexachlorobenzene-induced porphyria cutanea tarda (PCT), also known as porphyria turcica.

Epidemiologic Studies

Burns et al. (1974) found 0-310 ppb hexachlorobenzene in blood samples from 20 vegetable spraymen. There were no signs of PCT, and no correlations were observed between hexachlorobenzene levels and urinary porphyrin excretion, serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase or lactate dehydrogenase. Increased levels of urinary porphyrins were detected in 1 of 54 men occupationally exposed to hexachlorobenzene (Morley et al., 1973).

A medical survey was conducted by Dow Chemical Company (Currier et al., 1980) on 50 employees working at a chlorinated solvents plant in Louisiana, to determine blood hexachlorobenzene levels and signs suggestive of PCT or other adverse effects, as well as any changes in hematologic, clinical chemistry and urinalysis parameters. The results from this study are of limited

value because the various parameters studied during the 4-year period were analyzed by several laboratories using various methods and on different individuals. There was potential exposure to other substances also. During various times of the study, the time-weighted-average airborne concentrations of hexachlorobenzene ranged from <1-13 ppb, and wipe samples from surfaces in the control, laboratory and clerical work areas ranged from 0.03-1.24 μg/100 cm^2.

The laboratory analyses and physical examinations performed on the 1977 study group and on a control group from a polyethylene plant did not reveal any signs indicative of PCT. Blood levels of hexachlorobenzene, urinary porphyrin and coproporphyrin and the average years of exposure are listed in Table VI-1. A statistically significant ($p<0.05$) correlation was found between hexachlorobenzene levels in blood and the number of years worked in the plant. For the other studied parameters no statistically significant differences were noted between the 44 chlorinated solvents workers and the 44 control workers for 1977, except for higher protein levels and lower hematocrit values in the former workers, which were not considered to be biologically significant. In addition, significantly lower levels of urinary coproporphyrins and albumin were detected in white male workers with hexachlorobenzene blood levels ≥200 ppb than in those with hexachlorobenzene levels <200 ppb.

Burns and Miller (1975) studied plasma hexachlorobenzene residues of 86 residents living and/or working in an area exposed to the production, transportation and disposal of "hex" wastes (hexachlorobenzene and other chlorinated hydrocarbons) in Louisiana. Plasma hexachlorobenzene levels were

TABLE VI-1

Results of Blood and Urine Analysis in Men Employed in a Chlorinated Solvents Plant, 1974-1977[a]

Parameter	Study Group				Comparison Group
	1974 (n=50)	1975 (n=49)	1976 (n=49)	1977 (n=44)	1977 (n=44)
Blood HCB (µg/ℓ)	310.7 ± 287.7[b]	311.5 ± 242.9[b]	159.9 ± 142.7[c]	170.3 ± 111.8[c]	0.1 ± 0.6
Urinary uroporphyrins (µg/ℓ)	22.4 ± 21.1	20.9 ± 11.0	37.4 ± 14.4	26.2 ± 14.3	NR
Urinary coproporphyrins (µg/ℓ)	77.4 ± 40.5	67.2 ± 36.1	100.6 ± 40.8	95.2 ± 48.9	NR
Age (years)	30.1 ± 6.3	31.1 ± 6.6	30.8 ± 6.7	31.7 ± 7.1	31.3 ± 6.8
Plant-years	5.5 ± 3.9	6.3 ± 4.0	5.9 ± 4.5	6.6 ± 4.8	6.6 ± 4.4

[a]Source: Currier et al., 1980; 1974-1975 results conducted by Bioscience Laboratories; 1976-1977 results conducted by Pathology Laboratories (± Standard Deviation)

[b]In plasma

[c]In blood

N = Sample size

NR = Not reported

HCB = Hexachlorobenzene

measured and correlated with demographic characteristics, occupational hazards, food sample analyses and house dust analyses. Average plasma levels of hexachlorobenzene ranged from 2.4-3.6 ppb in exposed subjects as compared with 0.5 ppb in controls ($p<0.001$; Table VI-2).

Higher levels of hexachlorobenzene residues, which were statistically significant ($p<0.05$), were found in the male subjects (4.71 ppb) than in the female subjects (2.79 ppb). These were not associated with race or exposure to hexachlorobenzene through the consumption of homegrown vegetables and animals. About 68% of the house dust samples contained an average hexachlorobenzene concentration of 380 ppb as compared with 20 ppb in control samples. When the hexachlorobenzene levels in dust were compared with the mean plasma hexachlorobenzene levels for members of the same household, a significant correlation was obtained ($p<0.025$). In addition, blood samples from 11 workers employed for an average of 4.8 years (10 months to 15 years) at the chemical plant contained an average of 78.6 (14-233) ppb hexachlorobenzene.

Accidental Ingestion in Turkey

The hexachlorobenzene-induced PCT epidemic in Turkey, a result of exposure during 1955-1959 in individuals who used contaminated seed wheat for food, has been reviewed by Courtney (1979). Cam and Nigogosyan (1963) estimated that 0.05-0.2 g of hexachlorobenzene was consumed per day. The method of estimation was not described. PCT is a disease of disturbed porphyrin metabolism manifested by cutaneous lesions and is commonly followed by hypertrichosis (hairiness) and hyperpigmentation. The induction of porphyria by hexachlorobenzene has been reviewed (DeMatteis, 1967; Granick, 1965; Tschudy and Bonkowsky, 1972; Courtney, 1979). Porphyrias are

TABLE VI-2

HCB Plasma Levels in Exposed Individuals and Controls[a]

Parameter	Exposed[b]	Controls[b]
Number of subjects	86	43
Age (years)	39.8 ± 19.1	32.3 ± 18.6
Black/white ratio	1.0	2.3
HCB plasma residues (ppb)	2.4 ± 2.3[c]	0.5
Range (ppb)	0-23	0-1.8
Percent positive	99	95
Percent >1 ppb	99	5

[a]Source: Burns and Miller, 1975

[b]Values are mean ± 1 SD

[c]Level for random sample only, N=63 (3.6 ± 4.3 for random and biased samples, N=83)

HCB = Hexaclorobenzene

metabolic disorders of porphyrin metabolism that are characterized by increased excretion of porphyrins and their precursors. Normally, δ-aminolevulinic acid synthetase is the rate-limiting step in porphyrin synthesis and heme acts as an end-product inhibitor or an end-product repressor of δ-aminolevulinic acid synthetase. In hexachlorobenzene-induced porphyria, δ-aminolevulinic acid synthetase is induced but heme does not suppress or inhibit the enzyme. The activity of uroporphyrinogen decarboxylase is decreased; consequently, porphyrin and its precursors (e.g., uroporphyrinogen, coproporphyrinogen and occasionally series I porphyrins) are excreted mainly in the urine but also in the feces. Increased levels of porphyrins also can be measured in the liver, skin, intestinal tract and other tissues (Courtney, 1979). PCT appeared to occur more frequently in children 4-16 years of age, whereas the number of adults and children under 5 years of age reporting PCT was much lower (10-24% of cases were individuals over 15 years of age and <5% were children below the age of 4). A distinct disease described as "pink sore" was observed in children under 1 year of age and reached an epidemic scale. The clinical symptoms were weakness and convulsions and usually death in children whose mothers had clinical symptoms of PCT or who had ingested contaminated bread during gestation and/or lactation. The presence of hexachlorobenzene in the milk of nursing mothers suggested that pink sore was a manifestation of hexachlorobenzene toxicity. The reviewer states that there was a 95% mortality in these infants in addition to the very high incidence of stillbirths.

In a follow-up study, Cripps et al. (1981) examined 32 patients 20 years after the onset. Porphyrins were determined in urine and stool specimens of

29 patients and clinically significant porphyrin levels were observed in 5 patients. Clinical features such as hyperpigmentation, scarring, pinched facies, hypertrichosis, enlarged thyroid and distinctive arthritis were present in about half of the patients.

A detailed follow-up study was also conducted with 161 Turkish patients 25 years after the initial hexachlorobenzene incident (Peters et al., 1982). The patient group studied included some of the patients previously examined (Peters et al., 1966). Twenty-six patients were over 17 years of age at the time of acute toxicity, whereas the average age of the remaining patients was 7.1 years. An evaluation of the clinical signs and symptoms is summarized in Table VI-3.

The chronic disease state was manifested by generalized hyperpigmentation and hypertrichosis, scarring on the cheeks and hands, and tight sclerodermoid changes of the nose with perioral scarring. The most striking clinical features in those patients who developed signs of hexachlorobenzene toxicity at an average age of 7 years consisted of painless arthritic changes with osteoporosis of carpal, metacarpal and phalangeal bones and atrophy or failure to develop in the terminal phalanges. In addition, neurologic symptoms including weakness, paresthesias, myotonia, cogwheeling and painless arthritic changes of the hands and feet, were observed in 50-70% of the patients examined. Since the signs and symptoms 20-25 years later represented a continuum of signs and symptoms observed personally by Peters and Gocmen (1959-1963), it was concluded that the symptoms represented the effects of both hexachlorobenzene toxicity and changes caused by the induced mixed porphyria. Control patients from the villages inhabited

TABLE VI-3

Clinical Signs and Symptoms in Humans 25 Years After Exposure to Low Levels of HCB in Turkey, 1955-1959[a]

Clinical Signs/Symptoms	No. of Patients with Symptoms[b]	Percent
Porphyria--Neurological		
Weakness	117 (161)	73
Paresthesias	89 (161)	55
Sensory shading	75 (125)	60
Nervousness	39 (60)	65
Myotonia	35 (76)	46
"Cogwheeling"	34 (125)	27
Colic	84 (161)	52
Constipation	31 (161)	19
Recent red urine	17 (161)	11
Enlarged liver	10 (161)	6
Dermatologic		
Hyperpigmentation	125 (161)	78
Scarring	134 (161)	83
Hirsutism	81 (161)	50
Pinched facies	69 (161)	43
Fragile skin	62 (161)	39
Thyroid enlargement		
Total	64 (161)	40
Men	26 (98)	27
Women	38 (63)	60
Orthopedic and others		
Arthritis	108 (161)	67
Small hands	107 (161)	67
Short stature	74 (161)	46

[a]Source: Peters et al., 1982

[b]Numbers in parentheses represent total number of patients examined for this symptom

HCB = Hexachlorobenzene

by these patients included unaffected family members and clearly demonstrated the uniqueness of this disorder that allowed for ready identification of affected patients. In addition the 60% incidence of large thyroid tumors in the females proved a sharp contrast to the 5% incidence of thyroid tumors in the geographical area. No conclusions were drawn as to the incidence of cancer and mortality. Studies on these endpoints are still in progress and the length of time that has elapsed from the time of exposure may not yet be adequate for drawing conclusions.

A boy and three women of the exposed individuals treated in the early 1960's with i.v. and/or oral edetic acid (the metal chelating agent EDTA) showed no active symptoms when examined, and skin pigmentation and scarring were much less severe than in most of the other patients. Urine and/or stool porphyrin studies showed that seven patients had clearly recognizable increases in porphyrin levels (Table VI-4). Clinical chemistry and milk residue data are summarized in Table VI-5. Percent δ-aminolevulinic acid values were found to be above the upper normal limit of 4 mg/ℓ in 32/55 patients. The average residue levels in human milk samples from Turkish mothers with porphyria was 0.51 ± 0.75 ppm; 0.16 ± 0.23 ppm was found in milk samples from nonporphyric but hexachlorobenzene-exposed mothers.

Summary

A few epidemiologic studies with occupationally-exposed workers have been reported, together with studies and surveys conducted in Turkey and in the United States (i.e., Louisana), on the general population following accidental exposure to hexachlorobenzene. These studies qualitatively support the toxicity of hexachlorobenzene but give little dose response

TABLE VI-4

Porphyrin Levels in Patients and Controls*

	Stool (µg/g dry weight)			Urine (µg/l)	
	Coproporphyrin	Protoporphyrin	Uroporphyrin	Coproporphyrin	Uroporphyrin
Controls					
Turkey, mean ± SD (N=33)	4.80 ± 3.2	7.65 ± 9.83	1.41 ± 1.57	30.0 ± 23.6	5.80 ± 4.25
United States, mean ± SD (N=40)	6.1 ± 4.7	21.1 ± 11.6	2.8 ± 2.7	69.0 ± 27.0	9.0 ± 4.0
Hexachlorobenzene-Exposed Patients					
Patients with active porphyria (N=15)	70.14 (1.0-837.6)	12.19 (0.7-61.8)	25.8 (0.7-189.2)	174.5 (32.6-779.3)	111.4 (16-1607)
Remainder (N=146)	5.74 (0.5-4.1)	9.02 (0-103.4)	1.19 (0-12.6)	31.91 (0-198.4)	7.25 (0-29.5)

*Source: Peters et al., 1982

TABLE VI-5

Laboratory Test Results of Turkish Patients[a]

Test	Normal Range	Patient Range	No. of Abnormal Results[b]
Urine			
δ-Aminolevulinic acid, mg/ℓ	<4	0.14-10.1	32 (55)
Porphobilinogen, mg/ℓ	<1	0.11-1.04	0 (56)
Copper, ppm	0.01-0.06	0.01-0.046	0 (31)
Zinc, ppm	0.1-0.7	0.02-1.22	7 (31)
Serum			
Copper, µg/dℓ	70-155	88-153	0 (30)
Zinc, µg/dℓ	70-120	57-112	9 (29)
Creatine kinase, units/ℓ	women, <120	65-141	1 (8)
	men, <150	51-318	4 (11)
Iron, µg/dℓ	65-170	69-147	0 (29)
Thyroid function tests	5-11	2.2-10.1	women, 5 (10)
Thyroxine, µg/dℓ			men, 2 (9)
Triiodothyronine uptake, percent	37-59	36-51.1	women, 1 (10)
			men, 1 (9)
Free thyroxine index	1.85-6.5	0.9-4.6	women, 4 (10)
			men, 0 (9)
Blood			
Lead, erythrocyte, µg/dℓ	<35	2-17	0 (11)
Uroporphyrinogen synthetase[c]	>20	12.4-34.8	5 (30)
Milk hexachlorobenzene, ppm[d]			
Patients with porphyria	NA	0.51 (0-3.12)	53 (56)
Patients without porphyria	NA	0.16 (0-1.26)	16 (77)

[a]Source: Peters, et al., 1982

[b]Numbers in parentheses represent total number of patient specimens analyzed.

[c]Values expressed in nanomoles formed per milliliter of RBCs per hour

[d]Allowable limit in United States for cow's milk is 0.02 ppm

NA = Not applicable

information. Biologic monitoring of plasma levels shows clearly more hexachlorobenzene in plasma of exposed compared with nonexposed individuals, although no biologically significant adverse health effects were seen during the observation periods.

The exposure of humans to hexachlorobenzene in Turkey from 1955-1959 caused an epidemic of hexachlorobenzene-induced PCT, also known as porphrya turcica, which is manifested by disturbed porphyrin metabolism, cutaneous lesions and hyperpigmentation. The authors estimated that 0.05-0.2 g/day were ingested. In children under 1 year of age, pink sore was observed as well as 95% mortality in these infants.

Follow-up studies conducted with patients 20-25 years after the onset of porphyria showed that a few patients still had active porphyria, whereas >50% exhibited hyperpigmentation scarring as well as other dermatologic, neurologic and skeletal features of hexachlorobenzene toxicity. Hexachlorobenzene residues were also found in the blood, fat or breast milk of some patients.

A correlation was found between hexachlorobenzene levels in blood and the number of years worked in a chlorinated solvents plant. The concentration of urinary uroporphyrins and coproporphyrins in workers ranged from 21-37 and 67-101 µg/ℓ, respectively, for the period between 1974 and 1977. An epidemiologic survey conducted with 86 residents in the vicinity of this chlorinated solvents plant showed elevated hexachlorobenzene residues in plasma. Higher levels of hexachlorobenzene residues were found in males than in females, but these were not associated with race or food consumption.

VII. MECHANISMS OF TOXICITY

The exposure of humans to toxicologically significant levels of hexachlorobenzene occurred in Turkey from 1955-1959 by ingestion of contaminated grain, as reported by Cam (1959, 1960), Cam and Nigogosyan (1963), and Peters et al. (1966), and caused an epidemic of hexachlorobenzene-induced porphyria cutanea tarda (PCT), also known as porphyria turcicia. This disease is characterized by a marked elevation in the levels of uroporphyrins in the urine. Also seen, but to a lesser degree, are increases in coproporphyrins (Thiers, 1981). Photosensitivity is associated with PCT (Ellefson, 1982) and may be involved in the manifestation of cutaneous lesions and hyperpigmentation (Tonnuki et al., 1981; Cripps et al., 1981).

Although it is clear that exposure to hexachlorobenzene adversely affects the heme biosynthetic pathway, the exact mechanism of action by which hexachlorobenzene induces hepatic porphyria remains unknown. In addition, only a small proportion of those people exposed to hexachlorobenzene developed porphyria (Dogramaci, 1964), but such adverse effects appear to be long-term in both humans (Cripps et al., 1984) and experimental animals (Koss et al, 1983). As such, the toxicity of hexachlorobenzene poses a very interesting problem whose solution will likely provide an increased understanding of human porphyria, heme biosynthesis and the influence of xenobiotics on each.

Mechanism of Porphyria

The induction of porphyria by hexachlorobenzene has been extensively reviewed (Granick, 1965; DeMatteis, 1967; Tschudy and Bonkowsky, 1972;

Courtney, 1979), and experimental models of hexachlorobenzene-induced hepatic porphyria now exist in several animal species (reviewed by Elder, 1978; Smith and De Matteis, 1980).

It is clear that exposure to hexachlorobenzene adversely affects the heme biosynthetic pathway, but the exact target(s) of its toxic insult is still unknown. Numerous studies have demonstrated that exposure to hexachlorobenzene impairs metabolism of uroporphyrinogen III by decreasing the enzymatic activity of uroporphyrinogen decarboxylase (Elder et al., 1976, 1978; Kushner et al., 1976; Strik et al., 1980; San Martin de Viale et al., 1977; Koss et al., 1983). This loss of enzyme function is associated with decreased catalytic function and not with the concentration of uroporphyrinogen decarboxylase (Elder and Sheppard, 1982; Elder and Urquhart, 1986). As such, this decreased activity may be attributed to either the presence of an inhibitor or to modification of the enzyme itself. Two hypotheses have been presented to explain this decrease of uroporphyrinogen decarboxylase (DeMatteis, 1986). The first proposes that hexachlorobenzene is metabolized to a reactive intermediate capable of impairing enzyme function. As such, inducers of drug metabolizing enzymes, including hexachlorobenzene itself, can affect its toxicity. The second suggests a more generalized effect of hexachlorobenzene involving oxidative damage to membranes and proteins via the formation of peroxides and free radicals. This mechanism could directly involve hexachlorobenzene, or alternatively, hexachlorobenzene could act to induce liver concentrations of other enzymes capable of generating such reactive species (DeMatteis, 1986).

Metabolism

Just as metabolism is important to the conversion of hexachlorobenzene to more polar compounds, hence to its elimination and subsequent decreased body burden (Sundlof et al., 1982), it also appears to be equally important for the induction of the toxic effects attributed to this chemical (Koss et al., 1980a; Debets et al., 1980a; Wainstok de Calmanovici et al., 1984).

The metabolism of hexachlorobenzene has been reviewed (Renner, 1981; Renner and Nguyen, 1984) and is believed to have similar routes in rats and humans (Stonard, 1974). Primary metabolites, including pentachlorophenol and tetrachlorohydroquinone, are found in human urine, but pentachlorothiophenol, a major rat metabolite, is not (Edgerton et al., 1981).

Billi and coworkers have shown that certain of these metabolites can inhibit uroporphyrinogen decarboxylase in vitro (Billi et al., 1986a,b) and also are associated with increased liver porphyrin concentrations in vivo (Billi et al., 1986b). Tetrachlorohydroquinone and pentachlorophenol decreased uroporphyrinogen decarboxylase activity 64 and 25%, respectively. Hexachlorobenzene produced no effect (Billi et al. 1986a). However, as noted (Billi et al., 1986b), the effective inhibitory concentration of these metabolites was much greater than the concentration of these metabolites found in the livers of rats treated with hexachlorobenzene (Koss et al., 1978b). Others have shown that hexachlorobenzene is porphyrinogenic when added to primary chick embryo liver cells grown in culture. In this study the parent compound was more effective than certain metabolites including pentachlorophenol, and was dependent upon the cytochrome P-450 content of the cells (Debets et al., 1981).

Using [14]C-labeled hexachlorobenzene it was shown that the binding of ^{14}C to proteins is dependent upon cytochrome P-450 (Debets et al., 1981). However, hexachlorobenzene is a poor substrate for cytochrome P-450 (Van Ommen et al., 1986), but it does bind to cytochrome P-450 with high affinity and does produce the type I spectrum characteristic of cytochrome P-450 substrates (Takazawa and Strobel, 1986). These studies suggest that metabolism of hexachlorobenzene is prerequisite to its toxic effects, but the discrepancy between the effective concentrations in vivo and the production of reactive intermediates in vitro is not yet understood.

Oxidative Damage

An alternate mechanism has been proposed suggesting that exposure to hexachlorobenzene results in oxidative damage and perturbation of lipid membranes including increased permeability of liposomal membranes (Koszo et al., 1974) and direct membrane-fluidizing effects (Koszo et al., 1982).

In the latter study, chronic dosing at 0.2% hexachlorobenzene in the diet resulted in a significant decrease of the spin labeling order parameter indicative of increased membrane fluidity. Since both 5-aminolevulinic acid and porphyrin must cross the mitochondrial membrane, it is conceivable that alterations of membrane fluidity could alter the heme biosynthetic pathway (Koszo et al., 1982).

Observations supporting this theory have been reported (Neilson et al., 1979, 1980), but it was also noted that both ethanol and hexachlorobenzene exibit membrane-fluidizing effects, while only the latter results in significant increases in porphyrin excretion (Neilson et al., 1980).

However, ethanol has been shown to potentiate certain effects of hexachlorobenzene including ones associated with damage to the plasma membrane (Nikolaev et al., 1986).

Other studies have shown that exposure to hexachlorobenzene causes no irreversible damage to mitochondrial membranes (Masini et al., 1984a,b, 1985) and suggest that the hexachlorobenzene metabolite, pentachlorophenol, acts to uncouple mitochondrial oxidative phosphorylation. However, no clear correlation exists between the concentration of pentachlorophenol and the increase of urinary and hepatic porphyrins (Masini et al., 1985). Again it is unclear whether or not the metabolism of hexachlorobenzene significantly contributes to its toxicity in vivo.

The role of glutathione has also been investigated. Repeated exposure of rats to hexachlorobenzene was shown to decrease the activity of glutathione-S-transferase (Koss et al., 1980a). In addition, diethylmaleate, a compound known to deplete glutathione concentrations, potentiates the action of porphyrinogenic drugs (Puzynska et al., 1978). With decreased glutathione or transferase activity, reactive, electrophilic metabolites or oxygen-free radicals and peroxides have increased opportunity to react with sulfur-containing molecules including proteins such as uroporphyrinogenic decarboxylase.

As recently reviewed (DeMatteis, 1986), it is possible that chemicals like hexachlorobenzene affect porphyrin synthesis indirectly by stimulating the production of these oxygen-free radicals and peroxides, and that iron

synergistically enhances this effect by its ability to catalyze these reactions. Hexachlorobenzene may either stimulate the production of these reactive species directly, or alternatively, may induce enzymes that can produce such reactive intermediates (DeMatteis and Stonard, 1977). With respect to the latter hypothesis, it is of interest that hexachlorobenzene has been shown to induce activities of NADPH-cytochrome P-450 reductase (Goldstein et al., 1982; Debets et al., 1980a). This enzyme is known to be directly involved in lipid peroxidation and superoxide formation (Morehouse et al., 1984; Pederson and Aust, 1972) by NADPH and iron-dependent (Ernster and Nordenbrand, 1967) and hydroperoxide-dependent (O'Brien and Rahimtula, 1975) mechanisms. These can result in total destruction of microsomal P-450 and mitochondrial hemoproteins (Hrycry and O'Brien, 1971), and also in the indirect inactivation of other enzymes and the alteration of membrane structure (Tappel, 1973).

It is known that uroporphyrinogen decarboxylase contains many sulfhydryl groups, at least one of which is essential for catalytic activity (Sassa et al., 1984). Recent studies have demonstrated that the effects of hexachlorobenzene on uroporphyrinogen decarboxylase is to decrease its enzymatic activity, but the concentration of immunoreactive protein is not altered (Elder and Sheppard, 1982; Elder et al., 1976). It has been suggested that reactive oxygen species could be responsible for the alteration of uroporphyrinogen decarboxylase (Ferioli et al., 1984; Elder and Urquhart, 1986). However, the specific mechanism(s) of this effect are not yet understood, and this remains an important and interesting example of chemically-induced pathology.

Contributing Factors

Several factors can contribute to the porphyrinogenic action of hexachlorobenzene. These include the liver concentration of nonheme iron, as well as the sex (hormonal status) and the genetic background (strain) of the animals used. Nonheme iron has been shown to enhance the toxicity of hexachlorobenzene, and as discussed above, this may be due to its contribution to oxygen-free radical formation (reviewed by Smith et al., 1986).

Female rats are much more sensitive to the porphyrinogenic action of hexachlorobenzene, and an increase in sensitivity is seen in males given estrogens (Rizzardini and Smith, 1982). It is especially significant that in addition to the development of porphyria, female rats also show a higher incidence of liver tumors (Smith et al., 1986).

Finally, some strains of mice are more sensitive to the porphyrinogenic effect of hexachlorobenzene. This difference may be associated with differences of the Ah locus, a regulatory gene involved in the induction of several enzymes by polycyclic aromatic hydrocarbons. Nonetheless, it is not yet clear that a correlation exists between Ah responsiveness and the toxic effects of hexachlorobenzene (Smith et al., 1986; Linko et al., 1986; Hahn et al., 1986).

Time Course of Toxicity

Despite this understanding of hexachlorobenzene-induced hepatic porphyria, it is still difficult to explain the latency period between exposure and onset of overt porphyria (reviewed by Koss et al., 1986).

Moreover, it is not known why this porphyria, once induced, will persist long after the exposure has stopped, but this is true for both humans (Cripps et al., 1984) and experimental animals (Koss et al., 1983).

As such, the study by Koss et al. (1983) provides an important understanding of the progression of hepatic porphyria. These researchers administered 100 mg/kg hexachlorobenzene dissolved in olive oil every other day for 6 weeks, through stomach tube, to female Wistar rats and then observed the rats for an additional 18 months. The rats were evaluated during both the exposure period and the 18-month holding period for liver hexachlorobenzene levels, levels of liver porphyrins, and the activity of liver uroporphyrinogen decarboxylase. The results revealed a rapid increase in hexachlorobenzene liver levels, which reached a plateau after 10 days of treatment and remained constant until exposure was terminated at 6 weeks. The levels of liver hexachlorobenzene then decreased over time with no valid biologic half-life determinable. The liver porphyrin levels, however, started to rise slightly after 3 weeks of hexachlorobenzene exposure and reached a maximum liver porphyrin concentration ~7 months after the exposures had ceased (Table VII-1). The liver porphyrin levels decreased to a constant level ~14 months after ceasing hexachlorobenzene exposures. At 18 months, after ceasing exposures, the treated rat's liver porphyrin levels were still substantially higher than the levels in control rats. The distribution pattern of the liver porphyrins was observed to be changed as early as after the second hexachlorobenzene administration. The observed changes were increases in liver uroporphyrin levels and decreases in liver protoporphyrin and coproporphyrin levels. The change in porphyrin patterns was traced to the decreased activity of uroporphyrinogen decarboxylase

TABLE VII-1

Porphyrin Content and Uroporphyrinogen Decarboxylase Activity in the Liver Cytosol of Female Rats Pretreated with 100 mg/kg HCB Every Other Day for 6 Weeks[a]

Time After the End of Treatment	Porphyrin Content (nmol/6 mℓ cytosol)[b]	Enzyme Activity (pmol • mg^{-1} • min^{-1})[c]
1 day	14 ± 3[d]	ND[e]
7 months	133 ± 15	ND
14 months	9 ± 6	ND
18 months	8 ± 5	0.3 ± 0.2[d]
Controls	0.06 ± 0.04	0.5 ± 0.1

[a]Source: Koss et al., 1983

[b]6 mℓ cytosol correspond with 1 g liver tissue

[c]pmol coproporphyrinogen I (determined as coproporphyrin) formed from uroporphyrinogen I in 1 min by 1 mg cytosol protein

[d]Mean (± SD) of three or four animals

[e]ND = Not detectable. The lower detection limit was determined at 0.02 pmol • mg^{-1} • min^{-1} coproporphyrin

HCB = Hexachlorobenzene

activity, which was found to be not detectable at the end of the 6-week exposure period and the activity did not become detectable again until 18 months postexposure (see Table VII-1). These data led the investigators (Koss et al., 1983) to propose that there are four phases of hexachlorobenzene-induced porphyria:

> During the first phase an almost constant content of hexachlorobenzene and a gradual decrease of uroporphyrinogen decarboxylase activity is achieved. In the second phase a noticeable accumulation of porphyrins and a practically complete inhibition of decarboxylase activity are conspicuous. In the third phase, which occurs after hexachlorobenzene administration has been discontinued, a further accumulation of porphyrins and a continuing inhibition of uroporphyrinogen decarboxylase activity can be seen, even after extensive elimination of hexachlorobenzene. During the fourth phase a decrease in porphyrin content and a return of decarboxylase activity are clearly observable.

A possible reason for the continued inhibition of uroporphyrinogen decarboxylase activity, even after substantial elimination of hexachlorobenzene has occurred, was also discussed in this report. Koss et al. (1983) presented the scenario that once hexachlorobenzene had caused an inhibition of uroporphyrinogen decarboxylase activity and increased liver porphyrin levels that the accumulation of porphyrins could themselves maintain the inhibition of the enzyme activity.

Interactions

Certain chemicals have been shown to alter the toxicity and pharmacokinetics of hexachlorobenzene in mammals. Pentachlorophenol and iron increased the porphyrinogenic effect of hexachlorobenzene, whereas decachlorobiphenyl had no effect. Hexachlorobenzene pretreatment resulted in increased CCl_4 toxicity and altered immune responses in hexachlorobenzene-treated animals. In addition, hexachlorobenzene has been shown to

induce hepatic xenobiotic metabolism and thus has the potential to alter the rate and extent of metabolism of other chemicals.

Debets et al. (1980b) studied the effect of pentachlorophenol (PCP) on hexachlorobenzene toxicity. Groups of female rats were fed diets containing 1000 µg hexachlorobenzene/g, 500 µg pentachlorophenol/g, or both chemicals in the same amounts, and a fourth group served as the control. Pentachlorophenol accelerated the onset of hexachlorobenzene-induced porphyria, as indicated by an increase in urinary excretion of uroporphyrin and a decrease of porphyrins with two and three carboxylic groups. This increase occurred ~3 weeks earlier in the hexachlorobenzene plus pentachlorophenol-treated animals than in hexachlorobenzene-treated animals.

Rizzardini and Smith (1982) investigated diethylstilboestrol (DES) pretreatment on hexachlorobenzene metabolite excretion in young male and female F344/N rats. The rats were injected i.p. with four doses of DES dipropionate 20 µmoles/kg dissolved in arachis oil over a 24-day period and then given 14 mg/kg hexachlorobenzene by oral intubation for 7 days. The results indicated that the DES pretreatment stimulated the excretion of hexachlorobenzene metabolites, via urine and feces, in both males and females (Table VII-2).

Blekkenhorst et al. (1980) reported that the simultaneous i.m. administration of iron and hexachlorobenzene caused a marked potentiation of hexachlorobenzene porphyrinogenic effect in rats. This was shown by a decrease in hepatic uroporphyrinogen decarboxylase activity and increased urinary and

TABLE VII-2

Analysis of the Excreta from Rats Administered Hexachlorobenzene After an Initial Treatment with Diethylstilboestrol[a,b]

Sex and Treatment	Pentachlorophenol	Tetrachlorobenzene-1,4-diol (nmole/24 hours/kg bw)	Pentachlorothiophenol
Urine			
Male + oil	151 ± 19	3 ± 1	23 ± 3
Male + DES	190 ± 22	17 ± 2[c]	158 ± 9[c]
Female + oil	174 ± 17	16 ± 2[d]	142 ± 12[e]
Female + DES	453 ± 105[f]	35 ± 9	176 ± 7[f]
Feces			
Male + oil	85 ± 15	Trace	74 ± 23
Male + DES	160 ± 23[f]	Trace	166 ± 33
Female + oil	116 ± 35	Trace	65 ± 4
Female + DES	279 ± 80	Trace	149 ± 13[c]

[a]Source: Rizzardini and Smith, 1982

[b]Male and female rats (52-54 and 71-73 days old, respectively) were given 20 μmole of DES dipropionate/kg dissolved in arachis oil (10 mg/mℓ) or oil alone by i.p. injection on days 1, 4, 14 and 24. From day 25 all rats were given 14 mg of hexachlorobenzene/kg by oral intubation daily for 7 days. After the last dose 24-hour samples of urine and feces were collected, hydrolyzed and analyzed. Results are means ± S.E.M. (n=4/group).

[c]Significance of differences from rats not given DES, $p<0.001$

[d]Significance of differences from males, $p<0.005$

[e]Significance of differences from males, $p<0.001$

[f]Significance of differences from rats not given DES, $p<0.05$

Total excretions of these metabolites were: male, 336±57; male + DES, 691±70 ($p<0.01$); female, 513±62; female + DES, 1092±175 ($p<0.025$) nmole/24 hours/kg

fecal porphyrin excretion. Conversely, simultaneous bleeding of hexachlorobenzene-treated rats diminished the porphyrinogenic effect of hexachlorobenzene.

The role of iron in increasing the porphyrinogenicity of hexachlorobenzene was noted in female Sprague-Dawley rats fed 0 or 400 ppm of hexachlorobenzene in their diets for up to 118 days (Lambrecht et al., 1986). Ethylenediaminetetracetic acid (EDTA) was added to the study diets at a concentration of 0, 0.5 or 1.0%, resulting in six study groups. Dramatic increases in the urinary excretion of uroporphyrin and coproporphyrin were seen in the rats exposed to hexachlorobenzene for 81 days or longer. EDTA in the diet significantly decreased the amounts of porphyrins excreted in the urine. Hexachlorobenzene-induced liver porphyrin fluorescence was also decreased in the EDTA groups. EDTA significantly reduced the liver levels of iron, zinc and copper, which were greatly increased in the hexachlorobenzene-exposed rats. EDTA had no effect on the hexachlorobenzene-induced liver and kidney pathology observed. The authors concluded that the liver metal levels may play an important role in hexachlorobenzene-induced porphyria but not the hexachlorobenzene-induced pathology.

Goldstein et al. (1978) studied the comparative toxicity of pure hexachlorobenzene (purity >99%) and technical hexachlorobenzene (purity 92%), which was known to contain 200 ppm of decachlorobiphenyl and 4 ppm of octachlorodibenzofuran, in female CD rats fed diets containing 0, 30, 100, 300 or 1000 µg hexachlorobenzene/g for up to 15 weeks. Neither grade contained other chlorinated dibenzofurans or dibenzo-p-dioxins. Both grades

resulted in comparable effects (porphyria, cutaneous lesions, hyperexcitability, changes in liver enzymes and morphologic liver changes) in treated rats, although the technical grade appeared to be slightly more potent than pure hexachlorobenzene in its effects on the pulmonary endothelium. The impurities did not appear to have a synergistic effect.

Kluwe et al. (1982) reported that pretreatment of male Sprague-Dawley rats with hexachlorobenzene resulted in increased CCl_4 toxicity. The rats received seven doses of hexachlorobenzene at 30 mg/kg in corn oil once every 72 hours followed by an i.p. injection of CCl_4 at 0.0, 0.03, 0.05, 0.25, 1.0 or 2.0 mℓ/kg in 4 mℓ/kg corn oil 24 hours after the last hexachlorobenzene treatment. Hexachlorobenzene pretreatment increased the CCl_4-induced acute growth retardation, renal tubular functional impairment, hepatocellular necrosis and further reduced the survival of the animals. Variable results were reported in a study on the effect of hexachlorobenzene pretreatment of male albino Sprague-Dawley rats on the in vivo biotransformation, residue deposition, and elimination of ^{14}C-aldrin, 1-naphthol, DDT, hexachlorobenzene or mirex (Clark et al., 1981a). There was no evidence of qualitative changes in the biotransformation of any test compound that could be attributed to hexachlorobenzene pretreatment. Analysis of residue deposition gave mixed results: less ^{14}C residues were found in rats fed diets containing hexachlorobenzene and then treated with ^{14}C-aldrin, more ^{14}C residues were found after ^{14}C-DDT or ^{14}C-mirex treatment, and no difference was evident after ^{14}C-hexachlorobenzene or ^{14}C-1-naphthol treatment. Hexachlorobenzene also potentiates the effects of stress on male Sprague-Dawley rats (Clark et al., 1981b). Rats fed 250 ppm hexachlorobenzene resulted in an increased severe loss of body weight

when placed into crowded cages and compared with the weight loss of crowded control rats. Crowded rats fed hexachlorobenzene had higher tissue residues of hexachlorobenzene and higher mortality than the noncrowded hexachlorobenzene-treated rats or the control rats.

Summary

Hexachlorobenzene (HCB) affects the heme biosynthesis pathway and this is the mechanism by which porphyria is induced. Although many animal studies have been performed, the exact target is unclear. From in vitro experiments it is known that metabolites of HCB, such as pentachlorophenol, inhibit uroporphyrinogen dicarboxylase but HCB itself does not. An alternate mechanism that has been proposed is that HCB and its metabolites cause oxidative damage to cellular lipid membranes. Despite extensive investigation of these two separate mechanisms of action the issue has not been resolved; in fact, other mechanisms have been proposed and are also being explored.

VIII. QUANTIFICATION OF TOXICOLOGIC EFFECTS

Introduction

The quantification of toxicologic effects of a chemical consists of separate assessments of noncarcinogenic and carcinogenic health effects. Chemicals that do not produce carcinogenic effects are believed to have a threshold dose below which no adverse, noncarcinogenic health effects occur, while carcinogens are assumed to act without a threshold.

In the quantification of noncarcinogenic effects, a Reference Dose (RfD), [formerly termed the Acceptable Daily Intake (ADI)] is calculated. The RfD is an estimate (with uncertainty spanning perhaps an order magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious health effects during a lifetime. The RfD is derived from a no-observed-adverse-effect level (NOAEL), or lowest-observed-adverse-effect level (LOAEL), identified from a subchronic or chronic study, and divided by an uncertainty factor(s) times a modifying factor. The RfD is calculated as follows:

$$\text{RfD} = \frac{\text{(NOAEL or LOAEL)}}{\text{[Uncertainty Factor(s) x Modifying Factor]}} = \_\_\_\_ \text{ mg/kg bw/day}$$

Selection of the uncertainty factor to be employed in the calculation of the RfD is based upon professional judgment, while considering the entire data base of toxicologic effects for the chemical. In order to ensure that uncertainty factors are selected and applied in a consistent manner,

the U.S. EPA (1991) employs a modification to the guidelines proposed by the National Academy of Sciences (NAS, 1977, 1980) as follows:

Standard Uncertainty Factors (UFs)

- Use a 10-fold factor when extrapolating from valid experimental results from studies using prolonged exposure to average healthy humans. This factor is intended to account for the variation in sensitivity among the members of the human population. [10H]

- Use an additional 10-fold factor when extrapolating from valid results of long-term studies on experimental animals when results of studies of human exposure are not available or are inadequate. This factor is intended to account for the uncertainty in extrapolating animal data to the case of humans. [10A]

- Use an additional 10-fold factor when extrapolating from less than chronic results on experimental animals when there is no useful long-term human data. This factor is intended to account for the uncertainty in extrapolating from less than chronic NOAELs to chronic NOAELs. [10S]

- Use an additional 10-fold factor when deriving an RfD from a LOAEL instead of a NOAEL. This factor is intended to account for the uncertainty in extrapolating from LOAELs to NOAELs. [10L]

Modifying Factor (MF)

- Use professional judgment to determine another uncertainty factor (MF) that is greater than zero and less than or equal to 10. The magnitude of the MF depends upon the professional assessment of scientific uncertainties of the study and data base not explicitly treated above, e.g., the completeness of the overall data base and the number of species tested. The default value for the MF is 1.

The uncertainty factor used for a specific risk assessment is based principally upon scientific judgment rather than scientific fact and accounts for possible intra- and interspecies differences. Additional considerations not incorporated in the NAS/ODW guidelines for selection of an uncertainty factor include the use of a less than lifetime study for deriving an RfD, the significance of the adverse health effects and the counterbalancing of beneficial effects.

From the RfD, a Drinking Water Equivalent Level (DWEL) can be calculated. The DWEL represents a medium specific (i.e., drinking water) lifetime exposure at which adverse, noncarcinogenic health effects are not anticipated to occur. The DWEL assumes 100% exposure from drinking water. The DWEL provides the noncarcinogenic health effects basis for establishing a drinking water standard. For ingestion data, the DWEL is derived as follows:

$$\text{DWEL} = \frac{\text{(RfD) x (Body weight in kg)}}{\text{Drinking Water Volume in ℓ/day}} = \_\_\_\_ \text{ mg/ℓ}$$

where:

Body weight = assumed to be 70 kg for an adult
Drinking water volume = assumed to be 2 ℓ/day for an adult

In addition to the RfD and the DWEL, Health Advisories (HAs) for exposures of shorter duration (1-day, 10-day and longer-term) are determined. The HA values are used as informal guidance to municipalities and other organizations when emergency spills or contamination situations occur. The HAs are calculated using an equation similar to the RfD and DWEL; however, the NOAELs or LOAELs are identified from acute or subchronic studies. The HAs are derived as follows:

$$\text{HA} = \frac{\text{(NOAEL or LOAEL) x (bw)}}{\text{(UF) x (\_\_\_ ℓ/day)}} = \_\_\_\_ \text{ mg/ℓ}$$

Using the above equation, the following drinking water HAs are developed for noncarcinogenic effects:

1. 1-day HA for a 10 kg child ingesting 1 ℓ water per day.
2. 10-day HA for a 10 kg child ingesting 1 ℓ water per day.
3. Longer-term HA for a 10 kg child ingesting 1 ℓ water per day.
4. Longer-term HA for a 70 kg adult ingesting 2 ℓ water per day.

The 1-day HA calculated for a 10 kg child assumes a single acute exposure to the chemical and is generally derived from a study of <7 days duration. The 10-day HA assumes a limited exposure period of 1-2 weeks and is generally derived from a study of <30 days duration. The longer-term HA is derived for both the 10 kg child and a 70 kg adult and assumes an exposure period of ~7 years (or 10% of an individual's lifetime). The longer-term HA is generally derived from a study of subchronic duration (exposure for 10% of animal's lifetime).

The U.S. EPA categorizes the carcinogenic potential of a chemical, based on the overall weight-of-evidence, according to the following scheme:

> Group A: Human Carcinogen. Sufficient evidence exists from epidemiology studies to support a causal association between exposure to the chemical and human cancer.
>
> Group B: Probable Human Carcinogen. Sufficient evidence of carcinogenicity in animals with limited (Group B1) or inadequate (Group B2) evidence in humans.
>
> Group C: Possible Human Carcinogen. Limited evidence of carcinogenicity in animals in the absence of human data.
>
> Group D: Not Classified as to Human Carcinogenicity. Inadequate human and animal evidence of carcinogenicity or for which no data are available.
>
> Group E: Evidence of Noncarcinogenicity for Humans. No evidence of carcinogenicity in at least two adequate animal tests in different species or in both adequate epidemiologic and animal studies.

If toxicologic evidence leads to the classification of the contaminant as a known, probable or possible human carcinogen, mathematical models are used to calculate the estimated excess cancer risk associated with the ingestion of the contaminant in drinking water. The data used in these

estimates usually come from lifetime exposure studies using animals. In order to predict the risk for humans from animal data, animal doses must be converted to equivalent human doses. This conversion includes correction for noncontinuous exposure, less than lifetime studies and for differences in size. The factor that compensates for the size difference is the cube root of the ratio of the animal and human body weights. It is assumed that the average adult human body weight is 70 kg and that the average water consumption of an adult human is 2 ℓ of water per day.

For contaminants with a carcinogenic potential, chemical levels are correlated with a carcinogenic risk estimate by employing a cancer potency (unit risk) value together with the assumption for lifetime exposure from ingestion of water. The cancer unit risk is usually derived from a linearized multistage model with a 95% upper confidence limit providing a low dose estimate; that is, the true risk to humans, while not identifiable, is not likely to exceed the upper limit estimate and, in fact, may be lower. Excess cancer risk estimates may also be calculated using other models such as the one-hit, Weibull, logit and probit. There is little basis in the current understanding of the biologic mechanisms involved in cancer to suggest that any one of these models is able to predict risk more accurately than any other. Because each model is based upon differing assumptions, the estimates derived for each model can differ by several orders of magnitude.

The scientific data base used to calculate and support the setting of cancer risk rate levels has an inherent uncertainty that is due to the systematic and random errors in scientific measurement. In most cases, only studies using experimental animals have been performed. Thus, there is

uncertainty when the data are extrapolated to humans. When developing cancer risk rate levels, several other areas of uncertainty exist, such as the incomplete knowledge concerning the health effects of contaminants in drinking water, the impact of the experimental animal's age, sex and species, the nature of the target organ system(s) examined and the actual rate of exposure of the internal targets in experimental animals or humans. Dose-response data usually are available only for high levels of exposure and not for the lower levels of exposure closer to where a standard may be set. When there is exposure to more than one contaminant, additional uncertainty results from a lack of information about possible synergistic or antagonistic effects.

Noncarcinogenic Effects

The toxicity of long-term dietary exposure of humans to hexachlorobenzene was demonstrated by the epidemic of porphyria cutanea tarda (PCT) in Turkish citizens who accidentally consumed bread made from grain treated with hexachlorobenzene (Cam and Nigogosyan, 1963; Peters et al., 1966, 1982). The authors estimated that 0.05-0.2 g/day were ingested. In children less than 1 year of age, pink sore was observed as well as 95% mortality. In addition to the PCT-associated symptoms of skin lesions, hypertrichosis and hyperpigmentation, the exposure caused neurotoxicity and liver damage. Follow-up studies reported PCT symptoms, reduced growth and arthritic changes in the appendages of children who were directly or indirectly (i.e., through breast milk) exposed. Studies in rats have demonstrated hexachlorobenzene's ability to increase the incidence of stillbirths, decrease fetal growth and decrease postnatal survival (Grant et al., 1977; Khera, 1974). A study in rats reported that administration of

hexachlorobenzene during gestation increased significantly the number of fetuses with extra ribs. A study in mice found that hexachlorobenzene given on days 7-16 of gestation resulted in an increased incidence of fetal abnormalities when compared with controls (Courtney et al., 1976).

The acute oral toxicity of hexachlorobenzene has been found to be low, with LD_{50} values ranging from 1700-10,000 mg/kg (NAS, 1977; IARC, 1979; Sax, 1979). Subchronic oral toxicity studies with a number of mammalian species indicated statistically significant increases in liver and kidney weights in hexachlorobenzene-treated animals (Kuiper-Goodman et al., 1977; Boger et al., 1979; Koss et al., 1978b; Sundlof et al., 1981; Shirai et al., 1978). Studies have shown increases in other organs as well (Elissalde and Clark, 1979; Koss et al., 1978b). The livers from hexachlorobenzene-exposed animals have shown histologic changes such as irregularly shaped and moderately enlarged liver mitochondria and increases in the size of centrilobular hepatocytes (Kuiper-Goodman et al., 1977; Boger et al., 1979; Lambrecht et al., 1982a,b). Chronic oral toxicity studies revealed the same type of effects seen in the subchronic studies plus hexachlorobenzene-associated life-shortening and various hepatic and renal pathologies (Cabral et al., 1977, 1979; Smith and Cabral, 1980; Lambrecht et al., 1983a,b; Arnold et al., 1985). These subchronic and chronic effects were usually dose-related. Multiple alopecia and scabbing, together with neurologic effects, have also been observed in rats, mice and dogs (Headley et al., 1981; Sundlof et al., 1981). A dose-related histopathologic change in the ovaries of monkeys has also been reported (Iatropoulos et al., 1976; Knauf and Hobson, 1979).

Increased porphyrin levels in the liver and in urine have been reported for all species studied (Kuiper-Goodman et al., 1977; Koss et al., 1978a, 1983; Smith et al., 1980; Gralla et al., 1977; Rizzardini and Smith, 1982) except for the dog, which does not exhibit increased porphyrin levels (Gralla et al., 1977). Hexachlorobenzene was found to cause the accumulation of 5ß-H-steroids that induce porphyrin biosynthesis (Graef et al., 1979), and to inhibit uroporphyrinogen decarboxylases (Graef et al., 1979; Koss et al., 1983). The inhibition of uroporphyrinogen decarboxylases appears to be due to pentachlorophenol, a hexachlorobenzene metabolite (Rios de Molina et al., 1980). There is evidence that females are more susceptible to hexachlorobenzene-induced porphyria than are males, which may be related to the female estrogen levels and greater hexachlorobenzene metabolism (Rizzardini and Smith, 1982). Hexachlorobenzene was reported to produce a mixed-type induction of cytochromes resembling that produced by a combination of phenobarbital (P-450) and 3,4-benzpyrene (P-448) (Goldstein et al., 1982; Debets et al., 1980a). In addition, the activities of hepatic microsomal enzymes were found to be induced by hexachlorobenzene (Ariyoshi et al., 1974; Mehendale et al., 1975; Carlson and Tardiff, 1976; Chadwick et al., 1977; Carlson, 1978, 1980; Carlson et al., 1979).

Hexachlorobenzene has been shown to produce various types of tumors in animals. Lifetime dietary administration of hexachlorobenzene to hamsters, rats and mice increased the incidence of thyroid tumors in hamsters (Cabral et al., 1977), liver tumors in hamsters (Cabral et al., 1977), mice (Cabral et al., 1979) and rats (Smith and Cabral, 1980; Lambrecht, 1983; Arnold et al., 1985), kidney tumors in rats (Lambrecht, 1983) and adrenal tumors in rats (Arnold et al., 1985; Peters et al., 1983).

Quantification of Noncarcinogenic Effects

Table VIII-1 presents a summary of the toxicity studies on hexachlorobenzene that were considered for calculation of the 1-, 10-day and longer-term Health Advisories (HAs) and the lifetime Drinking Water Equivalent Level (DWEL).

Derivation of 1-Day Health Advisory. Currently available evidence for the acute toxicity of hexachlorobenzene is considered to be insufficient for calculation of a 1-day HA for a 10 kg child. There are acute oral LD_{50} studies with hexachlorobenzene that indicate low acute toxicity, as LD_{50} values are $\geq$1700 mg/kg, for this material in rats, rabbits, cats and mice. However, these studies do not provide an assessment of systemic toxicity which can be applied to a 1-day HA calculation. Conversely, the Kuiper-Goodman et al. (1977) study, which is the basis for the longer-term HA herein, gives a dose-response with effect and no-effect levels for systemic toxicity in male and female rats given hexachlorobenzene in the diet. The subchronic dosing pattern is a limitation in using the Kuiper-Goodman et al. (1977) study specifically for a 1-day HA calculation. Nonetheless, administration of hexachlorobenzene in the diet would more closely approximate exposure patterns with drinking water than bolus treatment via gavage or capsules, which was the method of treatment in the acute as well as several subchronic toxicity studies with hexachlorobenzene. Therefore, the longer-term HA for a 10 kg child of 0.05 mg/ℓ is also recommended for use as a 1-day HA.

Derivation of 10-Day Health Advisory. Currently available oral exposure toxicity data are considered insufficient for calculation of a 10-day HA for

TABLE VIII-1

Summary of Toxicity Studies on Hexachlorobenzene

Species	Route	Dose	Duration	Effects	Reference
Rat (females)	oral	100 mg/kg every other day	up to 43 days	Suggested covalent binding of hexachlorobenzene metabolites to cytosolic proteins	Koss et al., 1980a
Rat	oral (diet)	0.5 mg/kg/day	15 weeks exposed and held to 48 weeks	Transient increases in liver porphyrin levels in females after termination of exposure	Kulper-Goodman et al., 1977
		2.0 mg/kg/day	15 weeks exposed and held to 48 weeks	Increases in liver porphyrin levels in females after termination of exposure, increased size of centrilobular hepatocytes	
		8.0 mg/kg/day	15 weeks exposed and held to 48 weeks	Increased liver weights, increased liver, kidney and spleen porphyrin levels in females (porphyria), centrilobular liver lesions especially in females at 48 weeks	
		32.0 mg/kg/day	19 weeks exposed and held to 48 weeks	Increased mortality in females, intension tremors in males and females and ataxia in a few females, increased liver, kidney and spleen weights, increased liver, kidney and spleen porphyrin levels in females (porphyria), centrilobular liver lesions and splenomegaly	
Rat (females)	oral (gavage)	50 mg/kg every other day	15 weeks	Increased liver, kidney, spleen and adrenal weights, porphyria (increased liver porphyrin levels and increased excretion of porphyrins and precursors), tremors, hair loss and skin lesions	Koss et al., 1978b
Rats (females)	oral (gavage)	0.5 mg/kg twice weekly	29 weeks	Increase in relative liver weight	Böger et al., 1979
		2.0 mg/kg twice weekly	29 weeks	Increase in relative liver weight, moderately enlarged hepatocytes	
		8.0 mg/kg twice weekly	29 weeks	Porphyria, markedly enlarged hepatocytes, increase in relative liver weight	
		32.0 mg/kg twice weekly	29 weeks	Porphyria, markedly enlarged hepatocytes, increase in liver weights	
Rat (females)	oral (diet)	100 mg/kg diet	98 days	Porphyria (increased liver lobe porphyrins), decreased activity of uroporphyrinogen decarboxylase	Smith et al., 1980

TABLE VIII-1 (cont.)

Species	Route	Dose	Duration	Effects	Reference
Rat	oral (diet and nursing)	50 mg/kg diet	gestation until 5 weeks of age	Depressed resistance to L. monocytogenes and T. spiralis, enhanced thymus-dependent antibody response	Vos et al., 1979b
		150 mg/kg diet	gestation until 5 weeks of age	Increased serum IgM and IgG, depressed resistance to L. monocytogenes and T. spiralis, enhanced thymus-dependent antibody response, increased liver and adrenal weights	
Rat	oral (diet and nursing)	4, 20 or 100 mg/kg diet	gestation until 5 weeks of age	Increased IgM and IgG responses to tetanous toxiod, delayed-type hypersensitivity reactions to ovalbumin, noted accumulation of alveolar macrophages; no change in T. spiralis resistance	Vos et al., 1983a,b
Rat	oral (diet)	500, 1000 or 2000 mg/kg diet	3 weeks	Dose-related increases in relative spleen, lymph nodes, liver, adrenals, thyroid, testes and kidney weights, dose-related increase in serum IgM levels, no change in serum IgG levels, dose-related pathological changes in liver, lymph nodes and spleen	Vos et al., 1979a
Rat	oral (diet)	2000 mg/kg diet	10 weeks	Porphyria found microscopically at 5 weeks and grossly at 10 weeks using fluorescence	Gralla et al., 1977
Rat (male)	oral (diet)	2000 mg/kg diet	100 days	Elevated hepatic enzymes by 1 week and increased urinary porphyrin and ALA levels (porphyria) as early as 40 days	Lissner et al., 1975
Rat (female)	oral (diet)	3000 mg/kg diet	11 weeks	Decreased uroporphyrinogen decarboxylase activity and porphyria after 4 weeks	Elder et al., 1976
Rat (female)	oral (gavage)	50, 100 or 200 mg/kg	120 days	Dose- and time-dependent increase in liver and urine porphyrins (porphyria)	Carlson, 1977
Rat	oral (gavage)	14 mg/kg every other day	103 days	Porphyria in treated females, susceptibility of females to porphyria may be related to estrogen levels	Rizzardini and Smith, 1982
Rat (females)	oral (gavage)	100 mg/kg every other day	6 weeks exposed and held for additional 18 months	Porphyria (liver uroporphyrin levels peaked 7 months postexposure and levels had not returned to normal by 18 months), decreased liver protoporphyrin and coproporphyrin levels, inhibition of uroporphyrinogen decarboxylase activity until 18 months postexposure	Koss et al., 1983
Rat (females)	oral (diet)	6-8 mg/kg/day	75-90 weeks	Decline in body weights, porphyria, enlarged livers and liver tumors	Smith and Cabral, 1980

TABLE VIII-1 (cont.)

Species	Route	Dose	Duration	Effects	Reference
Rat	oral (diet)	75 mg/kg diet (4-5 mg/kg/day) 150 mg/kg diet (8-9.5 mg/kg/day)	up to 2 years	Porphyria, time-related appearance of severe hepatic and renal pathologies, after 1 year increases in hepatomas, hepatocarcinomas, bile duct adenomas, renal adenomas and renal carcinomas	Lambrecht et al., 1983a,b
Rat	oral (diet)	75 or 150 mg/kg diet	up to 2 years	Decreased nerve conduction velocities 8 and 31% in 75 and 150 ppm groups, respectively; muscles showed signs of denervation, fibrillations and pseudomyotonia	Sufit et al., 1986
Rat	oral (diet)	800 mg/kg diet	20 weeks	Reduced nerve conduction velocities, no muscle abnormalities as observed in 2-year study	Sufit et al., 1986
Rat	oral (diet)	0.32, 1.6, 8.0 or 40 mg/kg diet	~130 days	Hematologic changes at all dose levels in males, increases in liver and heart weights in males at 8.0 and 40 ppm diets, no treatment-related effects observed in bred females	Arnold et al., 1985
	oral (diet and nursing)	0.32 or 1.6 mg/kg diet	gestation through lifetime (130 weeks)	Glycogen depletion in 1.6 mg/kg males; no effects reported at 0.32 mg/kg	
		8.0 mg/kg diet	gestation through lifetime (130 weeks)	Increase in liver pathologies	
		40 mg/kg diet	gestation through lifetime (130 weeks)	Increased mortality as pups, increase in liver and kidney pathologies, increase in adrenal pheochromocytomas in females and parathyroid tumors in males	
Rat	oral (diet)	10 or 20 mg/kg diet	F_0 to F_4 generations	No effects reported	Grant et al., 1977
		40 mg/kg diet	F_0 to F_4 generations	Increases in liver weights and aniline hydroxylase activity	
		80 mg/kg diet	F_0 to F_4 generations	Decreased body weights, F_3 and F_4 generations had decreased lactation index and postnatal viability and increased stillbirths	
		160 mg/kg diet	F_0 to F_4 generations	Increased mortality and decreased lactation index starting in F_1 generation	
		320 and 640 mg/kg diet	F_0 to F_4 generations	20 and 50% mortality in F_0 320 and 640 mg/kg groups, respectively, greatly reduced fertility index and litter size and increase in stillbirths, viability index zero in F_1	

TABLE VIII-1 (cont.)

Species	Route	Dose	Duration	Effects	Reference
Rat	oral (diet)	60, 80, 100, 120 or 140 mg/kg diet	F_0 to F_{1a} and F_{1b} generations	Increased mortality in all groups at 21 days, 21-day LD_{50} values for pups were 100 and 140 mg/kg for F_{1a} and F_{1b} generations, respectively	Kitchin et al., 1982
Rat	oral (diet)	0 or 80 mg/kg diet	gestation and nursing or cross nursed with controls	Nursing exposure produced greater effects than did gestational exposure, effects noted were: smaller brains, hearts, kidneys and spleens, increased liver weights	Mendoza et al., 1978
Rat	oral (diet)	80 mg/kg diet	2 weeks prior to mating to 35-36 days after weaning	Increased porphyrin levels and decreased liver esterase activity in dams, no changes in gestation indices or neonatal survival	Mendoza et al., 1979
Rat	oral (gavage)	10, 20, 40, 60, 80 or 120 mg/kg	days 6-21 of gestation	Maternal toxicity (weight loss, tremors and convulsions) and reduced fetal weights at 120 and 80 mg/kg maternal doses, dose-related increase in incidence of unilateral and bilateral 14th rib, sternal defects were also noted in one experiment	Khera, 1974
Mouse	oral (diet)	2.5, 25 or 250 mg/kg diet	21 days	Dose-related increase in liver and decrease in prostate and seminal vesicle weights, dose-related alterations in testosterone metabolism, altered hepatic enzyme levels	Elissalde and Clark, 1979
Mouse (male)	oral (diet)	10 mg/kg diet (8.4 (mg/mouse/24 weeks) or 50 mg/kg diet (35.3 mg/mouse/ 24 weeks)	24 weeks	Dose-related reduction in weight gain, no tumor pathology observed	Shirai et al., 1978
Mouse (male)	oral (diet)	167 mg/kg diet	3-6 weeks	Impairment in host resistance as measured by increased sensitivity to S. typhosa and P. berghei, and decrease in IgA levels	Loose et al., 1978a,b
Mouse	oral (diet)	6, 12, 24 and 36* mg/kg/day	101-120 weeks *(15 weeks exposed held until 120 weeks)	Reduced growth rate at all dose levels, shortened lifespan associated with tremors and convulsions in 24 and 36 mg/kg/day groups, dose-dependent increase in liver-cell tumors in the 12, 24 and 36 mg/kg/day dose groups	Cabral et al., 1979
Mouse	oral (gavage)	100 mg/kg/day to pregnant mice	days 7-16 of gestation	Increased maternal livers and decreased fetal body weights, increased incidence of abnormal fetuses per litter observed	Courtney et al., 1976
Hamster	oral (diet)	200 or 400 mg/kg diet	90 days	Precirrhotic and cirrhotic hepatic lesions, bile-duct hyperplasias and hepatomas	Lambrecht et al., 1982a

TABLE VIII-1 (cont.)

Species	Route	Dose	Duration	Effects	Reference
Hamster	oral (diet)	4, 8 or 16 mg/kg/day	lifespan	Shortened lifespan in 16 mg/kg/day group, increase in hepatomas at all dose levels, increase in liver haemangioendothelioma in males and females and an increase in thyroid alveolar adenomas in males in 16 mg/kg/day group	Cabral et al., 1977
Cats (breeding females)	oral (diet)	3 or 8.7 mg/day/cat	142 days	Weight loss and increased disease susceptibility in bred females, dose-related decrease in litter size and survival of offspring, hepatomegaly in offspring	Hansen et al., 1979
Minks	oral (diet)	1 or 5 mg/kg diet	during gestation until 17 weeks of age	Dose-related increase in offspring mortality, induction of hepatic MFO enzymes in exposed offspring	Rush et al., 1983
Dog (female)	oral (capsule)	50 or 150 mg/kg/day	21 days	Liver and hepatocyte enlargement, dose-induced electroencephalogram dysrhythmias	Sundlof et al., 1981
Dog	oral (capsule)	1, 10, 100 or 1000 mg/day/dog	1 year	Increase in mortality, neutrophilia, and anorexia in the 100 and 1000 mg dose groups, dose-related nodular hyperplasia of gastric lymphoid tissue in all treated animals	Gralla et al., 1977
Monkey (female)	oral (gavage)	8, 32, 64 or 128 mg/kg/day	60 days	Dose-related pathology in liver, kidney, ovaries and thymus	Iatropoulus et al., 1976
Monkey	oral (nursing)	7.51-186 ppm milk	60 days	2 of 3 infants died as a result of exposures	Bailey et al., 1980

a 10 kg child. Therefore, the longer-term HA for a 10 kg child of 0.05 mg/ℓ is recommended for use as a 10-day HA.

Derivation of Longer-Term Health Advisory. The 15-week subchronic feeding study by Kuiper-Goodman et al. (1977) is selected for the derivation of the longer-term HA. The doses used in this study are on a mg hexachlorobenzene/kg bw basis, which is a preferred dose unit for HA calculations, and the data given in the report show dose responses with effect and no-effect levels for the effects observed. In the study by Arnold et al. (1985), F_0 males used as breeders for the F_1 generation had statistically significant increases in liver-to-body weight ratios and heart weights after exposure to 8 and 40 ppm hexachlorobenzene in the diet for 130 days. The study by Arnold et al. (1985) using the F_0 males could also be proposed for calculation of a longer-term HA, but the organ weight and body weight data were not reported to show the strength of the effects and the dose response, and the selection of the exposure levels on a ppm dietary basis could result in a less precise estimate of dose on a mg/kg bw basis.

Rush et al. (1983) observed a substantial reduction in the survival of mink offspring from mothers exposed to dietary levels of 1 and 5 ppm hexachlorobenzene from about 6 weeks before mating until weaning of offspring. Assuming a daily food consumption of 155 g and a body weight of 0.87 kg for female minks (Bleavins and Aulerich, 1981), 1 and 5 ppm dose levels of hexachlorobenzene would be equivalent to 0.155 and 0.775 mg/kg/day, respectively. Thus, the mink is quite sensitive to hexachlorobenzene effects on reproduction. However, this study is not proposed for use in the longer-term HA or DWEL calculations in that the mink is a species that has not been

extensively investigated as an animal model for toxicity testing. Furthermore, the gastrointestinal physiology of minks is different from that of humans.

In the Kuiper-Goodman et al. (1977) study, groups of 70 male and 70 female Charles River (COBS) rats were fed diets providing 0, 0.5, 2.0, 8.0 or 32.0 mg/kg bw/day of hexachlorobenzene, dissolved in corn oil, for as long as 15 weeks. Female rats were found to be more susceptible to hexachlorobenzene, as indicated by all parameters studied, and an "apparent" NOEL of 0.5 mg/kg/day was concluded by the authors. Increased liver porphyrin levels in females and increases in the size of centrilobular hepatocytes along with the depletion of hepatocellular marker enzymes were noted with higher doses. With the two highest doses, there were increased liver-to-body weight ratios in males and females and increased porphyrin levels in the kidney and spleen. Exposure to the highest dose resulted in decreased survival in females, splenomegaly in females, increases in spleen-to-body weight and kidney-to-body weight ratios in males and females, intension tremors in males and females, ataxia in females, and decreased body weight in males. Similar effects in liver were reported by Böger et al. (1979) after treating groups of 36 female Wistar rats twice weekly for 29 weeks with oral doses of 0.5, 2.0, 8.0 and 32.0 mg hexachlorobenzene/kg bw in olive oil.

The longer-term HA for a 10 kg child and a 70 kg adult are calculated using the NOEL of 0.5 mg/kg bw/day reported by Kuiper-Goodman et al. (1977) as follows:

For 10 kg child:

$$\text{Longer-Term HA} = \frac{(0.5 \text{ mg/kg bw/day})\ (10 \text{ kg})}{(100)\ (1 \text{ ℓ/day})} = 0.05 \text{ mg/ℓ}$$

where:

0.5 mg/kg bw/day	= NOEL identified in the Kuiper-Goodman et al. (1977) study
10 kg	= assumed weight of a child
100	= uncertainty factor, in accordance with NAS/ODW and Agency guidelines to account for use of an animal study.
1 ℓ/day	= assumed water consumption by a child

For a 70 kg adult:

$$\text{Longer-Term HA} = \frac{(0.5 \text{ mg/kg bw/day})\ (70 \text{ kg})}{(100)\ (2 \text{ ℓ/day})} = 0.175 \text{ mg/ℓ}$$

(rounded to 0.2 mg/ℓ)

where:

0.5 mg/kg bw/day	= NOEL identified in the Kuiper-Goodman et al. (1977) study
70 kg	= assumed weight of an adult
100	= uncertainty factor, in accordance with NAS/ODW and Agency guidelines to account for use of an animal study.
2 ℓ/day	= assumed water consumption of a 70 kg adult

Assessment of Lifetime Exposure and Derivation of DWEL. The derivation of the lifetime DWEL is based on a 130-week study of Arnold et al. (1985). This study involved feeding male and female Sprague-Dawley rats, the F_0 generation, diets containing 0, 0.32, 1.6, 8.0 or 40 ppm of hexachlorobenzene (analytical grade) for 90 days prior to mating and until 21 days after parturition (at weaning).

The number of offspring (F_1 generation) from these matings was reduced to 50 males and 50 females per dose group at 28 days of age and fed their respective parents' diets. Thus, the F_1 animals were exposed to hexachlorobenzene and metabolites in utero, from maternal nursing and from their diets for the remainder of their lifetime (130 weeks). No hexachlorobenzene-induced adverse effects were reported in the 0.32 and 1.6 ppm hexachlorobenzene F_1 groups, indicating that these levels are NOAELs. Although significant ($p<0.05$) increases in the incidences of periportal glycogen depletion (1.6 ppm), peribiliary lymphocytosis (0.32, 1.6 and 40 ppm), and peribiliary fibrosis (0.32 and 40 ppm) were observed in the F_1 male rat groups, these effects are not being considered as hexachlorobenzene induced adverse effects because they were observed in a large number of F_1 control males as well. The 8.0 ppm hexachlorobenzene F_1 groups were reported to have an increase ($p<0.05$) in hepatic centrilobular basophilic chromogenesis. The 40 ppm hexachlorobenzene F_1 groups were reported with increases ($p<0.05$) in pup mortality, hepatic centrilobular basophilic chromogenesis, severe chronic nephrosis in males, adrenal pheochromocytomas in females and parathyroid tumors in males.

A lifetime DWEL for hexachlorobenzene is calculated using a 100-fold uncertainty factor, which represents two 10-fold factors to account for both the intra- and interspecies variability to the toxicity of the chemical when specific data are lacking. It is difficult to estimate lifetime doses on a mg hexachlorobenzene/kg bw basis in this study because of the initial exposure of the animals to hexachlorobenzene and its metabolites in utero and during lactation. However, in an attempt to estimate the lifetime hexachlorobenzene doses on a mg/kg bw basis, the 1.6 mg/kg hexachlorobenzene

diet level, interpreted from this study as the highest NOAEL level, was converted to a daily intake dose of 0.08 mg/kg bw/day by averaging the dosage data provided by Arnold (1984). Using 0.08 mg/kg bw/day as a NOAEL from the Arnold et al. (1985) study the RfD and DWEL for a 70 kg adult is calculated as follows:

Step 1 - RfD Derivation

$$RfD = \frac{(0.08 \text{ mg/kg bw/day})}{(100)} = 0.0008 \text{ mg/kg bw/day}$$

where:

0.08 mg/kg bw/day	= NOAEL identified in the Arnold et al. (1985) study
100	= uncertainty factor, in accordance with NAS/ODW and Agency guidelines to account for use of an animal study.

Step 2 - DWEL Derivation

$$DWEL = \frac{(0.0008 \text{ mg/kg bw/day}) (70 \text{ kg})}{(2 \text{ ℓ/day})} = 0.028 \text{ mg/ℓ}$$

(rounded to 0.03 mg/ℓ)

where:

0.0008 mg/kg bw/day	= RfD
70 kg	= assumed weight of an adult
2 ℓ/day	= assumed water consumption by an adult

Carcinogenic Effects

This quantitative section deals with estimation of the unit risk for hexachlorobenzene as a potential carcinogen in water, and with the potency of hexachlorobenzene relative to other carcinogens that have been evaluated by the U.S. EPA Human Health Assessment Group (HHAG). The unit risk for a water pollutant is defined as the lifetime cancer risk to humans from daily exposure to a concentration of 1 µg/ℓ in water by ingestion. The U.S. EPA HHAG has prepared the rationale and the calculation for the unit risk estimate presented herein for the U.S. EPA (1985) Health Assessment Document for Chlorinated Benzenes. The HHAG has also classified hexachlorobenzene as a B2, probable human carcinogen.

The unit risk estimate for hexachlorobenzene represents an extrapolation below the dose range of experimental data. There is currently no solid scientific basis for any mathematical extrapolation model that relates exposure to cancer risk at the extremely low concentrations, including the unit concentration given above, that must be considered when evaluating environmental hazards. For practical reasons, the correspondingly low levels of risk cannot be measured directly either by animal experiments or by epidemiologic study. Therefore, low dose extrapolation must be based on current understanding of the mechanisms of carcinogenesis. At the present time the dominant view of the carcinogenic process involves the concept that most cancer-causing agents also cause irreversible damage to DNA. This position is based in part on the fact that a very large proportion of agents that cause cancer are also mutagenic. There is reason to expect that the quantal response that is characteristic of mutagenesis is associated with a linear (at low doses) non-threshold dose-response relationship. Indeed, there is substantial evidence from mutagenicity studies with both ionizing

radiation and a wide variety of chemicals that this type of dose-response model is the appropriate one to use. This is particularly true at the lower end of the dose-response curve; at high doses there can be an upward curvature, probably reflecting the effects of multistage processes on the mutagenic response. The linear non-threshold dose-response relationship is also consistent with the relatively few epidemiologic studies of cancer responses to specific agents that contain enough information to make the evaluation possible (e.g., radiation-induced leukemia, breast and thyroid cancer, skin cancer induced by arsenic in drinking water, liver cancer induced by aflatoxins in the diet). Some supporting evidence also exists from animal experiments (e.g., the initiation stage of the two-stage carcinogenesis model in rat liver and mouse skin).

Because its scientific basis, although limited, is the best of any of the current mathematical extrapolation models, the nonthreshold model, which is linear at low doses, has been adopted as the primary basis for risk extrapolation to low levels of the dose-response relationship. The risk estimates made with such a model should be regarded as conservative, representing the most plausible upper limit for the risk (i.e., the true risk is not likely to be higher than the estimate, but it could be lower).

For several reasons, the unit risk estimate based on animal bioassays is only an approximate indication of the absolute risk in populations exposed to known carcinogen concentrations. First, there are important species differences in uptake, metabolism and organ distribution of carcinogens, as well as species differences in target site susceptibility, immunologic responses, hormone function, dietary factors and disease. Second, the con-

cept of equivalent doses for humans compared with animals on a mg/surface area basis is virtually without experimental verification in regard to carcinogenic response. Third and finally, human populations are variable with respect to genetic constitution and diet, living environment, activity patterns and other cultural factors.

The unit risk estimate can give a rough indication of the relative potency of a given agent as compared with other carcinogens. Such estimates are, of course, more reliable when the comparisons are based on studies in which the test species, strain, sex and routes of exposure are similar.

The quantitative aspect of carcinogen risk assessment is addressed here because of its possible value in the regulatory decision-making process, e.g., in setting regulatory priorities, evaluating the adequacy of technology-based controls, etc. However, the imprecision of presently available technology for estimating cancer risks to humans at low levels of exposure should be recognized. At best, the linear extrapolation model used here provides a rough but plausible estimate of the upper limit of risk -- that is, with this model it is not likely that the true risk would be much more than the estimated risk, but it could be considerably lower. The risk estimates presented in subsequent sections should not be regarded, therefore, as accurate representations of the true cancer risks even when the exposures involved are accurately defined. The estimates presented may, however, be factored into regulatory decisions to the extent that the concept of upper-risk limits is found to be useful.

Procedures for the Determination of Unit Risk.

Low Dose Extrapolation Model -- The mathematical formulation chosen to describe the linear non-threshold dose-response relationship at low doses is the linearized multistage model (Crump and Watson, 1979). This model employs enough arbitrary constants to be able to fit almost any monotonically increasing dose-response data, and it incorporates a procedure for estimating the largest possible linear slope (in the 95% confidence limit sense) at low extrapolated doses that is consistent with the data at all dose levels of the experiment.

Let P(d) represent the lifetime risk (probability) of cancer at dose d. The multistage model has the form:

$$P(d) = 1 - \exp\left[-(q_0 + q_1 d + q_2 d^2 + \ldots + q_k d^k)\right]$$

where

$$q_i \geq 0, \text{ and } i = 0, 1, 2, \ldots, k$$

Equivalently,

$$P_t(d) = 1 - \exp\left[-(q_1 d + q_2 d^2 + \ldots q_k d^k)\right]$$

where

$$P_t(d) = \frac{P(d) - P(0)}{1 - P(0)}$$

is the extra risk over background rate at dose d.

The point estimate of the coefficients q_i, $i = 0, 1, 2, \ldots, k$, and consequently, the extra risk function, $P_t(d)$, at any given dose d, is calculated by maximizing the likelihood function of the data.

The point estimate and the 95% upper confidence limit of the extra risk, $P_t(d)$, are calculated by using the GLOBAL79 computer program developed by Crump and Watson (1979). At low doses, upper 95% confidence limits on the extra risk and lower 95% confidence limits on the dose producing a given risk are determined from a 95% upper confidence limit, q_1^*, on parameter q_1. Whenever $q_1 > 0$, at low doses the extra risk $P_t(d)$ has approximately the form $P_t(d) = q_1^* \times d$. Therefore, $q_1^* \times d$ is a 95% upper confidence limit on the extra risk and R/q_1^* is a 95% lower confidence limit on the dose, producing an extra risk of R. Let L_0 be the maximum value of the log-likelihood function. The upper-limit q_1^* is calculated by increasing q_1 to a value q_1^* such that when the log-likelihood is remaximized subject to this fixed value q_1^* for the linear coefficient, the resulting maximum value of the log-likelihood L_1 satisfies the equation

$$2 (L_0 - L_1) = 2.70554$$

where 2.70554 is the cumulative 90% point of the chi-square distribution with one degree of freedom, which corresponds to a 95% upper-limit (one-sided). This approach of computing the upper confidence limit for the extra risk $P_t(d)$ is an improvement on previous models. The upper confidence limit for the extra risk calculated at low doses is always linear. This is conceptually consistent with the linear non-threshold concept discussed earlier. The slope, q_1^*, is taken as an upper-bound of the potency of the chemical in inducing cancer at low doses. [In the section calculating the risk estimates, $P_t(d)$ will be abbreviated as P.]

In fitting the dose-response model, the number of terms in the polynomial is chosen equal to (h-1), where h is the number of dose groups in the experiment, including the control group.

Whenever the multistage model does not fit the data sufficiently, data at the highest dose is deleted and the model is refitted to the rest of the data. This is continued until an acceptable fit to the data is obtained. To determine whether or not a fit is acceptable, the chi-square statistic:

$$X^2 = \sum_{i=1}^{h} \frac{(X_i - N_i P_i)^2}{N_i P_i (1-P_i)}$$

is calculated where N_i is the number of animals in the i^{th} dose group, X_i is the number of animals in the i^{th} dose group with a tumor response, P_i is the probability of a response in the i^{th} dose group estimated by fitting the multistage model to the data, and h is the number of remaining groups. The fit is determined to be unacceptable whenever X^2 is larger than the cumulative 99% point of the chi-square distribution with f degrees of freedom, where f equals the number of dose groups minus the number of non-zero multistage coefficients.

Selection of Data -- For some chemicals, several studies in different animal species, strains and sexes, each run at several doses and different routes of exposure, are available. A choice must be made as to which of the data sets from several studies to use in the model. It may also be appropriate to correct for metabolism differences between species and for absorption factors via different routes of administration. The procedures used in evaluating these data are consistent with the approach of making a maximum-likely risk estimate. They are as follows:

1. The tumor incidence data are separated according to organ sites or tumor types. The set of data (i.e., dose and tumor incidence) used in the model is the set where the incidence is statistically significantly

higher than the control for at least one test dose level and/or where the tumor incidence rate shows a statistically significant trend with respect to dose level. The data set that gives the highest estimate of the lifetime carcinogenic risk, q_1^*, is selected in most cases. However, efforts are made to exclude data sets that produce spuriously high risk estimates because of a small number of animals. That is, if two sets of data show a similar dose-response relationship, and one has a very small sample size, the set of data having the larger sample size is selected for calculating the carcinogenic potency.

2. If there are two or more data sets of comparable size that are identical with respect to species, strain, sex and tumor sites, the geometric mean of q_1^*, estimated from each of these data sets, is used for risk assessment. The geometric mean of numbers A_1, A_2, ..., A_m is defined as

$$(A_1 \times A_2 \times \ldots \times A_m)^{1/m}.$$

3. If two or more significant tumor sites are observed in the same study, and if the data are available, the number of animals with at least one of the specific tumor sites under consideration is used as incidence data in the model.

Calculation of Human Equivalent Dosages -- Following the suggestion of Mantel and Schneiderman (1975), it is assumed that mg/surface area/day is an equivalent dose between species. Since, to a close approximation, the surface area is proportional to the two-thirds power of the weight, the exposure in $mg/day^{2/3}$ of the weight is also considered to be equivalent

exposure. In an animal experiment, this equivalent dose is computed in the following manner.

Let

L_e = duration of experiment

l_e = duration of exposure

m = average dose per day in mg during administration of the agent (i.e., during l_e), and

W = average weight of the experimental animal

Then, the lifetime exposure is

$$d = \frac{l_e \times m}{L_e \times W^{2/3}}$$

Oral. Often exposures are not given in units of mg/day, and it becomes necessary to convert the given exposures into mg/day. Similarly, in drinking water studies, exposure is expressed as ppm in the water. For example, in most feeding studies exposure is given in terms of ppm in the diet. In these cases, the exposure in mg/day is

$$m = \text{ppm} \times F \times r$$

where ppm is parts per million of the carcinogenic agent in the diet or water, F is the weight of the food or water consumed per day in kg, and r is the absorption fraction. In the absence of any data to the contrary, r is assumed to be equal to one. For a uniform diet, the weight of the food consumed is proportional to the calories required, which in turn is proportional to the surface area, or two-thirds power of the weight. Water demands are also assumed to be proportional to the surface area, so that

$$m \propto ppm \times W^{2/3} \times r$$

or

$$\frac{m}{rW^{2/3}} \propto ppm.$$

As a result, ppm in the diet or water is often assumed to be an equivalent exposure between species. However, this is not justified in dose extrapolation of laboratory animals to humans since the ratio of calories to food weight is very different in the diet of man as compared with laboratory animals, primarily due to differences in the moisture content of the foods eaten. For the same reason, the amount of drinking water required by each species also differs. It is, therefore, necessary to use an empirically-derived factor, $f = F/W$, which is the fraction of an organism's body weight that is consumed per day as food, expressed as follows:

		Fraction of Body Weight Consumed as	
Species	W	f_{food}	f_{water}
Man	70	0.028	0.029
Rats	0.35	0.05	0.078
Mice	0.03	0.13	0.17

Thus, when the exposure is given as a certain dietary or water concentration in ppm, the exposure in $mg/W^{2/3}$ is

$$\frac{m}{rW^{2/3}} = \frac{ppm \times F}{W^{2/3}} = \frac{ppm \times f \times W}{W^{2/3}} = ppm \times f \times W^{1/3}$$

When exposure is given in terms of mg/kg/day = $m/Wr = s$, the conversion is simply

$$\frac{m}{rW^{2/3}} = s \times W^{1/3}.$$

Calculation of the United Risk from Animal Studies -- The risk associated with d mg/kg$^{2/3}$/day is obtained from GLOBAL79 and, for most cases of interest to risk assessment, can be adequately approximated by $P(d) = 1 - \exp(-q_1^* d)$. A "unit risk" in units X is simply the risk corresponding to an exposure of X = 1. This value is estimated simply by finding the number of mg/kg$^{2/3}$/day that corresponds to one unit of X, and substituting this value into the above relationship. Note that an equivalent method of calculating unit risk would be to use mg/kg for the animal exposures, and then to increase the j^{th} polynomial coefficient by an amount

$$(W_h/W_a)^{j/3} \quad j = 1, 2, \ldots, k,$$

and to use mg/kg equivalents for the unit risk values.

Adjustments for Less Than Lifespan Duration of Experiment. If the duration of experiment L_e is less than the natural lifespan of the test animal L, the slope q_1^*, or more generally the exponent g(d), is increased by multiplying a factor $(L/L_e)^3$. We assume that if the average dose d is continued, the age-specific rate of cancer will continue to increase as a constant function of the background rate. The age-specific rates for humans increase at least by the third power of the age and often by a considerably higher power, as demonstrated by Doll (1971). Thus, it is expected that the cumulative tumor rate would increase by at least the third power of age. Using this fact, it is assumed that the slope q_1^*, or more generally the exponent g(d), would also increase by at least the third power of age. As a

result, if the slope q_1^* [or g(d)] is calculated at age L_e, it is expected that if the experiment had been continued for the full lifespan L at the given average exposure, the slope q_1^* [or g(d)] would have been increased by at least $(L/L_e)^3$.

This adjustment is conceptually consistent with the proportional hazard model proposed by Cox (1972) and the time-to-tumor model considered by Daffer et al. (1980), where the probability of cancer by age t and at dose d is given by

$$P(d,t) = 1 - \exp [-f(t) \times g(d)].$$

Unit Risk Estimates --

Data Available for Potency Calculation. Hexachlorobenzene has been shown to induce tumors in hamsters, mice and rats. The primary target organ appears to be the liver in all three of these species. Liver haemangioendotheliomas in hamsters and hepatocellular carcinomas in rats were significantly increased in the hexachlorobenzene-treated animals. The potency estimate calculated on the basis of hepatocellular carcinomas in female rats is used to derive unit risk estimates for hexachlorobenzene in water. This particular tumor site is selected for calculating unit risks because it is a malignant tumor in the primary target organ and results in the highest potency estimate.

Increased incidences of thyroid, parathyroid, adrenal and kidney tumors were also observed among these species. Fourteen data sets showing significant tumor incidences have been used herein to calculate the carcinogenic

potency of hexachlorobenzene. These calculations provide a range of estimates that, in part, reflect the uncertainties inherent in the risk assessment process. Tables VIII-2 through VIII-5 summarize the data used to calculate the potency of hexachlorobenzene.

Choice of Low-Dose Extrapolation -- In addition to the multistage model currently used by the U.S. EPA HHAG for low-dose extrapolation, HHAG also uses three other models, the probit, the Weibull and the one-hit models, to estimate the risks from exposure to hexachlorobenzene using the data for hepatocellular carcinoma in female rats. These models cover almost the entire spectrum of risk estimates that could be generated from the existing mathematical extrapolation models. These models are generally statistical in character, and are not derived from biologic arguments, except for the multistage model which has been used to support the somatic mutation hypothesis of carcinogenesis (Armitage and Doll, 1954; Whittemore, 1978; Whittemore and Keller, 1978). The main differences among these models is the rate at which the response function, P(d), approaches zero or P(0) as dose, d, decreases. For instance, the probit model would usually predict a smaller risk at low doses than the multistage model because of the difference of the decreasing rate in the low-dose region. However, it should be noted that one could always artificially give the multistage model the same (or even greater) rate of decrease as the probit model by making some dose transformation and/or by assuming that some of the parameters in the multistage model are zero. This, of course, is not reasonable without knowing, a priori, what the carcinogenic process for the agent is. Although the multistage model appears to be the most reasonable or at least the most general model to use, the point estimate generated from this model is of

TABLE VIII-2

Tumor Incidences in Male and Female Hamsters Given Hexachlorobenzene in Diet[a]

Dose[b] (mg/kg/day)	Thyroid	Hepatoma		Liver Hemangioendothelioma	
	Male	Male	Female	Male	Female
0	0/40	0/40	0/30	0/40	0/39
4	0/30	14/30	14/30	1/30	0/30
9	1/30	26/30	17/30	6/30	2/30
16	8/57	49/57	51/60	20/57	7/60

[a]Source: Cabral et al., 1977

[b]If mg/surface area/day is assumed to be equivalent between humans and animals, the dose in mg/kg/day is multiplied by a factor $(0.1/70)^{1/3}$, where 70 and 0.1 kg are, respectively, the average body weights of humans and hamsters.

TABLE VIII-3

Incidence of Liver Cell Tumors in Male and Female Swiss Mice Given Hexachlorobenzene Diet[a]

Dose[b] (mg/kg/day)	Male[c]	Female[c]
0	0/47	0/49
6	0/30	0/30
12	3/12	3/12
24	7/29	14/26

[a]Source: Cabral et al., 1979

[b]If the equivalent dose between humans and mice is assumed to be on the basis of body surface area, the dose in mg/kg/day is multiplied by a factor $(0.035/70)^{1/3}$, where 0.035 kg and 70 kg are, respectively, the average body weights of mice and humans.

[c]The number of animals that survived at the first observed liver cell tumor is used as the denominator.

TABLE VIII-4

Liver and Kidney Tumor Incidence Rates in Male and Female Sprague-Dawley Rats Given Hexachlorobenzene in Diet[a]

Sex	Dose[b] (mg/kg/day)	Hepatocellular Carcinoma	Hepatoma	Renal Cell Adenoma
Male	0	0/54	0/54	7/54
	4.24	3/52	10/52	41/52
	8.48	4/56	11/56	42/56
Female	0	0/52	0/52	1/52
	4.67	36/56	26/56	7/56
	9.34	48/55	35/55	15/54

[a]Source: Lambrecht et al., 1983a,b. Additional data from this study on adrenal pheochromocytoma has recently become available (Peters et al., 1983) but was not available when quantitative estimates were made.

[b]The dosages are calculated by the investigator based on the average food consumption of 22.6 g/rat/day and an average body weight of 400 g for male rats. For female rats, the average food consumption is 16.5 g/rat/day and the average body weight is 265 g. If the equivalent dose between humans and mice is assumed to be on the basis of body surface area, the dose presented in the table is multiplied by a factor $(W_a/70)^{1/3}$, where W_a is the body weight of male or female rats, and 70 kg is the human body weight.

TABLE VIII-5

Incidence Rate of Adrenal Pheochromocytoma in Female Sprague-Dawley Rats (F_1 generation) in a 2-Generation Feeding Study

Dose[a] - (mg/kg/day)	Incidence Rate[b] (used in calculations)	Revised Incidence Rate[c]
0	2/48	2/49
0.02	4/50	4/49
0.08	4/50	
0.40	5/49	4/49
1.90	17/49	

[a]If the equivalent dose between humans and rats is assumed to be on the basis of body surface, the dose in this table is multiplied by a factor $(0.35/70)^{1/3}$, where 70 kg and 0.35 kg are, respectively, assumed to be the body weight of humans and rats.

[b]Source: Arnold et al., 1985

[c]Source: Arnold, 1984. The amended 1984 data were not available when quantitative estimates were made.

limited value because it does not help to determine the shape of the dose-response curve beyond experimental exposure levels. Furthermore, point estimates at low doses extrapolated beyond experimental doses could be extremely unstable and could differ drastically, depending on the amount of the lowest experimental dose. Since upper-bound estimates from the multistage model at low doses are relatively more stable than point estimates, it is suggested that the upper-bound estimate for the risk (or the lower-bound estimate for the dose) be used in evaluating the carcinogenic potency of a suspect carcinogen. The upper-bound estimate can be taken as a plausible estimate if the true dose-response curve is actually linear at low doses. The upper-bound estimate means that the risks are not likely to be higher, but could be lower if the compound has a concave upward dose-response curve or a threshold at low doses. Another reason one can, at best, obtain an upper-bound estimate of the risk when animal data are used is that the estimated risk is a probability conditional to the assumption that an animal carcinogen is also a human carcinogen. Therefore, in reality, the actual risk could range from a value near zero to an upper-bound estimate.

Quantification of Carcinogenic Effects

Fourteen sets of tumor incidences which show significant increases (see Tables VIII-2 through VIII-5) are used herein to calculate the carcinogenic potency of hexachlorobenzene. Since preparing these calculations additional data from the Lambrecht et al. (1983a,b) study (adrenal pheochromocytoma) and from the Arnold et al. (1985) study (neoplastic liver nodules) have become available. Quantitative estimates have not been made using this data. Using the multistage model for low-dose extrapolation, as shown in

Table VIII-6, the potency estimates calculated on the basis of these data sets are approximately within an order of magnitude from each other, with the exception of the thyroid tumor. These potencies provide a range of estimates that reflects the uncertainties stemming from the differences in species, tumor sites, solvent vehicles and composition of diet. The range does not reflect uncertainty resulting from the use of different extrapolation models.

To calculate the unit risks of hexachlorobenzene in water, HHAG used an estimate of carcinogenic potency based upon the data for hepatocellular carcinoma in female rats, which is the highest potency among the carcinoma responses. This particular data set was preferred over the hepatoma only response. A combining of hepatomas and carcinomas was not possible because of a lack of individual animal data.

Risk Associated with 1 µg/ℓ of Hexachlorobenzene in Drinking Water -- Under the assumption that daily water consumption for a 70 kg person is 2 ℓ, the hexachlorobenzene intake in terms of mg/kg/day is

$$d = 2\ \ell \times 1\ \mu g/\ell \times 10^{-3}\ mg/\ell/70\ kg = 2.86 \times 10^{-5}\ mg/kg/day.$$

(rounded to 2.9×10^{-5} mg/kg/day)

Therefore, the risk from drinking water containing 1 µg/ℓ of hexachlorobenzene is estimated to be

$$P = 1.7 \times 2.86 \times 10^{-5} = 4.9 \times 10^{-5}.$$

TABLE VIII-6

The Carcinogenic Potency[a] of Hexachlorobenzene, Calculated on the Basis of 14 Data Sets,[b] Using the Linearized Multistage Model

Study	Date Base	Dose is Assumed to be Equivalent on the Basis of		Reference
		Body Weight	Surface Area	
Hamster	Thyroid (male)	9.3×10^{-3}	8.3×10^{-2}	Cabral et al., 1977
	Hepatoma:			
	Male	1.9×10^{-1}	1.7	
	Female	1.5×10^{-1}	1.3	
	Hemangioendothelioma:			
	Male	3.2×10^{-2}	2.8×10^{-1}	
	Female	1.1×10^{-2}	1.0×10^{-1}	
Mice	Liver cell:			Cabral et al., 1979
	Male	1.7×10^{-2}	2.1×10^{-1}	
	Female	1.4×10^{-2}	1.8×10^{-1}	

TABLE VIII-6 (cont.)

Study	Date Base	Dose is Assumed to be Equivalent on the Basis of: Body Weight	Surface Area	Reference
Rats	Renal cell:			Lambrecht et
	Male	2.5×10^{-1}	1.4	al., 1983a,b
	Female	4.2×10^{-2}	2.6×10^{-1}	
	Hepatocellular carcinoma:			
	Male	1.8×10^{-2}	1.0×10^{-1}	
	Female	2.7×10^{-1}	1.7	
	Hepatoma:			
	Male	4.7×10^{-2}	2.6×10^{-1}	
	Female	1.5×10^{-1}	9.0×10^{-1}	
Rats 2-generation study	Adrenal Pheochromocytoma (female)	2.8×10^{-1}	1.6	Arnold et al., 1985

[a] q_1^* $(mg/kg/day)^{-1}$ is the 95% upper confidence limit of the linear component in the multistage model.

[b] Since preparing these calculations, additional data from Lambrecht et al. (1983a,b) study (adrenal pheochromocytoma) and from Arnold et al. (1985) study (neoplastic liver nodules) have become available. These data have not been evaluated.

This calculation uses the carcinogenic potency $q_1^* = 1.7/(mg/kg/day)$, based on the data on hepatocellular carcinomas in female rats, assuming that dose per surface area is equivalent between rats and humans. If the equivalent dose is assumed to be on the basis of body weight, the unit risk, P, would be reduced to 7.6×10^{-6}.

Summary of Quantitative Estimation. Data on hepatocellular carcinomas in female rats after oral ingestion have been used to estimate the carcinogenic potency of hexachlorobenzene and the risks associated with one unit of the compound in drinking water. The upper bound cancer risks associated with 1 µg/ℓ of hexachlorobenzene in drinking water is estimated to be 4.9×10^{-5}. Accordingly, upper bound cancer risks of 10^{-6}, 10^{-5} and 10^{-4} would be associated with 0.02, 0.2 and 2 µg/ℓ, respectively, of hexachlorobenzene in drinking water. This estimate is calculated on the basis of the assumption that dose per surface area is equivalent among species. If the dose is assumed to be equivalent on the basis of body weight, the corresponding risk would be reduced approximately by a factor of 6. The carcinogenic potencies of hexachlorobenzene are also estimated on the basis of 13 other data sets, encompassing different tumor sites and animal species. Except for the case of thyroid tumors, these potency estimates differ from each other within a single order of magnitude. The range of the estimates reflects the uncertainties due to differences in species, tumor sites, solvent vehicles, composition of diet, etc.

Existing Guidelines, Recommendations and Standards

Occupational. Workplace standards have not been established in the United States. The USSR has established a TLV of 0.08 ppm (0.9 mg/m^3)

(Verschueren, 1977). In 1978, NIOSH classified hexachlorobenzene (HCB) as a Group II pesticide and recommended criteria for standards for occupations in pesticide manufacturing and formulating. These standards rely on engineering controls, work practices and medical surveillance programs, rather than workplace air limits, to protect workers from the adverse effects of pesticide exposure in manufacturing and formulating. NIOSH specifically chose not to establish scientifically valid environmental (workplace air) limits for pesticides (except those already promulgated), because exposure via other routes, especially dermal, had proven to be of critical importance for many pesticides and because NIOSH believed that "immediate action" was needed to protect workers in pesticide manufacturing and formulating plants (NIOSH, 1978).

Food. USDA regulates the use of hexachlorobenzene as a seed treatment for the control of wheat bunt (smut) under the Federal Seed Act (7 CFR 201).

The U.S. EPA (1991) verified a reference dose (RfD) in May 1988 for hexachlorobenzene. The RfD is 8E-4 mg/kg/day. A carcinogenicity reference dose has been verified through CRAVE and this value is a slope factor of 1.6 per mg/kg/day.

Water. The U.S. EPA (1980), in an Ambient Water Quality Criteria Document for Chlorinated Benzenes, determined that hexachlorobenzene is a suspected human carcinogen and since there is no recognized safe concentration for a human carcinogen, the recommended concentration of hexachlorobenzene in water for maximum protection of human health is zero. However, a zero level was thought to be unfeasible in some cases; therefore, water

levels that may result in incremental increases in cancer risk of lifetime exposure were estimated at 10^{-5} (one additional case of cancer for every 100,000 people exposed), 10^{-6} and 10^{-7}. The corresponding recommended criteria were 7.2, 0.72 and 0.072 ng/ℓ, respectively, assuming humans consume 2 ℓ of water and 6.5 g of fish and shellfish per day. The criteria were calculated by using the hepatoma data on male hamsters in the Cabral et al. (1977) carcinogenicity study and the multistage model.

Using the tumor data from the Cabral et al. (1979) carcinogenicity study with Swiss mice and the multistage model, the NAS (1983) averaged cancer risks based on the male and female mouse data to obtain a 95% upper limit of cancer risk of 1.85×10^{-6} with lifetime daily consumption of 1 ℓ of water containing 1 μg of hexachlorobenzene. Earlier, the NAS (1980) used this method and the tumor data in the Cabral et al. (1977) carcinogenicity study with male and female hamsters to calculate a 95% upper limit of cancer risk of 2.9×10^{-5}. The NAS (1980) also calculated a 7-day suggested no adverse response level (SNARL) of 0.03 mg/ℓ for hexachlorobenzene.

Special Groups at Risk

Infants and children (4-16 years of age) appear to be the most susceptible to exposure to hexachlorobenzene. This susceptibility was observed after the accidental ingestion of hexachlorobenzene-contaminated grain occurred in Turkey during 1955-1959 (Peters et al., 1982). A distinct disease described as "Pink Sore", which reached an epidemic scale, was observed in infants under 1 year of age. These infants' mothers had consumed the hexachlorobenzene-treated grain during gestation and/or lactation. This exposure has also been associated with the observed 95% 1-year-old

infant mortality and the high incidence of stillbirths. During the same Turkish accident, children (4-16 years of age) were found to be more susceptible to porphyria cutanea tarda than the adults.

There are strong indications that adult females may be more susceptible to hexachlorobenzene-induced porphyria than adult males, which is the case in the rodent studies (Rizzardini and Smith, 1982). According to these researchers, this increased susceptibility in adult females is related to their estrogen levels and faster metabolism of hexachlorobenzene.

Summary

Health advisories based on noncarcinogenic toxicity data and the carcinogenic risk assessment are given in Table VIII-7. Available data are concluded to be insufficient for calculation of 1-day and 10-day HAs. The longer-term HA, of 0.2 mg/ℓ for a 70 kg adult and 0.05 mg/ℓ for a 10 kg child, which is also being proposed as the 1-day and 10-day HA for 10 kg child, is based on the study by Kuiper-Goodman et al. (1977) in which male and female Charles River rats were fed hexachlorobenzene in the diet for as long as 15 weeks. An RfD of 0.0008 mg/kg bw/day and a DWEL of 0.03 mg/ℓ for a 70 kg adult is based on noncarcinogenic effects in male and female Sprague-Dawley rats exposed to hexachlorobenzene in utero, during lactation, and in the diet for the remainder of their lifetimes. However, there is sufficient evidence for the carcinogenicity of hexachlorobenzene in experimental animals. Based on a weight-of-evidence classification hexachlorobenzene is rated as a B2, probable human corcinogen. By using the 95% upper limit with the multistage model and the hepatocellular carcinoma data in female rats from the Lambrecht et al. (1983a,b) hexachlorobenzene

carcinogenicity study, lifetime exposures to hexachlorobenzene in drinking water at levels of $2x10^{-5}$, $2x10^{-4}$ and $2x10^{-3}$ mg/ℓ are associated with 10^{-6}, 10^{-5} and 10^{-4} cancer risks, respectively.

TABLE VIII-7

Summary of the Data for Hexachlorobenzene Used to Derive HAs and DWEL

Health Advisory	Species/Route	Dose (mg/kg bw/day)	Duration	Basis	Uncertainty Factors	Value[a] (mg/ℓ)	Reference
1-Day and 10-Day				Insufficient data Insufficient data			
Longer-term HA	rat/oral	0.5	15 weeks	NOAEL, higher doses cause an increase in liver, kidney and spleen porphyrin levels and centrilobular liver lesions	100	0.05[b] 0.2[c]	Kuiper-Goodman et al., 1977
DWEL	rat/oral	0.08	130 weeks	NOAEL, higher doses cause an increase in liver and kidney lesions	100	0.03[c]	Arnold et al., 1985
Cancer unit risk estimate	rat/oral	"linearized" multistage model	lifetime	Hepatocellular carcinomas	NA	2.0×10^{-5}[c,d]	Lambrecht et al., 1983a,b

[a]Hexachlorobenzene water solubility is referenced as 0.005 mg/ℓ @ 25°C

[b]for a 10 kg child

[c]for a 70 kg adult

[d]Water concentration associated with an upper level excess lifetime cancer risk of 10^{-6}. Values of 2×10^{-4} and 2×10^{-5} mg/ℓ are associated with upper level excess lifetime cancer risks of 10^{-5} and 10^{-4}, respectively.

NA = Not applicable

IX. REFERENCES

Abbott, D.C., G.B. Collins, R. Goulding and R.A. Hoodless. 1981. Organochlorine pesticide residues in human fat in the United Kingdom, 1976-7. Br. Med. J. 283: 1425-1428.

Albro, P.W. and R. Thomas. 1974. Intestinal absorption of hexachlorobenzene and hexachlorohexane isomers in rats. Bull. Environ. Contam. Toxicol. 12(3): 289-294.

Ariyoshi, T., M. Arakaki, K. Ideguchi and Y. Ishizuka. 1973. Relationship between chemical structure and drug metabolizing enzyme activities. Proc. 5th Symp. Drug Metab. Action. p. 187-194.

Armitage, P. and R. Doll. 1954. The age distribution of cancer and a multistage theory of carcinogenesis. Br. J. Cancer. 8: 1-12.

Arnold, D.L. 1983. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Arnold, D.L. 1984. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Arnold, D.L., C.A. Moodie, S.M. Charbonneau et al. 1985. Long-term toxicity of hexachlorobenzene in the rat and the effect of dietary vitamin A. Food Chem. Toxicol. 23(9): 779-793.

Bailey, J., V. Knauf, W. Mueller and W. Hobson. 1980. Transfer of hexachlorobenzene and polychlorinated biphenyls to nursing infant rhesus monkeys: Enhanced toxicity. Environ. Res. 21(1): 190-196.

Bakken, A.F. and M. Seip. 1976. Insecticides in human breast milk. Act. Paediat. Scand. 65: 535.

Billi, S.C., G. Koss and L.C. San Martin de Viale. 1986a. Screening for the ability of hexachlorobenzene metabolites to decrease rat liver porphyrinogen carboxylase. Res. Comm. Chem. Pathol. Pharmacol. 51: 325-335.

Billi, S.C., G. Koss and L.C. San Martin de Viale. 1986b. Ability of several hexachlorobenzene metabolites to decrease rat liver porphyrinogen carboxylase and to produce porphyrin accumulation in chick embryo liver. In: Hexachlorobenzene: Proc. of an International Symposium, C.R. Morris and J.R.P. Cabral, Ed. IARC Sci. Publ. No. 77, Lyon, France.

Bleavins, M.R. and R.J. Aulerich. 1981. Feed consumption and food passage time in mink (Mustela vison) and European ferrets (Mustela putorius furo). Lab. Animal Sci. 31(3): 268-269.

Bleavins, M.R., W.J. Breslin, R.J. Aulerich and R.K. Ringer. 1982. Excretion and placental and mammary transfer of hexachlorobenzene in the European ferret (Mustela putorius furo). J. Toxicol. Environ. Health. 10: 929-940.

Blekkenhorst, G.H., R.S. Day and L. Eales. 1980. The effect of bleeding and iron administration on the development of hexachlorobenzene-induced rat porphyria. Int. J. Biochem. 12(5-6): 1013-1017.

Böger, A., G. Koss, W. Koransky, R. Naumann and H. Frenzel. 1979. Rat liver alterations after chronic treatment with hexachlorobenzene. Virchows Arch. [Path Anat.] 382(2): 127-137.

Brady, M.N. and D.S. Siyali. 1972. Hexachlorobenzene in human body fat. Med. J. Aust. 1: 158-161.

Brandt, I., A. Lyden, P. Slanina and L. Albanus. 1980. Hexachlorobenzene (HCB) and some of its sulfur-containing metabolites: Tissue retention and excretion routes in mice. Dav. Toxicol. Environ. Sci., ISS Mech. Toxic. Hazard Eval. 8: 627-630.

Burns, J.E. and F.M. Miller. 1975. Hexachlorobenzene contamination: Its effects in a Louisiana population. Arch. Environ. Health. 30: 44-48.

Burns, J.E., F.M. Miller, E.D. Gomes and R.A. Albert. 1974. Hexachlorobenzene exposure from contaminated DCPA in vegetable spraymen. Arch. Environ. Health. 29: 192-194.

Cabral, J.R.P. 1983. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Cabral, J.R.P., P. Shubik, T. Mollner and F. Raitano. 1977. Carcinogenic activity of hexachlorobenzene in hamsters. Nature (London). 269: 510-511.

Cabral, J.R.P., T. Mollner, F. Raitano and P. Shubik. 1979. Carcinogenesis of hexachlorobenzene in mice. Int. J. Cancer. 23(1): 47-51.

Cam, C. 1959. Cutaneous porphyria related to intoxication. Dirim. 34: 11-15. (Tur.)

Cam, P.C. 1960. Une nouvelle dermatose epidemique des enfants. Ann. Dermatol. Syphiliger. 87: 393-397. (Fre.)

Cam, C. and G. Nigogosyan. 1963. Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. J. Am. Med. Assoc. 183(2): 88-91.

Carlson, G.P. 1977. Chlorinated benzene induction of hepatic porphyria. Experientia. 33(12): 1627-1629.

Carlson, G.P. 1978. Induction of cytochrome P-450 by halogenated benzenes. Biochem. Pharmacol. 27(3): 361-363.

Carlson, G.P. 1980. Effects of halogenated benzenes on arylesterase activity in vivo and in vitro. Res. Commun. Chem. Pathol. Pharmacol. 30(2): 361-364.

Carlson, G.P. and R.G. Tardiff. 1976. Effect of chlorinated benzenes on the metabolism of foreign organic compounds. Toxicol. Appl. Pharmacol. 36: 383-394.

Carlson, G.P., J.D. Dziezak and K.M. Johnson. 1979. Effect of halogenated benzenes on acetanilide esterase, acetanilide hydroxylase and procaine esterase in rats. Res. Commun. Chem. Pathol. Pharmacol. 25(1): 181-184.

Chadwick, R.W., C.J. Chadwick, J.J. Freal and C.C. Bryden. 1977. Comparative enzyme induction and lindane metabolism in rats pre-treated with various organochlorine pesticides. Xenobiotica. 7(4): 235-246.

Clark, D.E., G.W. Ivie and B.J. Camp. 1981a. Effects of dietary hexachlorobenzene on in vivo biotransformation, residue deposition and elimination of certain xenobiotics by rats. J. Agric. Food Chem. 29(3): 600-608.

Clark, D.E., M.H. Elissalde, J.J. Doyle and H.H. Mollenhauer. 1981b. Interaction of environmental stress and hexachlorobenzene in the laboratory rat. J. Toxicol. Environ. Health. 8(1-2): 297-306.

Courtney, K.D. 1979. Hexachlorobenzene (HCB): A review. Environ. Res. 20(2): 225-266.

Courtney, K.D. and E. Andrews. 1979. Mobilization of hexachlorobenzene (HCB) during gestation. Toxicol. Lett. 3(6): 357-363.

Courtney, K.D., M.F. Copeland and A. Robbins. 1976. The effects of pentachloronitrobenzene, hexachlorobenzene and related compounds on fetal development. Toxicol. Appl. Pharmacol. 35: 239-256.

Courtney, K.D., J.E. Andrews and D.J. Svendsgaard. 1979. Hexachlorobenzene (HCB) deposition in maternal and fetal tissues of rat and mouse. I. Chemical qualification of HCB in tissues. Environ. Res. 19(1): 1-13.

Cox, C.B. 1972. Regression model and life tables. J. Roy. Stat. Soc. B34: 187-220.

Cripps, D., H.A. Peters and A. Gocmen. 1981. Porphyria turcica (hexachlorobenzene intoxication) twenty years later. Br. J. Dermatol. 105(S19): 15.

Cripps, D.J., H.A. Peters, A. Gocmen and I. Dogramaci. 1984. Porphyria turcica due to hexachlorobenzene: A 20 to 30 year follow-up study on 204 patients. Br. J. Dermatol. 111: 413-422.

Crump, K.S. and W.W. Watson. 1979. GLOBAL79: A Fortran program to extrapolate dichotomous animal carcinogenicity data to low doses. Natl. Inst. Environ. Health Sci. Contract No. 1-ES-2123.

Curley, A., V.W. Burse, R.W. Jennings and E.C. Villanueva. 1973. Chlorinated hydrocarbon pesticides and related compounds in adipose tissue from people in Japan. Nature. 242: 338-340.

Currier, M.F., C.D. McClimans and G. Barna-Lloyd. 1980. Hexachlorobenzene blood levels and the health status of men employed in the manufacture of chlorinated solvents. J. Toxicol. Environ. Health. 6(2): 367-377.

Daffer, P.Z., K.S. Crump and M.D. Masterman. 1980. Asymptotic theory for analyzing dose-response survival data with application to the low-dose extrapolation problem. Math Biosci. 50: 207-230.

Debets, F.M.H., W.J.H.M.B. Hamers and J.J.T.W.A. Strik. 1980a. Metabolism as a prerequisite for the porphyrinogenic action of polyhalogenated aromatics, with special reference to hexachlorobenzene and polybrominated biphenyls (Firemaster BP-6). Int. J. Biochem. 12(5-6): 1019-1025.

Debets F.M.H., J.J.T.W.A. Strik and K. Olie. 1980b. Effects of pentachlorophenol on rat liver changes induced by hexachlorobenzene, with special reference to porphyria, and alterations in mixed function oxygenases. Toxicology. 15(3): 181-195.

Debets, F.M.A., J.H. Reinder, A.J.M. Debets, T.G. Lossbroek, J.J.T.W.A. Strik and G. Koss. 1981. Biotransformation and porphyrinogenic action of hexachlorobenzene and its metabolites in a primary liver cell culture. Toxicology. 19: 185-196.

DeLeon, I.R., M.A. Maberry, E.B. Overton et al. 1980. Rapid gas chromatographic method for the determination of volatile and semivolatile organochlorine compounds in soil and chemical waste disposal site samples. J. Chromatogr. Sci. 18: 85-88.

DeMatteis, F. 1967. Disturbances of liver porphyria metabolism caused by drugs. Pharmacol. Rev. 19(4): 523-557.

DeMatteis, F. 1986. Experimental hepatic porphyria caused by hexachlorobenzene: Mechanism of the metabolic block. In: Hexachlorobenzene: Proceedings of an International Symposium, C.R. Morris and J.R.P. Cabral, Ed. IARC Scientific Publ. No. 77, Oxford University Press, Oxford. p. 427-431.

DeMatteis, F. and M.D. Stonard. 1977. Experimental porphyrias as models for human hepatic porphyrias. Semin. Hematol. 14: 187-192.

Dogramaci, I. 1964. Porphyrias and porphyrin metabolism, with special reference to porphyria in childhood. Adv. Pediatr. 13: 11-63.

Doll, R. 1971. The age distribution of cancer implications for models of carcinogenesis. J. Royal Stat. Soc-Ser A. 134: 133.

Dougherty, R.C., M.J. Whitaker, S-Y. Tang, R. Bottcher, M. Keller and D.W. Kuehl. 1981. Sperm density and toxic substances: A potential key to environmental health hazards. Environ. Health Chem., Chem. Environ. Agents Potential Hum. Hazards (Symp.), J.D. McKinney, Ed. p. 263-278.

Edgerton, T.R., R.F. Moseman and L.H. Wright. 1981. Method development for the assessment of possible human exposure to pesticides and industrial chemicals. EPA/600/1-81-024. NTIS PB81-175796. 47 p.

Elder, G.H. 1978. Porphyria caused by hexachlorobenzene and other polyhalogenated hydrocarbons. In: Handbook of Experimental Pharmacology, Vol. 44, Heme and Hemoproteins, F. DeMatteis and W.N. Aldridge, Ed. Springer-Verlag, Berlin. p. 157-200.

Elder, G.H. and D.M. Sheppard. 1982. Immunoreactive uroporphyrinogen decarboxylase is unchanged in porphyria caused by TCDD and hexachlorobenzene. Biochem. Biophys. Res. Commun. 109: 113-120.

Elder, G.H. and A.J. Urquhart. 1986. Immunochemical studies of the uroporphyrinogen decarboxylase defect caused by hexachlorobenzene. In: Hexachlorobenzene: Proc. of an International Symposium, C.R. Morris and J.R.P. Cabral, Ed. IARC Sci. Publ. No. 77, p. 441-448. Lyon, France.

Elder, G.H., J.O. Evans and S.A. Matlin. 1976. The effect of the porphyrogenic compound, hexachlorobenzene, on the activity of hepatic uroporphyrinogen decarboxylase in rat. Clin. Sci. Mol. Med. 51: 71-80.

Elder, G.H., G.B. Lee and J.P. Torey. 1978. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N. Engl. J. Med. 299: 274-278.

Elissalde, M.H. and D.E. Clark. 1979. Testosterone metabolism by hexachlorobenzene-induced hepatic microsomal enzymes. Am. J. Vet. Res. 40(12): 1762-1766.

Ellefson, R.D. 1982. Porphyrinogens, porphyrins and the porphyrias. Mayo Clinic Proc. 57: 454-458.

Engst, R., R.M. Macholz and M. Kujawa. 1976. The metabolism of hexachlorobenzene (HCB) in rats. Bull. Environ. Contam. Toxicol. 16(2): 248-251.

Ernster, L. and K. Nordenbrand. 1967. In: Methods in Enzymology, R.W. Estabrook and M.E. Pullman, Ed. Academic Press, New York. p. 574.

Farmer, W.J., M.S. Yang, J. Letey and W.F. Spencer. 1980. Hexachlorobenzene: Its vapor pressure and vapor phase diffusion in soil. Soil Sci. Soc. Am. J. 44(4): 676-680.

Ferioli, A., C. Harvey and F. DeMatteis. 1984. Drug-induced accumulation of uroporphyrin in chicken hepatocyte culture. Structural requirements for the effect and role of exogenous iron. Biochem. J. 224: 769-777.

Goerz, G., W. Vizethum, K. Bolsen, Th. Krieg and R. Lissner. 1978. Hexachlorobenzene (HBC)-induced porphyria in rats. Effect of HCB-metabolites on heme biosynthesis. Arch. Dermatol. Res. 263(2): 189-196. (Ger.)

Goldstein, J.A., M. Friesen, T.M. Scotti, P. Hickman, J.R. Hass and H. Bergman. 1978. Assessment of the contribution of chlorinated dibenzo-p-dioxins and dibenzofurans to hexachlorobenzene-induced toxicity, porphyria, changes in mixed function oxygenases, and histopathological changes. Toxicol. Appl. Pharmacol. 46(3): 633-649.

Goldstein, J.A., P. Linko, J.N. Huckins and D.L. Stalling. 1982. Structure-activity relationships of chlorinated benzenes as inducers of different forms of cytochrome P-450 in rat liver. Chem. Biol. Interact. 41(2): 131-139.

Graef, V., S.W. Golf and G. Goerz. 1979. Effect of hexachlorobenzene on enzymes of steroid metabolism in rat liver. Arch. Toxicol. 43(2): 115-120.

Gralla, E.J., R.W. Fleischman, Y.K. Luthra et al. 1977. Toxic effects of hexachlorobenzene after daily administration to beagle dogs for one year. Toxicol. Appl. Pharmacol. 40(2): 227-239.

Granick, S. 1965. Hepatic porphyria and drug-induced or chemical porphyria. Ann. N.Y. Acad. Sci. 123: 188-197.

Grant, D.L., F. Iverson, G.U. Hatina and D.C. Villeneuve. 1974. Effects of hexachlorobenzene on liver porphyrin levels and microsomal enzymes in rats. Environ. Physiol. Biochem. 4: 159-165.

Grant, D.L., W.E.J. Phillips and G.V. Hatina. 1977. Effect of hexachlorobenzene on reproduction in the rat. Arch. Environ. Contam. Toxicol. 5(2): 207-216.

Guerzoni, M.E., L. Del Cupolo and I. Ponti. 1976. Mutagenic activity of pesticides. (Attivita mutagenica degli antiporossitari.) Riv. Sci. Technol. Alementi Nutri. Um. 6: 161-165.

Hahn, M.E., T.A. Gasiewicz, J.A. Goldstein and P. Linko. 1986. Effect of hexachlorobenzene on the specific binding of 2,3,7,8-TCDD to the hepatic AH receptor. Chemosphere. 15: 1691-1698.

Hansen, L.G., R.H. Teske, S.M. Sundlof and J. Simon. 1979. Hexachlorobenzene and feline reproduction: Effects of ground pork contaminated by dietary exposure or spiked with purified hexachlorobenzene. Vet. Hum. Toxicol. 21(4): 248-253.

Headley, D.B., R.W. Lambrecht, E. Erturk, H.A. Peters, C.R. Morris and G.T. Bryan. 1981. Neuropathology and tissue levels of hexachlorobenzene (HCB) fed to rats, mice and hamsters. Fed. Proc. Fed. Am. Soc. Exp. Biol. 40(3): 699. (Abstract)

Hofvander, Y., U. Hagman, C.-E. Linder, R. Vaz and S.A. Slorach. 1981. WHO collaborative breast feeding study. I. Organochlorine contaminants in individual samples of Swedish human milk, 1978-1979. Acta. Paediatr. Scand. 70(1): 3-8.

Howe, R.B. and K.S. Crump. 1982. GLOBAL82: A computer program to extrapolate quantal animal toxicity data to low doses. OSHA Contract No. 41 USC252C3.

Hrycry, E.G. and P.J. O'Brien. 1971. Cytochrome P-450 as a microsomal peroxidase utilizing a lipid peroxide substrate. Arch. Biochem. Biophys. 147: 14-27.

Hustert, K., M. Mansour, H. Parlar and F. Korte. 1981. Der EPA-Test-Eine Methode Zur Bestimmung Oes Photochemischen Abbaus Von Organischen Verbindungen in Aquatischen Systemen. Chemosphere. 10(9): 995-998. (Ger.)

IARC (International Agency for Research on Cancer). 1979. IARC monographs on the evaluation of the carcinogenic risk of chemical to humans. Hexachlorobenzene. IARC, Lyon, France. 20: 155-178.

Iatropoulos, M.J., A. Milling, W.F. Müller et al. 1975. Absorption, transport and organotropism of dichlorobiphenyl (DCB), dieldrin, and hexachlorobenzene (HCB) in rats. Environ. Res. 10(3): 384-389.

Iatropoulos, M.J., W. Hobson, V. Knauf and H.P. Adams. 1976. Morphological effects of hexachlorobenzene toxicity in female Rhesus monkeys. Toxicol. Appl. Pharmacol. 37: 433-444.

Iatropoulos, M.J., J. Bailey, H.P. Adams, F. Coulston and W. Hobson. 1978. Response of nursing infant Rhesus to Clophen A-30 or hexachlorobenzene given to their lactating mothers. Environ. Res. 16(1-3): 38-47.

Ingebrigtsen, K., J.U. Skaare, I. Nafstad and M. Førde. 1981. Studies on the biliary excretion and metabolites of hexachlorobenzene in the rat. Xenobiotica. 11(11): 795-800.

Khera, K.S. 1974. Teratogenicity and dominant lethal studies on hexachlorobenzene in rats. Food Cosmet. Toxicol. 12: 471-477.

Kitchin, K.T., R.E. Linder, T.M. Scotti, D. Walsh, A.D. Curley and D. Svensgaard. 1982. Offspring mortality and maternal lung pathology in female rats fed hexachlorobenzene. Toxicology. 23(1): 33-39.

Kluwe, W.M., J.B. Hook and J. Bernstein. 1982. Synergistic toxicity of carbon tetrachloride and several aromatic organohalide compounds. Toxicology (Ireland). 23(4): 321-336.

Knauf, V. and W. Hobson. 1979. Hexachlorobenzene ingestion by female Rhesus monkeys: Tissue distribution and clinical symptomatology. Bull. Environ. Contam. Toxicol. 21(1-2): 243-248.

Kohli, J., D. Jones and S. Safe. 1976. The metabolism of higher chlorinated benzene isomers. Can. J. Biochem. 54(3): 203-208.

Korte, F., D. Freitag, H. Geyer, W. Klein, A.G. Kraus and E. Lahaniatis. 1978. Ecotoxicologic profile analysis. A concept for establishing ecotoxicologic priority lists for chemicals. Chemosphere. 1: 79-102.

Koss, G. and W. Koransky. 1975. Studies on the toxicology of hexachlorobenzene. I. Pharmacokinetics. Arch. Toxicol. 34: 203-212.

Koss, G., W. Koransky and K. Steinbach. 1976. Studies on the toxicology of hexachlorobenzene. II. Identification and determination of metabolites. Arch. Toxicol. 35: 107-114.

Koss, G., J.J.T.W.A. Strik and C.A. Kan. 1978a. Metabolites of hexachlorobenzene in the excreta of different animal species. Int. Consv. Series. Exerpta Medica. 440: 211-212.

Koss, G., S. Seubert, A. Seubert, W. Koransky and H. Ippen. 1978b. Studies on the toxicology of hexachlorobenzene. III. Observations in a long-term experiment. Arch. Toxicol. 40(4): 285-294.

Koss, G., S. Seubert, A. Seubert, W. Koransky, P. Kraus and H. Ippenet. 1980a. Conversion products of hexachlorobenzene and their role in the disturbance of the porphyrin pathway in rats. Int. J. Biochem. 12(5-6): 1003-1006.

Koss, G., S. Seubert, A. Seubert, M. Herbert, W. Koransky and H. Ippen. 1980b. Hexachlorobenzene and 2,4,5,2',4',5'-hexachlorobiphenyl -- A comparison of their distribution, biotransformation and porphyrinogenic action in female rats. Dev. Toxicol. Environ. Sci., ISS. Mech. Toxic. Hazard Eval. 8: 517-520.

Koss, G., S. Seubert, A. Seubert, J. Seidel, W. Koransky and H. Ippen. 1983. Studies on the toxicology of hexachlorobenzene. V. Different phases of porphyria during and after treatment. Arch. Toxicol. 52: 13-22.

Koss, G., B. Stoffelns, S. Seubert, A. Seubert, W. Koransky and H. Ippen. 1986. Time course and extent of disturbance of the hepatic porphyrin pathway in hexachlorobenzene-exposed female rats. In: Hexachlorobenzene: Proc. of an International Symposium, C.R. Morris and J.R.P. Cabral, Ed. IARC Sci. Publ. No. 77, p. 493-495. Lyon, France.

Koszo, F., C. Siklosi and N. Simon. 1974. Liposome model experiment for the study of assumed membrane damage in porphyria cutanea tarda. Biochim. Biophys. Acta. 363: 182-189.

Koszo, F., C. Siklosi and N. Simon. 1978. Hexachlorobenzene porphyria and hexachlorobenzene catabolism in rats. Biochem. Biophys. Res. Commun. 80(4): 781-788.

Koszo, F., L.I. Horvath, N. Simon, C. Siklosi and M. Kiss. 1982. The role of possible membrane damage in porphyria cutanea tarda: A spin label study of rat liver membranes. Biochem. Pharmacol. 31: 11-17.

Kovar, J. and D. Krewski. 1981. RISK81: A computer program for low-dose extrapolation of quantal response toxicity data. Dept. Health Welfare, Canada.

Kraybill, H. 1983. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Kuiper-Goodman, T., D. Krewski, H. Combley, M. Doran and D.L. Grant. 1976. Hexachlorobenzene-induced smooth endoplasmic reticulum in rat livers: A correlated stereologic and biochemical study. National Bureau of Standards Special Publ. 431, Proc. 4th Int. Cong. Stereology, Gaithersburg, September 1975. p. 351-354.

Kuiper-Goodman, T., D.L. Grant, C.A. Moodie, G.O. Korsrud and I.C. Munro. 1977. Subacute toxicity of hexachlorobenzene in the rat. Toxicol. Appl. Pharmacol. 40(3): 529-549.

Kushner, J.P., A.J. Barbuto and G.R. Lee. 1976. An inherited enzymatic defect in porphyria cutanea tarda. Decreased uroporphyrinogen decarboxylase activity. J. Clin. Invest. 58: 1089.

Lambrecht, R.W. 1983. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Lambrecht, R.W. 1984. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Lambrecht, R.W., B.A. Darcey, E. Ertürk et al. 1981. Tissue levels and fate of hexachlorobenzene (HCB) disappearance in fat and liver of rats, mice and hamsters after oral administration. Proc. Am. Assoc. Cancer Res. 22: 127 (Abstr.)

Lambrecht, R.W., E. Ertürk, E. Grunden et al. 1982a. Hepatotoxicity and tumorigenicity of hexachlorobenzene (HCB) in Syrian golden hamsters (H) after subchronic administration. Fed. Proc. 41:(3): 329. (Abstr.)

Lambrecht, R.W., E. Ertürk, E. Grunden et al. 1982b. Renal toxicity and tumorigenicity of hexachlorobenzene (HCB) in rats. Proc. Am. Assoc. Cancer Res. 23: 54. (Abstr.)

Lambrecht, R.W., E. Ertrük, E.E. Grunden, H.A. Peters, C.R. Morris and G.T. Bryan. 1983a. Renal tumors in rats (R) chronically exposed to hexachlorobenzene (HCB). Proc. Am. Assoc. Cancer Res. 24: 59. (Abstr.)

Lambrecht, R.W., E. Ertrük, E.E. Grinden, H.A. Peters, C.R. Morris and G.T. Bryan. 1983b. Hepatocarcinogenicity of chronically administered hexachlorobenzene in rats. Fed. Proc. 42(4): 786. (Abstr.)

Lambrecht, R.W. E. Ertürk, H.A. Peters, C.R. Morris and G.T. Bryan. 1986. Effects of ethylenediaminetetracetic acid on hexachlorobenzene-induced changes in rats. In: Hexachlorobenzene: Proc. of an International Symposium, C.R. Morris and J.R.P. Cabral, Ed. IARC Sci. Publ. No. 77, p. 505-506. Lyon, France.

Lawlor, T., S.R. Haworth and P. Voytek. 1979. Evaluation of the genetic activity of nine chlorinated phenols, seven chlorinated benzenes, and three chlorinated hexanes. Environ. Mutagen. 1: 143. (Abstr.)

Leoni, V. and S.U. D'Arca. 1976. Experimental data and critical review of the occurrence of hexachlorobenzene in the Italian environment. Sci. Total Environ. 5(3): 253-272.

Linko, P. H.N. Yeowell, T.A. Gasiewicz and J.A. Goldstein. 1986. Induction of cytochrome P-450 isozymes by hexachlorobenzene in rats and aromatic hydrocarbon (Ah)-responsive mice. J. Biochem. Toxicol. 1: 95-107.

Lissner, R., G. Gortz, M.G. Eichenauer and H. Ippen. 1975. Hexachlorobenzene-induced prophyria in rats. Relationship between porphyrin excretion and induction of drug metabolizing liver enzymes. Biochem. Pharmacol. 24: 1729-1731.

Loose, L.D., K.A. Pittman, K.F. Benitz, J.B. Silkworth, W. Mueller and F. Coulston. 1978a. Environmental chemical-induced immune dysfunction. Ecotoxicol. Environ. Safety. 2(2): 173-198.

Loose, L.D., J.B. Silkworth, K.A. Pittman, K.-F. Benitz and W. Mueller. 1978b. Impaired host resistance to endotoxin and malaria in polychlorinated biphenyl- and hexachlorobenzene-treated mice. Infect. Immun. 20(1): 30-35.

MacKay, D., W.Y. Shiu and R.P. Sutherland. 1979. Determination of air-water Henry's Law constants for hydrophobic pollutants. Environ. Sci. Technol. 13(3): 333-337.

Mantel, N. and M.A. Schneiderman. 1975. Estimating "safe" levels, a hazardous undertaking. Cancer Res. 35: 1379-1386.

Masini, A., D. Ceccarelli-Stanzani, T. Trenti, E. Rocchi and E. Ventura. 1984a. Structural and functional properties of rat liver mitochondria in hexachlorobenzene induced experimental porphyria. Biochem. Biophys. Res. Comm. 118: 356-363.

Masini, A., D. Ceccarelli-Stanzani, T. Trenti and E. Ventura. 1984b. Transmembrane potential of liver mitochondria from hexachlorobenzene- and iron-treated rats. Biochim. Biophys. Acta. 802: 253-258.

Masini, A., D. Ceccarelli-Stanzani, A. Tomasi, T. Trenti and E. Ventura. 1985. The role of pentachlorophenol in causing mitochondrial derangement in hexachlorobenzene induced experimental porphyria. Biochem. Pharmacol. 34: 1171-1174.

Mehendale, H.M., M. Field and H.B. Matthews. 1975. Metabolism and effects of hexachlorobenzene on hepatic microsomal enzymes in the rat. J. Agric. Food Chem. 23(2): 261-265.

Mendoza, C.E., B.T. Collins, J.B. Shields and G.W. Laver. 1978. Effects of hexachlorobenzene or hexabromobenzene on body and organ weights of preweanling rats after a reciprocal transfer between the treated and control dams. J. Agric. Food Chem. 26(4): 941-945.

Mendoza, C.E., J.B. Shields and G.W. Laver. 1979. Comparison of the porphyrinogenic activity of hexabromobenzene and hexachlorobenzene in primiparous Wistar rats. Bull. Environ. Contam. Toxicol. 21(3): 358-364.

Mes, J. and D.J. Davies. 1979. Presence of polychlorinated biphenyl and organochlorine pesticide residues and the absence of polychlorinated terphenyls in Canadian human milk samples. Bull. Environ. Contam. Toxicol. 21(3): 381-387.

Mitruka, B.M., H.M. Rownsley and D.V. Vadehra, Ed. 1976. Nutrition, Breeding and Management of Experimental Animals, Chapter 2. In: Animals for Medical Research, Models for the Study of Human Disease. John Wiley and Sons, New York.

Mollner, T. 1983. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Morehouse, L.A., C.E. Thomas and S.D. Aust. 1984. Superoxide generation by NADPH cytochrome P-450 reductase: The effect of iron chelators and the role of superoxide in microsomal lipid peroxidation. Arch. Biochem. Biophys. 232: 366-377.

Morley, A., D. Geary and F. Harben. 1973. Hexachlorobenzene pesticides and porphyria. Med. J. Aust. 1: 565.

NAS (National Academy of Sciences). 1977. Drinking Water and Health. Safe Drinking Water Committee, NAS, Washington, DC. p. 667-673, 798-799.

NAS (National Academy of Sciences). 1980. Drinking Water and Health. Vol. 3, p. 25-67.

NAS (National Academy of Sciences). 1983. Risk Assessment in the Federal Government: Managing the Process. National Academy Press, Washington, DC.

Neilson, I.R., F.T. Chaykowski, M.A. Singer and G.S. Marks. 1979. A possible association between membrane-fluidizing properties and porphyrin-inducing activity of drugs. Biochem. Pharmacol. 28: 3589-3598.

Neilson, I.R., M.A. Singer and G.S. Marks. 1980. Association between the membrane-fluidizing properties and porphyrin-inducing activity of alfaxalone and related steroids. Molec. Pharmacol. 18: 144-147.

Nikolaev, V., E. Naydenova, M. Kerimova, S. Dimov and E. Ivanov. 1986. Rat liver plasma membrane damage in hexachlorobenzene intoxication and its potentiation by ethanol. Toxicol. Lett. 32: 269-273.

NIOSH (National Institute for Occupational Safety and Health). 1978. Criteria for a Recommended Standard...Occupational Exposure During the Manufacture and Formulations of Pesticides. Cincinnati, OH. DHEW (NIOSH) Publ. No. 78-174.

NLM (National Library of Medicine). 1979. Hexachlorobenzene. Toxicology Data Base, Bethesda, MD. TDB No. 1724.

O'Brien, P.J. and A. Rahimtula. 1975. Involvement of cytochrome P-450 in the intracellular formation of lipid peroxides. J. Agric. Food Chem. 23: 154-158.

Pederson, T.C. and S.D. Aust. 1972. NADPH-dependent lipid peroxidation catalyzed by purified NADPH-cytochrome c reductase from rat liver microsomes. Biochem. Biophys. Res. Commun. 48: 789-795.

Pereira, M.S. 1983. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Pereira, M.A., S.L. Herren, A.L. Britt and M. Khoury. 1982. Sex difference in enhancement of GGTase-positive foci by hexachlorobenzene and lindane in rat liver. Cancer Lett. 15(1): 95-102.

Peters, H., D. Cripps, J.T. Bryan and G. Gosman. 1983. 5th Annual Progress Report of Epidemiologic Study of Populations Previously Exposed to Hexachlorobenzene. EPA Contract 68-01-5002.

Peters, H.A., S.A.M. Johnson, S. Cam et al. 1966. Hexachlorobenzene-induced porphyria: Effect of chelation of the disease, porphyria and metal metabolism. Am. J. Med. Sci. 251: 314-322.

Peters, H.A., A. Gocmen, D.J. Cripps, G.T. Bryan and I. Dogramaci. 1982. Epidemiology of hexachlorobenzene-induced porphyria in Turkey. Clinical and laboratory follow-up after 25 years. Arch. Neurol. 39(12): 744-749.

Puzynska, L., P.R.M. Kerklan, G. Koss, J.J.T.W.A. Strik and J.H. Koeman. 1978. Porphyrinogenic action of hexachlorobenzene in combination with diethylmaleate and phenobarbital in rats. Abstract 7. International Congr. Pharmacol., Paris, France.

Renner, G. 1981. Biotransformation of the fungicides hexachlorobenzene and pentachloronitrobenzene. Xenobiotica. 11(7): 435-446.

Renner, G. and P.T. Nguyen. 1984. Biotransformation of derivatives of the fungicides pentachloronitrobenzene and hexachlorobenzene in mammals. Xenobiotica. 14: 693-704.

Richter, E. and S.G. Schäfer. 1981. Intestinal excretion of hexachlorobenzene. Arch. Toxicol. 47(3): 233-239.

Richter, E., G. Renner, J. Bayerl and M. Wick. 1981. Differences in the biotransformation of hexachlorobenzene (HCB) in male and female rats. Chemosphere. 10(7): 779-785.

Rinkus, S.J. and M.S. Legator. 1980. The need for both in vitro and in vivo systems in mutagenicity screening. In: Chemical Mutagens, Vol. 6, A. Hollander, Ed. Plenum Press, New York. p. 365-473.

Rios de Molina, M.C., R. Wainstok de Calmanovici and L.C. San Martin de Viale. 1980. Investigations on the presence of porphyrinogen carboxylyase inhibitor in the liver of rats intoxicated with hexachlorobenzene. Int. J. Biochem. 12(5-6): 1027-1032.

Rizzardini, M. and A.G. Smith. 1982. Sex differences in the metabolism of hexachlorobenzene by rats and the development of porphyria in females. Biochem. Pharmacol. 31(22): 3543-3548.

Rozman, K., W. Mueller, F. Coulston and F. Korte. 1977. Long-term feeding study of hexachlorobenzene in rhesus monkeys. Chemosphere. 6(2-3): 81-84.

Rozman, K., T. Rozman and H. Greim. 1981. Enhanced fecal elimination of stored hexachlorobenzene from rats and rhesus monkeys by hexadecane or mineral oil. Toxicology. 22(1): 33-44.

Rush, G.F., J.H. Smith, K. Maita et al. 1983. Perinatal hexachlorobenzene toxicity in the mink. Environ. Res. 31: 116-124.

San Martin De Viale, L.C., M. Del Carmen Rios De Molina, R. Wainstock De Calmonovici and J.C. Tomio. 1977. Porphyrins and porphyrinogen decarboxylase in hexachlorobenzene-induced porphyria. Biochem. J. 168: 393-400.

Sassa, S., H. De Verneuil, K.E. Anderson and A. Kappas. 1984. Purification and properties of human erythrocyte uroporphyrinogen decarboxylase: Immunological demonstration of the enzyme defect in porphyria cutanea tarda. Trans. Assoc. Am. Phys. 96: 65-75.

Sax, N.I. 1979. Dangerous Properties of Industrial Materials, 5th ed. Van Nostrand Reinhold Co., NY. p. 716.

Shirai T., Y. Miyata, K. Nakanishi, G. Murasaki and N. Ito. 1978. Hepatocarcinogenicity of polychlorinated terphenyl (PCT) in ICR mice and its enhancement by hexachlorobenzene (HCB). Cancer Lett. 4(5): 271-275.

Siklosi, C., N. Simon and F. Koszo. 1981. Effect of some hexachlorobenzene catabolites on the porphyrin metabolism of rats. Dermatosen Beruf. Umwelt. 29(2): 40-42.

Simon, G.S., R.G. Tardiff and J.F. Borzelleca. 1979. Failure of hexachlorobenzene to induce dominant lethal mutations in the rat. Toxicol. Appl. Pharmacol. 47(2): 415-419.

Skaare, J.U. 1981. Persistent organochlorinated compounds in Norwegian human milk in 1979. Acta. Pharmacol. Toxicol. (Copenhagen). 49(5): 384-389.

Smith, A.G. and J.R. Cabral. 1980. Liver-cell tumors in rats fed hexachloro- benzene. Cancer Lett. 11(2): 169-172.

Smith, A.G. and F. De Matteis. 1980. Drugs and the hepatic porphyrias. Clin. Haematol. 9: 399-425.

Smith, A.G., J.E. Francis and F. De Matteis. 1980. Lobes of rat liver respond at different rates to challenge by dietary hexachlorobenzene. Biochem. Pharmacol. 29(23): 3127-3131.

Smith, A.G., F.P. Stewart and J.E. Francis. 1986. Genetic, iron status and sex factors of porphyria induced by hexachlorobenzene. In: Hexachlorobenzene: Proceedings of an International Symposium, C.R. Morris and J.R.P. Cabral, Ed. IARC Scientific Publ. No. 77, Oxford University Press, Oxford. p. 433-439.

Stonard, M.D. 1974. Experimental hepatic porphyria induced by hexachlorobenzene as a model for human symptomatic porphyria. Br. J. Haematol. 27: 617-625.

Strik, J.J.T.W.A., F.M.A. Debets and G. Koss. 1980. Chemical porphyria. In: Halogenated Biphenyls, Terphenyls, Naphthalenes and Related Products, R.D. Kimbrough, Ed. Elsevier, North-Holland Biomedical Press, Amsterdam. p. 191-239.

Sufit, R.L., R. Hodack, R. Arends, H.A. Peters, E. Ertürk and O.J. Cripps. 1986. Decreased conduction velocity and pseudomyotonia in hexachlorobenzene-fed rats. In: Hexachlorobenzene: Proc. of an International Symposium, C.R. Morris and J.R.P. Cabral, Ed. IARC Sci. Publ. No. 77, p. 361-362. Lyon, France.

Sundlof, S.M., A.J. Parker, J. Simon, J.L. Dorner and L.G. Hansen. 1981. Sub-acute toxicity of hexachlorobenzene in female beagles, including electroencephalographic changes. Vet. Hum. Toxicol. 23(2): 92-96.

Sundlof, S.F., L.G. Hansen, G.D. Koritz and S.M. Sundlof. 1982. The pharmacokinetics of hexachlorobenzene in male beagles. Distribution, excretion, and pharmacokinetic model. Drug Metab. Dispos. 10(4): 371-381.

Szymczynski, G.A. and S.M. Waliszewski. 1981. Comparison of the content of chlorinated pesticide residues in human semen, testicles and fat tissues. Andrologia. 13(3): 250-252.

Takahashi, W., D. Saidin, G. Takei and L. Wong. 1981. Organochloride pesticide residues in human milk in Hawaii, 1979-80. Bull. Environ. Contam. Toxicol. 27(4): 506-511.

Takazawa, R.S. and H.W. Strobel. 1986. Cytochrome P-450 mediated reductive dehalogenation of the perhalogenated aromatic compound hexachlorobenzene. Biochemistry. 25: 4804-4809.

Tappel, A.L. 1973. Lipid peroxidation damage to cell components. Fed. Proc. 32: 1870-1874.

Theiss, J.C., G.D. Stoner, M.B. Shimkin and E. Weisburger. 1977. Test for carcinogenicity of organic contaminants of United States drinking waters by pulmonary tumor response in strain A mice. Cancer Res. 37: 2717-2720.

Thiers, B.H. 1981. The porphyrias. J. Am. Acad. Dermatol. 5: 621-625.

Tonnuki, W., N. Kumai and T. Miura. 1981. Histopathological studies on sun-exposed hexachlorobenzene-induced porphyric rat skin. Tohoku J. Exp. Med. 134: 425-430.

Tschudy, D.P. and H.L. Bonkowsky. 1972. Experimental porphyria. Fed. Proc. 31(1): 147-159.

U.S. EPA. 1980. Ambient Water Quality Criteria Document for Chlorinated Benzenes. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Water Regulations and Standards, Washington, DC. EPA 440/5-80-028. NTIS PB 81-117392.

U.S. EPA. 1982. Test methods: Methods of organic chemical analysis of municipal and industrial wastewater. J.E. Longbottom and J.J. Lichtenberg, Ed. Environ. Monit. Sup. Lab., Cincinnati, OH. EPA 600/4-82-057.

U.S. EPA. 1985. Health Assessment Document for Chlorinated Benzenes. Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH. EPA 600/8-84-015F. NTIS PB85-150332.

U.S. EPA. 1991. Integrated Risk Information System (IRIS). Online. Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH.

Van Ommen, B., A.E.P. Adang, L. Brader, M.A. Posthumus, F. Müller and P.J. Van Bladeren. 1986. The microsomal metabolism of hexachlorobenzene. Biochem. Pharmacol. 35: 3233-3238.

Verschueren, K. 1977. Handbook of Environmental Data on Organic Chemicals. Von Nostrand Reinhold Co., New York.

Villeneuve, D.C. and S.L. Hierlihy. 1975. Placental transfer of hexachlorobenzene in the rat. Bull. Environ. Contam. Toxicol. 13(4): 489-491.

Villeneuve, D.C. and W.H. Newsome. 1975. Toxicity and tissue levels in the rat and guinea pig following acute hexachlorobenzene administration. Bull. Environ. Contam. Toxicol. 14(3): 297-300.

Villeneuve, D.C., L.G. Panopio and D.L. Grant. 1974. Placental transfer of hexachlorobenzene in the rabbit. Toxicol. Appl. Pharmacol. 29: 108. (Abstr.)

Vos, J.G., M.J. van Logten, J.G. Kreeftenberg and W. Kruizinga. 1979a. Hexachlorobenzene-induced stimulation of the humoral immune response in rats. Ann. N.Y. Acad. Sci. 320: 535-550.

Vos, J.G., M.J. van Logten, J.G. Kreeftenberg, P.A. Steerenberg and W. Kruizinga. 1979b. Effect of hexachlorobenzene on the immune system of rats following combined pre- and postnatal exposure. Drug Chem. Toxicol. 2(1-2): 61-76.

Vos, J.G., E.I. Krajnc, P.K. Beekhof and M.J. Van Logten. 1983a. Methods for testing immune effects of toxic chemicals: Evaluation of the immunotoxicity of various pesticides in the rat. In: IUPAC Pesticide Chemistry. Human Welfare and the Environment, J. Miyamoto and P.C. Kearney, Ed. Pergamon Press, Oxford. p. 497-504.

Vos, J.G., G.M.J. Brouwer, F.X.R. Van Leeuwen and S. Wagenaar. 1983b. Toxicity of hexachlorobenzene in the rat following combined pre- and post-natal exposure: Comparison of effects on immune system, liver and lung. In: Immunotoxicology, D.V. Parke, G.G. Gibson and R. Hubbard, Ed. Academic Press, London. p. 219-235.

Wainstok de Calmanovici, R., M.D. Rios de Molina, M.C. Taira de Yamasato, J.M. Tomio and L.C. San Martin de Viale. 1984. Mechanism of hexachlorobenzene-induced porphyria in rats: Effect of phenobarbitone pretreatment. Biochem. J. 218: 753-763.

Weast, R.C., Ed. 1981. CRC Handbook of Chemistry and Physics, 61st ed. CRC Press, Inc., Cleveland, OH.

Weisburger, E. 1983. Personal communication to Murial M. Lippman, ERNACO, Inc., Silver Springs, MD.

Westoo, G. and K. Noren. 1978. Organochlorine contaminants in human milk, Stockholm 1967-1977. Ambio. 7(2): 62-64.

Whittemore, A. 1978. Quantitative theories of carcinogenesis. In: Advances in Cancer Research, Vol. 27. Academic Press, New York, NY. p. 55-58.

Whittemore, A. and B. Keller. 1978. Quantitative theory of carcinogenesis. Soc. Ind. Appl. Math. Rev. 20: 1-30.

Yalkowsky, S.H. and S.C. Valvani. 1980. Solubility and partitioning. I. Solubility of nonelectrolytes in water. J. Pharm. Sci. 69(8): 912-922.

Yang, R.S.H., K.A. Pittman, D.R. Rourke and V.B. Stein. 1978. Pharmacokinetics and metabolism of hexachlorobenzene in the rat and the rhesus monkey. J. Agric. Food Chem. 26(5): 1076-1083.

Zabik, M.E. and R. Schemmel. 1980. Influence of diet on hexachlorobenzene accumulation in Osborne Mendel rats. J. Environ. Pathol. Toxicol. 4(5-6): 97-103.